Metal-chelated phospholipid complex, metal-chelated phospholipid complex nanoparticle and drug-lipid particle, and preparation methods and uses thereof

MYPI2025000633A0Undetermined Publication Date: 2024-02-09HUNAN LONSTAR BIOTECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000633
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-08-09
Filing Date
2023-08-04
Publication Date
2024-02-09

AI Technical Summary

Technical Problem

In existing nucleic acid drug delivery systems, the use of cationic lipids and ionizable lipids results in high cytotoxicity and immunogenicity, making it difficult to fundamentally solve the toxicity problem of nanoparticle delivery systems.

Method used

A metal-phospholipid complex is used, which is a complex formed by phospholipid molecules, linker molecules and metal ions connected through coordination bonds. It is used to wrap and deliver negatively charged drugs, avoid the use of cationic lipids and ionizable lipids, and reduce the cost of toxicity.

Benefits of technology

It significantly reduces the toxicity of the nanoparticle delivery system, improves biological safety, and enhances the carrying capacity of negatively charged drugs in the living body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025000633_DRAWING_001
    Figure PI2025000633_DRAWING_001
  • Figure PI2025000633_DRAWING_002
    Figure PI2025000633_DRAWING_002
  • Figure PI2025000633_DRAWING_003
    Figure PI2025000633_DRAWING_003
Patent Text Reader

Abstract

The present disclosure provides a metal-chelated phospholipid complex, a metal-chelated phospholipid complex nanoparticle and a drug-lipid particle, and preparation methods and uses thereof, which relates to the field of biotechnology. The metal-chelated phospholipid complex is formed by reaction of a phospholipid molecular moeity, a linker molecular moeity, and a metal ion moiety. The metal-chelated phospholipid complex nanoparticle comprises a metal-chelated phospholipid complex, a particle aggregation-inhibiting conjugated lipid, and a non-cationic lipid or a non-ionizable lipid. The drug-lipid particle comprises a drug and the metal-chelated phospholipid complex nanoparticle. The metal chelated phospholipid complex has a function in adsorbing drugs with negative charges and self-assembling with other lipids into metal-chelated phospholipid complex nanoparticle (MPP), so as to avoid the use of cationic lipid or ionizable lipid under the condition of ensuring the effectiveness which is not less than that of LNP, so that the toxicity of the drug-lipid particle is greatly reduced compared with LNP, the biological safety is remarkably improved, and the delivery of drugs with negative charges in organisms is facilitated. The most illustrative figure is Fig. 2-10
Need to check novelty before this filing date? Find Prior Art

Description

Metal-phospholipid complex, metal-phospholipid complex particles and drug-lipid particles and preparation methods and applications thereof

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] The present disclosure claims priority to three Chinese patent applications, application number 202210951941.8 filed with the China Patent Office on August 9, 2022, entitled “Drug-lipid particles, preparation methods and applications thereof”, application number 202210950392.2 filed with the China Patent Office on August 9, 2022, entitled “Metal-phospholipid complex particles, preparation methods and applications thereof”, and application number 202210950391.8 filed with the China Patent Office on August 9, 2022, entitled “Metal-phospholipid complex, preparation methods and applications thereof”, the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present disclosure relates to the field of biotechnology, and in particular to a metal-phospholipid complex, metal-phospholipid complex particles, and drug-lipid particles, as well as preparation methods and applications thereof. Background Art

[0004] With the continuous advancement of molecular biology techniques, our understanding of the relationship between genes and diseases is deepening. Nucleic acid drugs, artificially synthesized DNA or RNA fragments with therapeutic potential, have attracted considerable attention due to their enormous potential for application in disease diagnosis and treatment. These drugs can act directly on pathogenic target genes or mRNAs, exerting therapeutic effects at the genetic level. Compared with traditional small molecule and antibody drugs, nucleic acid drugs are not limited by the druggability of their target proteins, can treat a wider range of diseases, and can regulate the expression of pathogenic genes at their root. Nucleic acid drugs also offer significant advantages such as high efficacy, low toxicity, and high specificity, and are expected to become the third largest type of drug after small molecule and antibody drugs.

[0005] However, nucleic acid drugs are easily degraded by nucleases in the body, and their large molecular weight and negative charge make them difficult to cross cell membranes to exert their effects. Therefore, finding safe and effective delivery systems for nucleic acid drugs is a critical bottleneck in their development. Currently, vectors capable of delivering nucleic acid drugs can be divided into viral and non-viral vectors. Viral vectors induce an immune response upon entry into the human body and are therefore less commonly used. Among non-viral vectors, nanoparticles and small molecule conjugates are the most commonly used. Compared with small molecule conjugates directly conjugated to nucleic acid drugs, nanoparticles can more effectively encapsulate nucleic acid drugs, preventing their rapid degradation by nucleases in the body and thereby increasing their circulation time. Nanoparticles encapsulate nucleic acids by adsorbing negatively charged nucleic acids onto positively charged cationic lipids. However, cationic lipids are highly cytotoxic, with the following mechanisms of action: ① cell atrophy, decreased mitotic activity, and cytoplasmic vacuolation; ② interaction with biological proteins such as protein kinase C, thereby disrupting their activity; and ③ activation of p38 mitogen-activated protein kinase and nuclear factor-κB transcription factors, triggering the secretion of various proinflammatory cytokines and chemokines. In addition, ionizable lipids are lipids containing positively charged ionizable amine groups. They are uncharged under physiological conditions (pH = 7.4), but are protonated and positively charged at lower pH values. Therefore, ionizable lipids can be used to partially or completely replace cationic lipids as the main component of nanoparticles, responsible for adsorbing nucleic acids. When nanoparticles containing ionizable lipids enter the lysosomes of biological cells, the ionizable lipids become positively charged lipids in the low pH environment (pH = 4.0-6.5) within the lysosomes. Although ionizable lipids reduce the cytotoxic and highly inflammatory effects of some permanently positively charged cationic lipids, their cytotoxicity and immunogenicity are still high. Lipid nanoparticles (LNPs) based on cationic lipids and / or ionizable lipids are currently available clinically as nanoparticle nucleic acid drug delivery systems. Cationic lipids and / or ionizable lipids are the main components of LNPs and are responsible for the adsorption of nucleic acids. At the same time, the cytotoxicity and immunogenicity mediated by cationic lipids and / or ionizable lipids remain one of the important reasons for the high toxicity of LNPs.

[0006] Therefore, when using a delivery system to deliver negatively charged drugs (such as nucleic acid drugs, protein drugs, polypeptide drugs, small molecule drugs, etc.), nanoparticle delivery systems developed based on cationic lipids and / or ionizable lipids cannot fundamentally solve the toxicity problem of nanoparticle delivery systems. There is an urgent need for a liposome delivery system with low toxicity that does not use cationic lipids and / or ionizable lipids.

[0007] Summary of the Invention

[0008] The purpose of the present disclosure is to provide a metal-phospholipid complex and a preparation method thereof, so as to at least alleviate one technical problem existing in the prior art.

[0009] In order to achieve the above objectives, the present disclosure adopts the following technical solutions:

[0010] The metal-phospholipid complex provided by the present disclosure is composed of a phospholipid molecule portion, a linker molecule portion and a metal ion portion, wherein the phospholipid molecule portion is connected to the linker molecule portion, and the linker molecule portion is connected to the metal ion portion via a coordination bond, and the metal-phospholipid complex is not a cationic lipid or an ionizable lipid.

[0011] Furthermore, the phospholipid molecule is partially selected from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylglycerol (PG), 1-phosphoceramide (SP), phosphatidylinositol (PI), phosphatidylthreonine (PT), sphingomyelin (SM), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS), lysophosphatidic acid (LPA), lysophosphatidylglycerol (LPG), lysophosphatidylinositol (LPI), lysophosphatidylthreonine (LPT), lysosphingomyelin (LSM), 1-sphingosine phosphate (S1P), and a combination of one or more thereof. Among them, the "their" in "and their derivatives" refers to "phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylglycerol (PG), 1-phosphoceramide (SP), phosphatidylinositol (PI), phosphatidylthreonine (PT), sphingomyelin (SM), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS), lysophosphatidic acid (LPA), lysophosphatidylglycerol (LPG), lysophosphatidylinositol (LPI), lysophosphatidylthreonine (LPT), lysosphingomyelin (LSM), 1-sphingosine phosphate (S1P)". In the present disclosure, "and their derivatives" have similar meanings. The phospholipid molecule portion may be, for example but not limited to, phosphatidylcholine (PC), phosphatidylcholine (PC) derivatives, phosphatidylethanolamine (PE), phosphatidylethanolamine (PE) derivatives, phosphatidylglycerol (PG), phosphatidylglycerol (PG) derivatives, phosphatidylglycerol (PG) and phosphatidylcholine (PC), phosphatidylcholine (PC) and phosphatidylcholine (PC) derivatives, etc.

[0012] Furthermore, the phospholipid molecule is selected from

[0013]

[0014]

[0015]

[0016]

[0017] and combinations of one or more of their derivatives;

[0018] Wherein, R1 and R2 are independently:

[0019] Furthermore, the phospholipid molecule is partially selected from phosphatidylcholine (PC) (Formula 1), phosphatidylethanolamine (PE) (Formula 2), phosphatidic acid (PA) (Formula 4), phosphatidylglycerol (PG) (Formula 5), ​​and a combination of one or more of their derivatives.

[0020] Furthermore, the phospholipid molecule is partially selected from distearoylphosphatidylcholine (DSPC), distearoylphosphatidylethanolamine (DSPE), distearoylphosphatidic acid (DSPA), distearoylphosphatidylglycerol (DSPG), and a combination of one or more thereof.

[0021] Furthermore, the phospholipid molecule is selected from and combinations of one or more of their derivatives.

[0022] Furthermore, the phospholipid molecule is selected from DSPC (Formula 46), DSPE (Formula 47), DSPA (Formula 48), or DSPG (Formula 49).

[0023] Furthermore, the linker molecule is partially selected from curcumin, chlorogenic acid, anthocyanin, quercetin, dihydromyricetin, hesperetin, naringenin, apigenin, catechin, tea polyphenols, epigallocatechin gallate, ellagic acid, morin, epicatechin gallate, catechin gallate, epigallocatechin gallate or picarapine C, and a combination of one or more of their derivatives.

[0024] Furthermore, the linker molecule is selected from

[0025] R7 and R8 are H, OH or OCH3, R3 is H or a glycosyl group, and R4, R5 and R6 are OH or a glycosyl group;

[0026]

[0027] and combinations of one or more of their derivatives.

[0028] Further, the linker molecule is selected from curcumin (Formula 19), A combination of one or more of .

[0029] Furthermore, the linker molecule is partially selected from curcumin (Formula 19), hesperetin (Formula 24), tea polyphenols (Formula 28), and a combination of one or more of their derivatives.

[0030] Furthermore, the linker molecule is partially selected from curcumin (Formula 19), hesperetin (Formula 24) or tea polyphenols (Formula 28).

[0031] Furthermore, the metal ion is selected from Fe 3+ 、Ag + 、Ba 2+ , Ca 2+ 、Cd 2+ 、Cu 2+ 、Fe 2+ 、Mn 2+ Mg 2+ 、Mo 2+ 、Zn 2+ , Pt 2+ 、Au 2+ 、Al 3+ 、Ce 3+ 、Co 3+ Cr 3+ 、Eu 3+ 、Gd 3+ 、Ni 3+ 、W 3+ 、V 3+ 、Zr 3+ A combination of one or more of .

[0032] Furthermore, the metal ion is selected from Fe 3+ , Ca 2+ 、Al 3+ A combination of one or more of .

[0033] Furthermore, the metal ion is selected from Fe 3+ , Ca 2+ or Al 3+ .

[0034] Furthermore, the metal-phospholipid complex is made of a phospholipid molecule portion, a linker molecule portion and a metal ion portion, wherein the phospholipid molecule portion is selected from DSPC, DSPE or DSPA, the linker molecule portion is selected from curcumin, hesperidin or tea polyphenols, and the metal ion portion is selected from Fe 3+, Ca 2+ or Al 3+ .

[0035] Furthermore, the metal-phospholipid complex is made of a phospholipid molecule portion, a linker molecule portion and a metal ion portion, wherein the phospholipid molecule portion is selected from DSPC (Formula 46), DSPE (Formula 47) or DSPA (Formula 48), the linker molecule portion is selected from curcumin (Formula 19), hesperidin (Formula 24) or tea polyphenols (Formula 28), and the metal ion portion is selected from Fe 3+ , Ca 2+ or Al 3+ .

[0036] Furthermore, the molar ratio of the phospholipid molecule part, the linker molecule part and the metal ion part is 1:1:(0.5-2).

[0037] Furthermore, the phospholipid molecule portion is DSPC (Formula 46), the linker molecule portion is selected from curcumin (Formula 19), and the metal ion portion is selected from Fe 3+ .

[0038] Furthermore, the molar ratio of the phospholipid molecule part, the linker molecule part and the metal ion part is 1:1:1.

[0039] Furthermore, DSPC, curcumin and Fe 3+ / Al 3+ The molar ratio is 1:1:1.

[0040] Furthermore, DSPC, hesperetin and Fe 3+ / Al 3+ The molar ratio is 1:1:1.

[0041] Furthermore, DSPC, tea polyphenols and Fe 3+ / Al 3+ The molar ratio is 1:1:2.

[0042] Furthermore, Fe 3+ Selected from FeCl3, Al 3+ Selected from Al(NO3)3·9H2O.

[0043] The present disclosure provides a method for preparing a metal-phospholipid complex, comprising the following steps:

[0044] Step 1: Reaction and connection of phospholipid molecules with linker molecules to form phospholipid complexes;

[0045] Step 2: reacting the phospholipid complex prepared in step 1 with metal ions through coordination bonds to form a metal-phospholipid complex.

[0046] Furthermore, in step 1, the phospholipid molecule and the linker molecule are dissolved in ethanol for reaction, and then n-hexane is added for precipitation to obtain the phospholipid complex. Furthermore, the reaction conditions include a reaction temperature of 65° C. for 2 hours.

[0047] Furthermore, the molar ratio of the phospholipid molecule to the linker molecule is 1:1.

[0048] Furthermore, in step 2, the phospholipid complex and the metal ion are dissolved in ethanol and reacted to obtain the metal-phospholipid complex. Furthermore, the reaction conditions include reacting at 60° C. for 2 hours.

[0049] Furthermore, the molar ratio of the phospholipid complex to the metal ion is 1:(1-2).

[0050] The present disclosure provides a metal-chelated phospholipid complex nanoparticle (MPP), which contains (i) the metal-phospholipid complex, (ii) a conjugated lipid that inhibits particle aggregation, wherein the conjugated lipid that inhibits particle aggregation is not a cationic lipid or an ionizable lipid; and (iii) a non-cationic lipid or a non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation. Wherein, "(iii) a non-cationic lipid or a non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation" can be simply referred to as "non-cationic lipid or non-ionizable lipid".

[0051] Furthermore, the conjugated lipid that inhibits particle aggregation includes polyethylene glycol (PEG)-lipid conjugates and / or PEG-dialkoxypropyl (DAA).

[0052] Further, the PEG-lipid conjugate is selected from

[0053]

[0054] , and a combination of one or more of their derivatives;

[0055] R1 and R2 are independently: caproyl, lauroyl, myristoyl, palmitoyl, stearoyl, oleoyl, linoleoyl, erucyl, arachidoyl or phytanoyl.

[0056] Furthermore, the PEG-lipid conjugate is selected from a combination of one or more of DSPE-PEG2000, DSPE-PEG700, DSPE-PEG1000 or DSPE-PEG5000.

[0057] Further, the PEG-lipid conjugate is selected from A combination of one or more of .

[0058] Further, the PEG-lipid conjugate is selected from DSPE-PEG2000 (Formula 53), DSPE-PEG700 (Formula 50), DSPE-PEG1000 (Formula 51) or DSPE-PEG5000 (Formula 52).

[0059] Furthermore, in (iii), the non-cationic lipid or non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid for inhibiting particle aggregation is a combination of one or more of cholesterol and its derivatives.

[0060] Furthermore, in (iii), the non-cationic lipid or non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid for inhibiting particle aggregation is cholesterol (Formula 40) and combinations of one or more of their derivatives.

[0061] Furthermore, the non-cationic lipid or non-ionizable lipid in (iii) is cholesterol (Formula 40).

[0062] Furthermore, in (iii), in addition to the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation, the non-cationic lipid or non-ionizable lipid, in addition to cholesterol, also includes one or more combinations selected from phosphatidylcholine PC, phosphatidylethanolamine PE, phosphatidylserine PS, phosphatidic acid PA, phosphatidylglycerol PG, 1-phosphoceramide SP, phosphatidylinositol PI, phosphatidylthreonine PT, sphingomyelin SM, lysophosphatidylcholine LPC, lysophosphatidylethanolamine LPE, lysophosphatidylserine LPS, lysophosphatidic acid LPA, lysophosphatidylglycerol LPG, lysophosphatidylinositol LPI, lysophosphatidylthreonine LPT, lysosphingomyelin LSM, 1-phospho-sphingosine S1P, cholesterol sulfate, and their derivatives.

[0063] Furthermore, in (iii), in addition to the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation, the non-cationic lipid or non-ionizable lipid, in addition to cholesterol, also includes a member selected from: and combinations of one or more of their derivatives;

[0064] Wherein, R1 and R2 are: caproyl, lauroyl, myristoyl, palmitoyl, stearoyl, oleoyl, linoleoyl, erucyl, arachidoyl or phytanoyl.

[0065] Furthermore, the non-cationic lipid or non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid for inhibiting particle aggregation in (iii) includes cholesterol, and a combination of one or more selected from DSPC, DSPE, DSPA or DSPG.

[0066] Furthermore, the non-cationic lipid or non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation in (iii) includes cholesterol (Formula 40), and a combination of one or more selected from DSPC (Formula 46), DSPE (Formula 47), DSPA (Formula 48) or DSPG (Formula 49).

[0067] Furthermore, the non-cationic lipid or non-ionizable lipid described in (iii) includes cholesterol (Formula 40) and DSPC (Formula 46).

[0068] Furthermore, the metal-phospholipid complex particles are made of (i) a metal-phospholipid complex, (ii) a conjugated lipid that inhibits particle aggregation, and (iii) a non-cationic lipid or non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation, wherein the metal-phospholipid complex has a molar proportion of 10% to 40% in the raw material, the conjugated lipid that inhibits particle aggregation has a molar proportion of 2% to 10% in the raw material, the cholesterol has a molar proportion of 35% to 75% in the raw material, and the non-cationic lipid or non-ionizable lipid other than cholesterol has a molar proportion of 0% to 40% in the raw material.

[0069] Furthermore, the metal-phospholipid complex particles are made of (i) metal-phospholipid complex, (ii) conjugated lipids that inhibit particle aggregation, and (iii) non-cationic lipids or non-ionizable lipids, the metal-phospholipid complex accounts for 5% to less than 10% by mole in the raw material, the conjugated lipids that inhibit particle aggregation account for 2% to 10% by mole in the raw material, the cholesterol accounts for 15% to less than 35%, 35% to 75%, or greater than 75% to 80% by mole in the raw material, and the non-cationic lipids or non-ionizable lipids other than cholesterol account for 0% to 40% or greater than 40% to 51% by mole in the raw material. Or

[0070] The molar proportion of the metal-phospholipid complex in the raw material is greater than 40% to 50%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 2% to 10%, the molar proportion of cholesterol in the raw material is 15% to less than 35%, 35% to 75% or greater than 75% to 80%, and the molar proportion of the non-cationic lipid or non-ionizable lipid other than cholesterol in the raw material is 0% to 40% or greater than 40% to 51%. Or

[0071] The molar proportion of the metal-phospholipid complex in the raw material is 10% to 40%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 2% to 10%, the molar proportion of cholesterol in the raw material is 15% to less than 35% or greater than 75% to 80%, and the molar proportion of the non-cationic lipid or non-ionizable lipid other than cholesterol in the raw material is 0% to 40% or greater than 40% to 51%.

[0072] Furthermore, the molar proportion of the metal-phospholipid complex in the raw material is 7% to less than 10%, 10% to 30%, or 20% to 30%, preferably 25%.

[0073] Furthermore, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10% or 5% to 10%, preferably 10%.

[0074] Furthermore, the molar proportion of cholesterol in the raw material is 15% to less than 35%, 35% to 56% or 35% to 55%, preferably 40%.

[0075] Furthermore, the molar proportion of non-cationic lipids or non-ionizable lipids other than cholesterol in the raw material is 5% to 30%, 25% to 40%, greater than 40% to 45% or 20% to 25%.

[0076] Furthermore, the molar proportion of the metal-phospholipid complex in the raw material is 15% to 25%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 4% to 10%, the molar proportion of the cholesterol in the raw material is 40% to 46%, the molar proportion of the DSPC in the raw material is 25% to 35%, and the metal ion portion of the metal-phospholipid complex is selected from Fe 3+ .

[0077] Furthermore, the metal-phospholipid complex (metal ion part is Fe 3+ ) accounts for 15% by mole in the raw material, the conjugated lipid that inhibits particle aggregation accounts for 4% by mole in the raw material, the cholesterol accounts for 46% by mole in the raw material, and the DSPC accounts for 35% by mole in the raw material; or the metal-phospholipid complex (the metal ion part is Fe 3+) has a molar ratio of 25% in the raw material, the conjugated lipid that inhibits particle aggregation has a molar ratio of 10% in the raw material, the cholesterol has a molar ratio of 40% in the raw material, and the DSPC has a molar ratio of 25% in the raw material.

[0078] Furthermore, the molar proportion of the metal-phospholipid complex in the raw material is 10% to 30%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10%, the molar proportion of the cholesterol in the raw material is 35% to 56%, and the molar proportion of the DSPC in the raw material is 34% to 40%; the metal ion part in the metal-phospholipid complex is selected from Al 3+ .

[0079] Furthermore, the molar proportion of the metal-phospholipid complex in the raw material is 10% to 30%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10%, the molar proportion of the cholesterol in the raw material is 35% to 56%, the molar proportion of the DSPC in the raw material is 40% to 45%, and the metal ion portion of the metal-phospholipid complex is selected from Al 3+ ;or

[0080] The molar proportion of the metal-phospholipid complex in the raw material is 10% to 30%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10%, the molar proportion of the cholesterol in the raw material is 15% to 35%, the molar proportion of the DSPC in the raw material is 34% to 40% or greater than 40% to 45%, and the metal ion part of the metal-phospholipid complex is selected from Al 3+ ;or

[0081] The molar proportion of the metal-phospholipid complex in the raw material is 7% to less than 10%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10%, the molar proportion of the cholesterol in the raw material is 15% to less than 35% or 35% to 56%, the molar proportion of the DSPC in the raw material is 34% to 40% or greater than 40% to 45%, and the metal ion part of the metal-phospholipid complex is selected from Al 3+ .

[0082] Furthermore, the metal-phospholipid complex (metal ion part is Al 3+ ) accounts for 7% by mole in the raw material, the conjugated lipid that inhibits particle aggregation accounts for 3% by mole in the raw material, the cholesterol accounts for 56% by mole in the raw material, and the DSPC accounts for 34% by mole in the raw material.

[0083] Furthermore, the metal-phospholipid complex is DSPC, curcumin and Fe 3+The molar ratio of DSPE-PEG2000 to DSPC is 1:1:1, the conjugated lipid that inhibits particle aggregation is DSPE-PEG2000, the non-cationic lipid or non-ionizable lipid is cholesterol and DSPC, the molar proportion of the metal-phospholipid complex in the raw material is 15%, the molar proportion of DSPE-PEG2000 in the raw material is 4%, the molar proportion of cholesterol in the raw material is 46%, and the molar proportion of DSPC in the raw material is 35%.

[0084] Furthermore, the metal-phospholipid complex is DSPC, curcumin and Fe 3+ The molar ratio of DSPE-PEG2000 to DSPC is 1:1:1, the conjugated lipid that inhibits particle aggregation is DSPE-PEG2000, the non-cationic lipid or non-ionizable lipid is cholesterol and DSPC, the molar proportion of the metal-phospholipid complex in the raw material is 25%, the molar proportion of DSPE-PEG2000 in the raw material is 10%, the molar proportion of cholesterol in the raw material is 40%, and the molar proportion of DSPC in the raw material is 25%.

[0085] Furthermore, the metal-phospholipid complex is DSPC, curcumin and Al 3+ The molar ratio of DSPE-PEG2000 to DSPC is 1:1:1, the conjugated lipid that inhibits particle aggregation is DSPE-PEG2000, the non-cationic lipid or non-ionizable lipid is cholesterol and DSPC, the molar proportion of the metal-phospholipid complex in the raw material is 7%, the molar proportion of DSPE-PEG2000 in the raw material is 3%, the molar proportion of cholesterol in the raw material is 56%, and the molar proportion of DSPC in the raw material is 34%.

[0086] The present disclosure provides a method for preparing the above-mentioned metal-phospholipid complex particles, comprising mixing (i) a metal-phospholipid complex, (ii) a conjugated lipid that inhibits particle aggregation, and (iii) a non-cationic lipid or a non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation to obtain the metal-phospholipid complex particles.

[0087] The present disclosure provides a drug-lipid particle comprising:

[0088] (a) a drug, wherein the drug is a negatively charged molecule; and

[0089] (b) Metal-chelated phospholipid complex nanoparticles (MPP), which are the metal-chelated phospholipid complex nanoparticles disclosed in the present invention.

[0090] Furthermore, the drug is encapsulated in the metal-phospholipid complex particles.

[0091] Furthermore, the drug is selected from one or more combinations of nucleic acids, proteins, polypeptides, small molecules, nucleic acid analogs, protein analogs and polypeptide analogs.

[0092] Furthermore, the nucleic acid is selected from one or more combinations of mRNA, siRNA, sgRNA, ASO, circRNA, microRNA, DNA, ecDNA, and artificial nucleic acid.

[0093] Furthermore, the nucleic acid is an mRNA sequence encoding eGFP (Enhanced Green Fluorescent Protein) as shown in SEQ ID No.1, an mRNA sequence encoding the receptor binding domain RBD of the novel coronavirus S1 subunit as shown in SEQ ID No.2, an mRNA sequence encoding NY-ESO-1 (New York esophageal squamous cell carcinoma 1) as shown in SEQ ID No.3, an siRNA sequence whose antisense chain is SEQ ID No.4 and whose sense chain is SEQ ID No.21 for the Bcl-2 gene (B-cell lymphoma / Leukemia-2), an siRNA sequence whose antisense chain is SEQ ID No.6 and whose sense chain is SEQ ID No.23 for the PLK1 gene (Polo-like Kinase 1), an siRNA sequence for the Gal-1 gene as shown in SEQ ID No.8, an ASO sequence for the STAT-3 gene as shown in SEQ ID No.10, and an siRNA sequence for the STAT-3 gene as shown in SEQ ID No. The ASO sequence of the α-syn gene (α-synuclein) shown in No. 12, the ASO sequence of the Bcl-2 gene shown in SEQ ID No. 14, the mRNA sequence encoding the wild-type novel coronavirus S protein shown in SEQ ID No. 16, the double-stranded DNA sequence with the antisense chain as SEQ ID No. 17 and the sense chain as SEQ ID NO. 25, the single-stranded DNA shown in SEQ ID No. 18, or the siRNA sequence of the B7-H4 gene with the sense chain as SEQ ID No. 19 and the antisense chain as SEQ ID No. 26.

[0094] The present disclosure provides a method for preparing the above-mentioned drug-lipid particles, wherein the drug is encapsulated in metal-phospholipid complex particles to obtain the drug-lipid particles.

[0095] Furthermore, the metal-phospholipid complex, the conjugated lipid that inhibits particle aggregation, and the non-cationic lipid or non-ionizable lipid are dissolved in an organic compound to form an organic phase, the drug is dissolved in a buffer solution to form an aqueous phase, and the organic phase and the aqueous phase are mixed to obtain drug-lipid particles.

[0096] Furthermore, the organic compound is ethanol.

[0097] Furthermore, the buffer is enzyme-free PBS buffer.

[0098] Furthermore, the mixing method of the organic phase and the aqueous phase includes a microfluidic chip or ultrasound.

[0099] Furthermore, (a) the drug, (i) the metal-phospholipid complex, (ii) the conjugated lipid for inhibiting particle aggregation, and (iii) the non-cationic lipid or the non-ionizable lipid are mixed to obtain the drug-lipid particle.

[0100] The present disclosure provides the use of the aforementioned metal-phospholipid complex in a nucleic acid delivery system. Furthermore, the nucleic acid delivery system is used to introduce a nucleic acid into a cell. Furthermore, the nucleic acid is used to silence the expression of a target sequence in a mammalian subject, to deliver a drug in vivo, to deliver a drug from within a mammal to a mammalian cell, or to treat a disease or condition in a mammal.

[0101] The present disclosure provides the use of the aforementioned metal-phospholipid complex particles or drug-lipid particles in a composition for drug delivery. Furthermore, the composition is used to introduce the drug into cells. The composition is a pharmaceutical agent. Furthermore, the pharmaceutical agent is used to silence the expression of a target sequence in a mammalian subject, to deliver a drug in vivo in a mammal, to deliver a drug from the body to mammalian cells, or to treat a disease or condition in a mammal.

[0102] The present disclosure provides use of the above-mentioned metal-phospholipid complex or metal-phospholipid complex particles or drug-lipid particles or agents in preventing / treating diseases or disorders in mammals.

[0103] In the above technical solution, further, the mammal is a human. Further, the disease or condition is associated with the expression of a gene, and the gene contains a target sequence for the drug. Further, the disease or condition includes cancer, viral infection, autoimmune disease, diabetes or Alzheimer's disease. Further, the viral infection includes hepatitis A, hepatitis B, hepatitis C, SARS-Cov-2 (2019 novel coronavirus), HIV (AIDS virus), HPV (human papillomavirus), influenza, smallpox or syphilis. Further, the cancer includes liver cancer, glioma, melanoma, lung cancer, pancreatic cancer or breast cancer.

[0104] Furthermore, the drug is a vaccine. Furthermore, the administration route of the drug includes intrathecal injection, intramuscular administration, intracranial injection, intravenous injection or intratumoral injection.

[0105] A pharmaceutical agent containing the metal-phospholipid complex or metal-phospholipid complex particles or drug-lipid particles disclosed herein.

[0106] Furthermore, the medicine is a vaccine.

[0107] Furthermore, the vaccine is a new coronavirus vaccine.

[0108] Compared with the prior art, the present invention has the following beneficial effects:

[0109] The metal-phospholipid complex provided by the present invention mainly functions to adsorb negatively charged drugs, and self-assembles with other lipids into metal-phospholipid complex particles (MPP). While ensuring an effectiveness no less than that of LNPs based on cationic lipids and / or ionizable lipids, cationic lipids and ionizable lipids are not used. Therefore, compared with LNPs, the toxicity is greatly reduced, the biosafety is significantly improved, and it is more conducive to the delivery of negatively charged drugs in vivo. BRIEF DESCRIPTION OF THE DRAWINGS

[0110] In order to more clearly illustrate the specific embodiments of the present disclosure or the technical solutions in the prior art, the drawings required for use in the specific embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0111] Figure 1-1 is an example of eGFP-mRNA@MPP (Fe 3+ ) The percentage of eGFP-positive cells caused by 293T transfection;

[0112] Figure 1-2 is a diagram of RBD-mRNA@MPP(Fe 3+ ) RBD expression level caused by 293T transfection;

[0113] Figure 1-3 is an RBD-mRNA@MPP(Fe 3+ ) ability to induce humoral immunity;

[0114] Figures 1-4 are NY-ESO-1-mRNA@MPP(Fe 3+ ) ability to induce humoral immunity;

[0115] Figure 1-5 is an RBD-mRNA@MPP(Fe 3+ ) ability to induce cellular immunity;

[0116] Figures 1-6 are NY-ESO-1-mRNA@MPP(Fe 3+ ) ability to induce cellular immunity;

[0117] Figures 1-7 are diagrams of eGFP-mRNA@MPP (Al 3+ ) The percentage of eGFP-positive cells caused by 293T transfection;

[0118] Figures 1-8 are RBD-mRNA@MPP (Al 3+ ) RBD expression level caused by 293T transfection;

[0119] Figure 1-9 is an RBD-mRNA@MPP (Al 3+ ) ability to induce humoral immunity;

[0120] Figure 1-10 is NY-ESO-1-mRNA@MPP (Al 3+ ) ability to induce humoral immunity;

[0121] Figure 1-11 is an RBD-mRNA@MPP (Al 3+ ) ability to induce cellular immunity;

[0122] Figure 1-12 is NY-ESO-1-mRNA@MPP (Al 3+ ) ability to induce cellular immunity;

[0123] Figure 1-13 is a diagram of Bcl-2-siRNA@MPP(Fe 3+ ) ability to silence target genes;

[0124] Figure 1-14 is a diagram of PLK1-siRNA@MPP(Fe 3+ ) ability to silence target genes;

[0125] Figure 1-15 is a Gal-1-siRNA@MPP(Fe 3+ ) ability to silence target genes;

[0126] Figure 1-16 is a diagram of Bcl-2-siRNA@MPP (Al 3+ ) ability to silence target genes;

[0127] Figure 1-17 is a diagram of PLK1-siRNA@MPP (Al 3+ ) ability to silence target genes;

[0128] Figure 1-18 is a Gal-1-siRNA@MPP (Al 3+ ) ability to silence target genes;

[0129] Figure 1-19 is a diagram of STAT3-ASO@MPP (Fe 3-ASO) provided in Example 3.7.1 of the present disclosure. 3+ ) the ability to silence target genes in cells;

[0130] Figure 1-20 is a diagram of α-syn-ASO@MPP(Fe 3+ ) the ability to silence target genes in cells;

[0131] Figure 1-21 is a diagram of Bcl-2-ASO@MPP(Fe 3+ ) the ability to silence target genes in cells;

[0132] Figure 1-22 is a diagram of STAT3-ASO@MPP (Al 3+ ) the ability to silence target genes in cells;

[0133] Figure 1-23 is a diagram of α-syn-ASO@MPP (Al 3+ ) the ability to silence target genes in cells;

[0134] Figure 1-24 is a diagram of Bcl-2-ASO@MPP (Al 3+ ) the ability to silence target genes in cells;

[0135] Figure 1-25 is a diagram of S-mRNA@MPP(Fe 3+ ) Expression level of S protein caused by transfection of 293T cells;

[0136] Figure 1-26 shows the drug (dsDNA and ssDNA)-lipid particles (Fe 3+ ) function;

[0137] Figure 1-27 is a diagram of S-mRNA@MPP (Al3+ ) Expression level of S protein caused by transfection of 293T cells;

[0138] Figure 1-28 is a diagram of the drug (dsDNA and ssDNA)-lipid particles (Al 3+ ) function;

[0139] FIG2-1 is a differential scanning calorimetry diagram of the phospholipid complex provided in Example 4.1 of the present disclosure;

[0140] Figure 2-2 is a metal-phospholipid complex (Fe 3+ )’s UV absorption pattern;

[0141] Figure 2-3 is a metal-phospholipid complex (Al 3+ )’s UV absorption pattern;

[0142] Figure 2-4 is a graph showing the Fe 3+ characterization of shedding from metal-phospholipid complexes;

[0143] Figure 2-5 shows the drug-metal-phospholipid complex particles (Fe 3+ ) elemental analysis;

[0144] Figure 2-6 shows the drug-metal-phospholipid complex particles (Al 3+ ) Electron microscopic analysis of MPP;

[0145] Figures 2-7 show the efficiency of nucleic acid (mRNA and siRNA) encapsulation by drug-lipid particles provided in Example 7 of the present disclosure;

[0146] Figures 2-8 show the nucleic acid lysosomal escape ability of siRNA / mRNA@MPP and siRNA / mRNA@LNP provided in Example 8 of the present disclosure;

[0147] Figure 2-9 shows the eGFP-positive cell rates of MPP and LNP provided in Example 9 of the present disclosure;

[0148] Figure 2-10 is a comparison of the ability of MPP and LNP to promote mRNA expression provided in Example 10 of the present disclosure;

[0149] Figure 2-11 is a comparison of the ability of MPP and LNP to promote humoral immunity provided in Example 10 of the present disclosure;

[0150] Figure 2-12 is a comparison of the ability of MPP and LNP to promote cellular immunity provided in Example 10 of the present disclosure;

[0151] FIG3-1 shows the effect of intratumoral injection of drug-metal-phospholipid complex particles provided in Example 13 of the present disclosure on the treatment of liver cancer. DETAILED DESCRIPTION

[0152] definition

[0153] For ease of explanation, the specific terms described in this specification, the embodiments and the appended claims are collectively described here. Unless otherwise defined in this specification, the meaning of the scientific and technical terms used herein is the same as that understood and used by those with ordinary knowledge in the technical field to which the present disclosure belongs. In addition, unless the context requires otherwise, it should be understood that singular terms should include the same plural form, and plural terms should include the singular. Specifically, unless the context clearly indicates otherwise, the terms "at least one (kind)" and "one (kind) or more" used herein and in the appended claims include one (kind), two (kinds), three (kinds) or more (kinds).

[0154] Although the numerical ranges and parameters used to define the broader scope of this disclosure are approximate, the numerical values ​​of the specific examples are presented herein as precisely as possible. However, any numerical value inherently contains standard deviations that are inherent to individual testing methods. As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "about" means that the actual value falls within an acceptable standard error of the mean, as determined by one of ordinary skill in the art to which this disclosure relates. Except in the experimental examples, or unless otherwise expressly indicated, all ranges, amounts, values, and percentages used herein (e.g., to describe material amounts, time periods, temperatures, operating conditions, quantitative ratios, and the like) are to be understood as modified by the word "about." Therefore, unless otherwise indicated, the numerical parameters disclosed in this specification and the accompanying claims are approximate and are subject to change as needed. At a minimum, these numerical parameters should be understood to include the number of significant digits indicated and to apply normal rounding.

[0155] The term "lipid" refers to a group of organic compounds that include, but are not limited to, lipids of fatty acids. They are generally divided into three categories: "simple lipids," "compound lipids," and "derivative lipids." "Simple lipids" include fats and oils, as well as waxes; "compound lipids" include phospholipids and glycolipids; and "derivative lipids" include steroids.

[0156] The term "lipid vesicle" refers to any lipid composition that can be used to deliver a compound, including, but not limited to, liposomes, in which an aqueous volume is encapsulated by an amphiphilic lipid bilayer; or in which lipids encapsulate an interior containing macromolecular components, such as mRNA, with a reduced aqueous interior; or lipid aggregates or micelles, in which the encapsulated components are contained in a relatively chaotic lipid mixture. Herein, metal-phospholipid complex particles (MPPs) are "lipid vesicles," and drugs, such as nucleic acid mRNA, are encapsulated in MPPs as encapsulated components, and the "encapsulation" can be full encapsulation and / or partial encapsulation.

[0157] The term "phospholipid" refers to lipids containing phosphate groups. These complex lipids are also known as phospholipids or phospholipids. Phospholipids are the primary components of biological membranes and are divided into two main categories: glycerophospholipids and sphingomyelins, composed of glycerol and sphingosine, respectively. Phospholipids are amphiphilic molecules, with a hydrophilic, nitrogen- or phosphorus-containing head at one end and a long, hydrophobic (lipophilic) hydrocarbon chain at the other. Because of this, phospholipid molecules are positioned close together at their hydrophilic and hydrophobic ends, often forming the phospholipid bilayer, the structure of the cell membrane, along with other molecules such as proteins, glycolipids, and cholesterol.

[0158] The phrase "phospholipid molecule portion" herein refers to the structure originally belonging to the phospholipid molecule after the phospholipid molecule reacts with other substances.

[0159] The phrase "part of a linker molecule" as used herein refers to a structure that originally belongs to the linker molecule after the linker molecule reacts with other substances.

[0160] The phrase "metal ion moiety" herein refers to the structure originally belonging to the metal ion after the metal ion moiety reacts with other substances.

[0161] The phrase "phospholipid complex" herein refers to a complex formed by reacting and linking the above-mentioned phospholipid molecule portion having a phosphate group with the above-mentioned linker molecule portion.

[0162] The phrase "metal-phospholipid complex" herein refers to a complex composed of the above-mentioned phospholipid molecule portion having a phosphate group, the above-mentioned linker molecule portion, and the above-mentioned metal ion portion, wherein the above-mentioned phospholipid molecule portion is connected to the above-mentioned linker molecule portion, and the above-mentioned linker portion is connected to the above-mentioned metal ion portion through a coordination bond, and the metal-phospholipid complex is neither a cationic lipid nor an ionizable lipid.

[0163] The term "ionizable lipid" refers to a lipid containing a positively charged ionizable amine group that can be protonated to become positively charged at lower pH values ​​but is uncharged at physiological pH conditions.

[0164] The term "neutral lipid" refers to any of a number of lipid species that exist in an uncharged or neutral zwitterionic form at a selected pH. At physiological pH, such lipids include, for example, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, cephalin, cholesterol, cerebrosides, and diacylglycerol.

[0165] The term "anionic lipid" refers to any lipid that is negatively charged at physiological pH. These lipids include, but are not limited to, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-lauroylphosphatidylethanolamine, N-succinylphosphatidylethanolamine, N-glutarylphosphatidylethanolamine, lysylphosphatidylglycerol, palmitoyloleoylphosphatidylglycerol (POPG), and other anionic groups attached to neutral lipids.

[0166] The term "cationic lipid" refers to any of a number of lipid species that carry a net positive charge at a selected pH, such as physiological pH. These lipids include, but are not limited to, N,N-dioleyl-N,N-dimethylammonium chloride ("DODAC"); N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride ("DOTMA"); N,N-distearyl-N,N-dimethylammonium bromide ("DDAB"); N-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride ("DOTAP"); 3-(N-(N',N'-dimethylaminoethane)carbamoyl)cholesterol ("DC-Chol") and N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide ("DMRIE"). The following lipids are cationic and have a positive charge below physiological pH: DODAP, DODMA, DMDMA, etc.

[0167] The term "hydrophobic lipid" refers to a compound having a non-polar group, including, but not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups, and these groups are optionally substituted with one or more aromatic, alicyclic or heterocyclic groups. Suitable examples include, but are not limited to, diacylglycerols, dialkylglycerols, NN-dialkylamino, 1,2-diacyloxy-3-aminopropane and 1,2-dialkyl-3-aminopropane.

[0168] The term "non-cationic lipid or non-ionizable lipid" refers to a lipid that is neither a cationic lipid nor a non-ionizable lipid, and may be, for example, an anionic lipid or a neutral lipid.

[0169] Among the components of the metal-phospholipid complex particles, the "non-cationic lipids or non-ionizable lipids other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation" in (iii) refers to the lipids remaining in the metal-phospholipid complex particles after excluding the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation.

[0170] The term "fusogenicity" refers to the ability of a liposome, drug-lipid particle or other drug delivery system to fuse with a cell membrane. The membrane may be the plasma membrane or the membrane surrounding a cell organelle, such as an endosome, nucleus, or the like.

[0171] In the metal-phospholipid complex particles, non-cationic lipids or non-ionizable lipids other than the metal-phospholipid complex and the conjugated lipids that inhibit particle aggregation are primarily present as vesicle-forming lipids, and the term "vesicle-forming lipid" is intended to include any amphiphilic lipid having a hydrophobic portion and a polar head group and which can spontaneously form bilayer vesicles in water, exemplified by most phospholipids.

[0172] In the metal-phospholipid complex particles, the conjugated lipids that inhibit particle aggregation are primarily present as vesicle-adopting lipids. The term "vesicle-adopting lipid" is intended to include any amphiphilic lipid that stably associates with the lipid bilayer, as well as other amphiphilic lipids whose hydrophobic portion contacts the inner, hydrophobic region of the bilayer membrane and whose polar head group portion faces the outer, polar surface of the membrane. Vesicle-adopting lipids include lipids that are independently capable of adopting a non-lamellar phase and are also capable of adopting a bilayer structure in the presence of a bilayer-stabilizing component. Conjugated lipids that inhibit drug-lipid particle aggregation include, but are not limited to, polyamide oligomers (e.g., ATTA-lipid derivatives), peptides, proteins, detergents, lipid derivatives, PEG-lipid derivatives such as PEG conjugated to dialkoxypropyl groups, PEG conjugated to diacylglycerols, PEG conjugated to phosphatidylethanolamine, and PEG conjugated to ceramide (see, U.S. Patent No. 5,885,613, incorporated herein by reference).

[0173] The term "amphiphilic lipid" refers to any suitable material, wherein the hydrophobic portion of the lipid material is oriented toward the hydrophobic phase, while the hydrophilic portion is oriented toward the aqueous phase. Amphiphilic lipids are typically the main components of lipid vesicles. The hydrophilic nature comes from the presence of polar or charged groups such as carbohydrates, phosphates, carboxyls, sulfates, aminos, sulfhydryls, nitros, hydroxyls, and other similar groups. Hydrophobicity can be imparted by the inclusion of non-polar groups, including, but not limited to, long-chain saturated and unsaturated aliphatic hydrocarbon groups and such groups substituted by one or more aromatic, alicyclic, or heterocyclic groups. Examples of amphiphilic compounds include, but are not limited to, phospholipids, amino lipids, and sphingolipids. The representative examples of phospholipid include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine, dipalmitoylphosphatidylcholine, dioleoylphosphatidylcholine, distearoylphosphatidylcholine or dilinoleoylphosphatidylcholine. Other compounds lacking phosphorus are also in the group that is called as amphipathic lipid such as sphingomyelin, sphingosylglycolipid family, diacylglycerol and beta-acyloxy acid. In addition, above-mentioned amphipathic lipid can be mixed with other lipid, and this lipid comprises triglyceride and sterol.

[0174] The term "diacylglycerol" refers to a compound having a 2-fatty acyl chain, wherein R1 and R2 each independently have 2 to 30 carbon atoms bonded to the 1- and 2-positions of glycerol via ester bonds. The acyl groups may be saturated or have varying degrees of unsaturation. Diacylglycerol has the following formula 54:

[0175] The term "diacylglycerol-conjugated polyethylene glycol" refers to the conjugated lipid that inhibits particle aggregation in the present disclosure, which can be a diacylglycerol-conjugated polyethylene glycol, i.e., a diacylglycerol-polyethylene glycol conjugate (DAG-PEG conjugate or PEG-DAG conjugate). In a preferred embodiment, the DAG-PEG conjugate is a dilaurylglycerol (C12)-PEG conjugate, a ditetradecylglycerol (C14)-PEG conjugate (DMG), a dipalmitoylglycerol (C16)-PEG conjugate, or a distearylglycerol (C18)-PEG conjugate (DSG). Those skilled in the art will readily understand that other diacylglycerols can be used in the DAG-PEG conjugates of the present disclosure. Suitable DAG-PEG conjugates for use in the present disclosure and methods of making and using them are disclosed in U.S. Application No. 10 / 136,707, published as USPA 2003 / 0077829, and PCT Patent Application No. CA 02 / 00669, each of which is incorporated by reference in its entirety.

[0176] The term "dialkoxypropyl" refers to a compound having a 2-alkyl chain, wherein R1 and R2 each independently have 2 to 30 carbon atoms. The alkyl group may be saturated or have varying degrees of unsaturation. Dialkoxypropyl has the following formula 55:

[0177] The term "dialkoxypropyl-coupled PEG" refers to the conjugated lipid that inhibits particle aggregation in the present disclosure, which can be a dialkoxypropyl-coupled PEG, i.e., a dialkoxypropyl conjugate (PEG-DAA conjugate). In a preferred embodiment, the PEG-DAA conjugate has the following formula 56:

[0178] In Formula 56, R1 and R2 are independently selected and are long-chain alkyl groups having from about 10 to about 22 carbon atoms. The long-chain alkyl group may be saturated or unsaturated. Suitable alkyl groups include, but are not limited to, lauryl (C12), tetradecyl (C14), hexadecyl (C16), octadecyl (C18), and icosyl (C20). In a preferred embodiment, R1 and R2 are the same, i.e., both R1 and R2 are tetradecyl (i.e., dioctadecyl), both R1 and R2 are octadecyl (i.e., dioctadecyl), etc. In Formula 56, PEG is a polyethylene glycol having an average molecular weight of from about 550 to about 10,000 daltons and is optionally substituted at the terminal hydroxyl position by an alkyl, alkoxy, acyl, or aryl group. In a preferred embodiment, PEG has an average molecular weight of from about 1,000 to about 5,000 daltons, more preferably, an average molecular weight of from about 1,000 to about 3,000 daltons, and even more preferably, an average molecular weight of about 2,000 daltons. PEG can be optionally substituted with alkyl, alkoxy, acyl, or aryl groups. In Formula 56, L is a linker moiety. Any linker moiety suitable for coupling PEG to the dialkoxypropyl backbone can be used. Suitable linker moieties include, but are not limited to, amido (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), carbonate (OC(O)O-), carbamate (-NHC(O)O-), urea (-NHC(O)NH-), succinyl (-(O)CCH2CH2C(O)-), ethers, disulfides, and combinations thereof. Other suitable linkers are well known in the art.

[0179] Phosphatidylethanolamine can be conjugated to polyethylene glycol to form a bilayer stabilizing component as a conjugated lipid that inhibits particle aggregation in the present disclosure. The phosphatidylethanolamine has various acyl chain groups with different chain lengths and degrees of saturation. These phosphatidylethanolamines are commercially available or can be isolated or synthesized using conventional techniques known to those skilled in the art. Phosphatidylethanolamines containing saturated or unsaturated fatty acids are preferred, having a carbon chain length in the range of C10-C20. Phosphatidylethanolamines with mono- or di-unsaturated fatty acids and mixtures of saturated and unsaturated fatty acids can also be used. Suitable phosphatidylethanolamines include, but are not limited to, the following: dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE) and distearoylphosphatidylethanolamine (DSPE).

[0180] Like phosphatidylethanolamine, ceramide can be coupled with polyethylene glycol to form a bilayer stabilizing component as a conjugated lipid that inhibits particle aggregation in the present disclosure. The ceramide has multiple acyl chain groups with different chain lengths and degrees of saturation. It should be clear to those skilled in the art that, compared to phosphatidylethanolamine, ceramide has only one acyl group, which can be easily varied according to its chain length and degree of saturation. Ceramides suitable for use in accordance with the present disclosure are commercially available. In addition, ceramides can be isolated, for example, from eggs and brain using well-known separation techniques, or synthesized using the methods and techniques disclosed in U.S. Patent No. 5,820,873, which is incorporated herein by reference. Using the synthetic pathways proposed in the aforementioned applications, ceramides with saturated or unsaturated fatty acids can be prepared, wherein the fatty acids have carbon chain lengths ranging from C2 to C31.

[0181] The term "ATTA" or "polyamide" refers to, but is not limited to, compounds disclosed in U.S. Patent Nos. 6,320,017 and 6,586,559, both of which are incorporated herein by reference. These compounds include compounds having the following formula 57:

[0182] wherein: R is a member selected from the group consisting of hydrogen, alkyl, and acyl; R1 is a member selected from the group consisting of hydrogen and alkyl; or optionally, R and R1 and the nitrogen atom to which they are bound form an azido moiety; R2 is a member selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl, and an amino acid side chain; R3 is a member selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, thiol, hydrazine, amino, and NR4R5, wherein R4 and R5 are independently hydrogen or alkyl; n is 4-80; m is 2-6; p is 1-4; and q is 0 or 1. It will be apparent to those skilled in the art that other polyamides can be used in the compounds of the present disclosure.

[0183] The term "congener" refers to an analog that performs the same or similar function, or a derivative of the same parent core that performs the same or similar function.

[0184] As used herein, the terms "mRNA" or "messenger polyribonucleotide" or "messenger RNA" or "messenger RNA" are used interchangeably and refer to a single-stranded polyribonucleotide that is transcribed using one strand of DNA as a template, carries genetic information, and can direct protein synthesis.

[0185] As used herein, the terms "sgRNA," "small guide RNA," "guide RNA," or "gRNA" are used interchangeably and are small noncoding RNAs that pair with pre-mRNAs to guide the insertion or deletion of uridine residues into kinetoplastids during RNA editing. gRNAs edit RNA molecules, approximately 60-80 nucleotides in length, transcribed from separate genes.

[0186] As used herein, the terms "circRNA" or "circular RNA" or "cyclic polyribonucleotide" or "circular RNA" are used interchangeably and refer to a polyribonucleotide molecule having a structure without free ends (i.e., without free 3' and / or 5' ends), such as a polyribonucleotide that forms a ring or annular structure through covalent or non-covalent bonds.

[0187] As used herein, the terms "microRNA" or "miRNA" or "microRNA" are used interchangeably and refer to a non-coding single-stranded polyribonucleotide of approximately 22 nucleotides in length with free 3' and 5' ends, which can inhibit the translation of target gene protein by binding to the 3'-untranslated region (3'-UTR) of the mRNA of the target gene, thereby regulating the biological function of the cell.

[0188] As used herein, the terms "ASO" or "antisense oligonucleotide" or "antisense oligonucleotide" are used interchangeably and refer to artificially synthesized nucleic acid fragments that are complementary to a certain segment of a target gene or mRNA, and can bind to the target gene / mRNA through the principle of base complementarity, thereby blocking the expression of the gene, including antisense DNA and antisense RNA.

[0189] As used herein, the terms "siRNA" or "small interfering" or "short interfering" or "silencing RNA" or "small interfering RNA" or "short interfering RNA" or "silencing RNA" are used interchangeably and refer to a class of double-stranded RNA molecules with a length of 20 to 25 nucleotides that can induce the degradation of target gene mRNA.

[0190] As used herein, the terms "ecDNA" or "extrachromosomal circular DNA" are used interchangeably and refer to DNA that has fallen off chromosomes and exists in a circular structure.

[0191] The term "nucleic acid derivative" refers to a modification or replacement of a nucleic acid sequence, including but not limited to chemical modification of residues, replacement of nucleotides or deoxynucleotides, modification of the sequence to increase half-life or stability, and labeling modification. For example, chemical modification includes but is not limited to phosphorylation, methylation, amination, sulfhydrylation, replacement of oxygen with sulfur, replacement of oxygen with selenium, or isotopization of any one or more bases. Replacement of nucleotides or deoxynucleotides includes but is not limited to nucleic acid analogs that replace the sugar-phosphate backbone with polypeptides or other backbones (replacing DNA or RNA with PNA). Modifications to sequences that increase half-life or stability include but are not limited to modification with PEG linkage and fluorine modification. Labeling modification includes but is not limited to connection to fluorescent groups, amino groups, biotin, digoxigenin, small peptides, etc.

[0192] The term "artificial nucleic acid" refers to a nucleic acid molecule that has been artificially modified, including but not limited to base modifications, ribose modifications, PNA, etc.

[0193] The term "nucleic acid" refers to a polymer that exists in a single or double-stranded form and comprises at least two deoxynucleotides or nucleotides. Unless specifically limited, the term encompasses nucleic acids comprising known analogs of natural nucleotides that have binding properties similar to reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise noted, specific nucleic acid sequences also implicitly encompass variants (e.g., degenerate codon substitutions), alleles, orthologues, SNPs, and complementary sequences, as well as sequences clearly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed bases and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Cassol et al. (1992); Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). A "nucleotide" comprises the sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. The nucleotides are linked via the phosphate group. "Bases" include purines and pyrimidines, which further include the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and natural analogs, as well as synthetic derivatives of purines and pyrimidines, including, but not limited to, modifications that substitute new reactive groups such as, but not limited to, amines, alcohols, thiols, carboxylates, and alkyl halides. DNA can be present as antisense, plasmid DNA, portions of plasmid DNA, pre-compressed DNA, products of polymerase chain reaction (PCR), vectors (P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives of these groups. The term nucleic acid is used interchangeably with gene, cDNA, mRNA encoded by a gene, and interfering RNA molecules.

[0194] The term "gene" refers to a nucleic acid (e.g., DNA or RNA) sequence that includes a partial or full-length coding sequence necessary for the production of a polypeptide or polypeptide precursor (e.g., a polypeptide or polypeptide precursor from hepatitis A, B, C, D, E, G virus; or herpes simplex virus).

[0195] As used herein, "gene product" refers to the product of a gene such as, but not limited to, the transcript of DNA, mRNA.

[0196] The phrase "silencing the expression of the target gene" refers to the ability of the disclosed siRNA to initiate the silencing of the target gene. In order to determine the extent of gene silencing, a sample or assay of cells in the target organism or culture is compared with a control sample, wherein the cells of the target organism or culture express a specific construct and the control does not express the construct. The control sample (lacking expression of the construct) is set to a relative value of 100%. When the test value relative to the control is about 90%, preferably 50%, more preferably 25%-0%, the inhibition of the expression of the target gene is successfully obtained. Suitable assays include, for example, using techniques known to those skilled in the art such as dot blots, Northern blotting, in situ hybridization, ELISA, immunoprecipitation, enzyme action, and phenotypic assays known to those skilled in the art to detect protein or mRNA levels.

[0197] A "therapeutically effective amount" or "effective amount" of siRNA is an amount sufficient to produce the desired effect, eg, a decrease in expression of the target sequence as compared to normal expression levels detected in the absence of the siRNA.

[0198] As used herein, the term "aqueous solution" refers to a composition that comprises, in whole or in part, water.

[0199] As used herein, the term "organic lipid solution" refers to a composition comprising in whole or in part an organic solvent with lipids.

[0200] As used herein, "systemic delivery" refers to the delivery that causes a compound to be widely biodistributed in an organism. Some techniques of administration can result in systemic delivery of certain compounds, but cannot result in systemic delivery of other compounds. Systemic delivery refers to effective, preferably therapeutic, contact of a compound with a large portion of the body. In order to obtain a wide range of biodistribution, a blood survival period is generally required so that the compound is not rapidly degraded or cleared (such as by initially passing through an organ (liver, lung, etc.) or by rapid, nonspecific cell binding) before reaching the disease site at the distal end of the administration site. Systemic delivery of drug-lipid particles can be carried out in any manner known in the art, including, for example, intravenous, subcutaneous, intraperitoneal, and in a preferred embodiment, systemic delivery of drug-lipid particles is by intravenous delivery.

[0201] As used herein, "local delivery" refers to the delivery of a compound directly to a target site in the body. For example, a compound can be delivered locally by direct injection into a disease site such as a tumor or other target site such as an inflammatory site or a target organ such as the liver, heart, pancreas, kidney, etc.

[0202] Metal-phospholipid complexes

[0203] In the present disclosure, the metal-phospholipid complex is composed of a phospholipid molecule portion, a linker molecule portion, and a metal ion portion.

[0204] Regarding the phospholipid molecule, it should be noted that the cis-trans isomers of the phospholipid molecule disclosed herein will not affect the effects to be achieved by the protection content of the disclosure.

[0205] As for the linker molecule, it is mainly derived from natural plant extracts, such as curcumin, which has a wide range of biological effects, including antibacterial, antiviral, antifungal, antioxidant and anti-inflammatory activities. In addition, it is also an effective immunomodulator that can regulate the activity of various immune cells such as T cells, B cells, macrophages, neutrophils, natural killer cells and dendritic cells, promote the balance of immunity, and enhance the body's immunity. Based on the potential immune-enhancing, anti-inflammatory, antioxidant and anti-SARS-CoV-2 effects of curcumin molecules, it is expected to become a potential auxiliary treatment for COVID-19. In addition, the safety of curcumin molecules is extremely high and has been listed in the catalog of food additives and pharmaceutical excipients. Its safety is conducive to the clinical drug registration of the drug-lipid as a whole, shortening the length of clinical drug registration.

[0206] Regarding the metal ion portion, the coordination bond between the linker molecule portion and the metal ion portion in the metal-phospholipid complex will break under low pH conditions such as lysosomes (pH = 5.0), and the metal ion will fall off from the metal-phospholipid complex.

[0207] The ratio of each component in the metal-phospholipid complex can be adjusted based on the structure of the specific metal-phospholipid complex components. The basis for this adjustment is that because the phospholipid molecule and the linker molecule are connected by hydrogen bonds, as long as the phospholipid molecule contains multiple phosphate groups, the ratio of the phospholipid molecule to the linker molecule can be adjusted according to the number of phosphate groups contained in the phospholipid molecule during the synthesis of the phospholipid complex. That is, when the phospholipid molecule contains two phosphate groups, the ratio of the phospholipid molecule to the linker molecule can be adjusted to 1:2; when the phospholipid molecule contains three phosphate groups, the ratio of the phospholipid molecule to the linker molecule can be adjusted to 1:3. Because the hydroxyl group of the linker molecule is connected to the metal ion by coordination bonds, as long as the linker molecule contains multiple binding sites, the ratio of the linker molecule to the metal ion can be adjusted according to the number of binding sites contained in the linker.

[0208] Phospholipid molecules with phosphate groups are first linked to linker molecules to form a phospholipid complex, which is then linked to metal ions to form a metal-phospholipid complex. Specifically, the phospholipid molecules and linker molecules are dissolved in an appropriate amount of ethanol at a molar ratio, reacted at approximately 65°C, and then precipitated by adding n-hexane to form the phospholipid complex. The phospholipid complex is then dissolved in an appropriate amount of ethanol at a molar ratio with metal ions (such as FeCl3) and reacted at approximately 60°C to form the metal-phospholipid complex.

[0209] Metal-chelated phospholipid complex nanoparticles (MPP)

[0210] The principle of loading nucleic acids onto metal-phospholipid complex particles assembled from metal-phospholipid complexes is as follows: the linker molecule is bound to the phospholipid molecule through hydrogen bonds, while the linker molecule is connected to the metal ion through a coordination bond, forming a metal-phospholipid complex. The metal ion of the metal-phospholipid complex is connected to the negatively charged drug through a coordination bond, thereby ensuring that the metal-phospholipid complex and other components (conjugated lipids that inhibit particle aggregation, and non-cationic lipids or non-ionizable lipids other than the metal-phospholipid complex and the conjugated lipids that inhibit particle aggregation) self-assemble into MPPs while simultaneously loading the negatively charged drug into the nanoparticle MPPs. In this article, the "non-cationic lipids or non-ionizable lipids other than the metal-phospholipid complex and the conjugated lipids that inhibit particle aggregation" refers to component (iii) in the metal-phospholipid complex particles.

[0211] In some embodiments, the conjugated lipid that inhibits particle aggregation refers to a conjugated lipid that inhibits drug-lipid particle aggregation, and its main function is to prevent the aggregation of drug-lipid particles, such as PEG coupled to a dialkoxypropyl group, PEG coupled to diacylglycerol, PEG coupled to phosphatidylethanolamine, and PEG conjugated to ceramide, preferably a PEG-lipid conjugate. In this case, the cis-trans isomers of the lipid will not affect the effect to be achieved by the content of the present disclosure.

[0212] In some embodiments, the molar proportion of the metal-phospholipid complex in the raw material is 5% to less than 10%, 10% to 40%, or greater than 40% to 50%, for example, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% or 50%.

[0213] In a preferred embodiment, the molar proportion of the metal-phospholipid complex in the raw material is 7% to 40%, for example, it can be 10% to 40%, 7% to 30%, 15% to 25%, 20% to 30%, and more preferably 15%, 25%, 7% or 30%.

[0214] In some embodiments, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 2% to 10%, for example, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%. For example, it can be 3% to 10%, 4% to 10%, 5% to 10%, and more preferably 3%, 4% or 10%.

[0215] In some embodiments, the non-cationic lipid or non-ionizable lipid is cholesterol, and the molar proportion of cholesterol in the raw material is 15% to less than 35%, 35% to 75%, or greater than 75% to 80%, for example, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, %, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79% or 80%. For example, it can be 35% to 75%, 15% to 56%, 40% to 46% and 35% to 55%, preferably 15%, 40%, 46% or 56%.

[0216] In some embodiments, in addition to cholesterol, the metal-phospholipid complex particles may optionally contain other non-cationic lipids or non-ionizable lipids, which may account for 0% to 40% or more than 40% to 51% by mole in the raw material, for example, 0%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 111 %, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50% or 51%. For example, 5% to 30%, 25% to 35%, 34% to 45%, 20% to 25%, preferably 25%, 35%, 34% or 45%.

[0217] Drug-lipid particles

[0218] The drug-lipid particles described herein typically include a drug (which is a negatively charged molecule, which can be selected from the group consisting of one or more combinations of nucleic acids, proteins, polypeptides, small molecules, nucleic acid analogs, protein analogs, polypeptide analogs, nucleic acids selected from the group consisting of one or more combinations of mRNA, siRNA, circular RNA, microRNA, DNA, ecDNA, artificial nucleic acids), a metal-phospholipid complex, a non-cationic lipid or non-ionizable lipid, and a bilayer stabilizing component, such as a conjugated lipid that inhibits particle aggregation. In addition, the nucleic acids encapsulated in the drug-lipid particles of the present disclosure are resistant to degradation by nucleases in aqueous solution.

[0219] In some embodiments, the drug is fully encapsulated inside the metal-phospholipid complex particles to avoid drug degradation, thereby achieving drug delivery into cells.

[0220] In some embodiments, the drug-lipid particles provided by the present disclosure have a small diameter suitable for systemic delivery, with a particle size of 30 to 400 nm; a surface potential of -10 to 10 mV; stability of at least 3 days, preferably more than 7 days; and a cell delivery efficiency of at least 40%, for example, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%.

[0221] In some embodiments, the drug of the drug-lipid particle is preferably a nucleic acid, and the nucleic acid component typically includes mRNA, interfering RNA (i.e., siRNA), which can be provided in several forms, including, for example, one or more isolated small interfering RNA (siRNA) duplexes, longer double-stranded RNA (dsRNA), or siRNA or dsRNA translated from a transcription cassette in a DNA plasmid.

[0222] The RNA population can be used to provide long precursor RNAs, or long precursor RNAs having substantial or complete identity to a selected target sequence that can be used to prepare siRNA. The RNAs can be isolated, synthesized, and / or cloned from cells or tissues according to methods well known to those skilled in the art. The RNA can be a mixed population (obtained from cells or tissues, transcribed from cDNA, etc.), or can represent a single target sequence. The RNA can be naturally occurring, for example, isolated from a tissue or cell sample, for example, synthesized in vitro using T7 or SP6 polymerase and PCR products or cloned cDNA; or chemically synthesized.

[0223] To form long dsRNA, for synthetic RNAs, the complement can also be transcribed in vitro and hybridized to form dsRNA. If a naturally occurring RNA population is used, for example, by transcribing cDNAs corresponding to the RNA population, or by using RNA polymerase, RNA complements are also provided (e.g., to form dsRNA, which is digested by E. coli RNAse III or Dicer). The precursor RNA is then hybridized to form double-stranded RNAs and digested. The dsRNAs can be directly encapsulated in SNALPs or can be digested in vitro before encapsulation.

[0224] Alternatively, one or more DNA plasmids encoding one or more siRNA templates can be encapsulated within nucleic acid-lipid particles. For example, siRNAs based on the naturally occurring transcription units of small nuclear RNA U6 or human RNase P RNA H1 can be transcribed as sequences that automatically fold into duplexes with hairpin loops from DNA templates in plasmids harboring RNA polymerase III transcription units (see, Brummelkamp, ​​et al., Science 296:550 (2002); Donzé, et al., Nucleic Acids Res. 30:e46 (2002); Paddison, et al., Genes Dev. 16:948 (2002); Yu, et al., Proc. Natl. Acad. Sci. 99:6047 (2002); Lee, et al., Nat. Biotech. 20:500 (2002); Miyagishi, et al., Nat. Biotech. 20:497 (2002); Paul, et al., Proc. Natl. Acad. Sci. 99:6047 (2002); Lee, et al., Nat. Biotech. 20:500 (2002); Miyagishi, et al., Nat. Biotech. 20:497 (2002); Paul, et al., Proc. Natl. Acad. Sci. 10:1017 (2002); et al., Nat. Biotech. 20: 505 (2002); and Sui, et al., Proc. Natl. Acad. Sci. 99: 5515 (2002). Typically, the transcription unit or cassette will contain an RNA transcription promoter sequence, such as the H1-RNA or U6 promoter, operably linked to a template for transcription of the desired siRNA sequence and a termination sequence comprising 2-3 uridine residues and a polythymidine (T5) sequence (polyadenylation signal) (Brummelkamp, ​​Science, supra). The selected promoter can provide constitutive or inducible transcription. Compositions and methods for transcription of DNA-guided RNA interference molecules are described in detail in U.S. Patent No. 6,573,099, which is incorporated herein by reference. Preferably, the synthetic or transcribed siRNA has a 3' overhang of about 1-4, preferably about 2-3 nucleotides and a 5' phosphate terminus (Elbashir, et al., Genes Dev. 15: 188 (2001); et al., Cell 107:309 (2001). The transcription unit is incorporated into a plasmid or DNA vector from which the interfering RNA is transcribed. Plasmids suitable for in vivo delivery of genetic material for therapeutic purposes are described in detail in U.S. Patent Nos. 5,962,428 and 5,910,488, both of which are incorporated herein by reference. Selected plasmids can provide transient or stable delivery to target cells. It will be apparent to those skilled in the art that a plasmid initially designed to express a desired gene sequence can be modified to include a transcription unit cassette for transcribing siRNA.

[0225] Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, preparing and screening cDNA libraries, and performing PCR are well known in the art (see, e.g., Gubler & Hoffman, Gene 25:263-269 (1983); Sambrook et al., supra; Ausubel et al., supra), as are PCR methods (see U.S. Patents 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., eds., 1990)). Expression libraries are also well known to those skilled in the art. Additional basic texts disclosing the general methods used in the present disclosure include Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994)).

[0226] Applications of metal-phospholipid complexes, metal-phospholipid complex particles, and drug-lipid particles

[0227] In some embodiments, when the drug is a nucleic acid, metal-phospholipid complexes and metal-phospholipid complex particles can be used to facilitate drug lysosomal escape and promote nucleic acid expression. Metal-phospholipid complexes and metal-phospholipid complex particles can also be used to deliver drugs, introducing them into cells, thereby preventing and treating applicable diseases or conditions.

[0228] In some embodiments, the disclosure provides the application of the drug-lipid particles, for example, for compositions, which can achieve the delivery of drugs or introduce drugs into cells. Compositions are, for example, medicaments, which can achieve: silencing the expression of target sequences in mammalian subjects, delivering drugs in mammals (medicaments such as for treating tumors, imaging agents, etc.), delivering drugs from the body to mammalian cells or treating mammalian diseases or conditions, etc. In medicaments, drug-lipid particles are the main active ingredients, which can be prepared into different dosage forms according to actual needs, such as solid dosage forms (powders, granules, pills, tablets, gels), semi-solid dosage forms (external ointments, pastes), liquid dosage forms (decoctions, mixtures, syrups, wines, injections), gaseous dosage forms (aerosols, smoke agents), etc.; such as dosage forms for gastrointestinal administration, dosage forms for rectal administration, and dosage forms for non-gastrointestinal administration, etc.

[0229] In some embodiments, the present disclosure provides products prepared from the above-mentioned metal-phospholipid complexes, metal-phospholipid complex particles, and drug-lipid particles. The products have the above-mentioned functions and uses of metal-phospholipid complexes, metal-phospholipid complex particles, and drug-lipid particles. The specific types can be, for example, but not limited to, kits, medicines, etc., and the products may optionally contain other excipients.

[0230] For target genes of drug-lipid particles: Generally, it is desirable to deliver drug-lipid particles so that the translation (i.e., expression) of the target gene product is downregulated or silenced. Suitable classifications of gene products include, but are not limited to, genes associated with viral infection and survival, genes associated with metabolic diseases and disorders (e.g., diseases and disorders in which the liver is a target, and liver diseases and disorders), genes associated with tumorigenesis and cell transformation, angiogenic genes, immunomodulator genes such as those associated with inflammation and autoimmune responses, ligand receptor genes, and genes associated with neurodegenerative disorders.

[0231] Genes associated with viral infection and survival include those expressed by viruses to bind, enter, and replicate in cells, particularly viral sequences associated with chronic viral diseases. For example, viral sequences include sequences of hepatitis viruses (Hamasaki, et al., FEBS Lett. 543:51 (2003); Yokota, et al, EMBO Rep. 4:602 (2003); Schlomai, et al, Hepatology 37:764 (2003); Wilson, et al, Proc. Natl. Acad. Sci. 100:2783 (2003); Kapadia, et al, Proc. Natl. Acad. Sci. 100:2014 (2003); and FIELDSVIROLOGY (Knipe et al. eds. 2001)), human immunodeficiency virus (HIV) (Banerjea, et al, Mol Ther. 8:62 (2003); Song, et al, 2003). al., J. Virol. 77:7174 (2003); Stephenson JAMA 289:1494 (2003); Qin, et al., Proc. Natl. Acad. Sci. 100:183 (2003)), herpes virus (Jia, et al., J. Virol. 77:3301 (2003)), and human papillomavirus (HPV) (Hall, et al., J. Virol. 77:6066 (2003); Jiang, et al., Oncogene 21:6041 (2002)). Exemplary hepadnavirus nucleic acid sequences that can be silenced include, but are not limited to, nucleic acid sequences involved in transcription and translation (e.g., En1, En2, X, P), nucleic acid sequences encoding structural proteins (e.g., core proteins including C and C-related proteins; capsid and envelope proteins including S, M, and / or L proteins, or fragments thereof) (see, e.g., FIELDS VIROLOGY, 2001, supra). Hepatitis C nucleic acid sequences that can be silenced include, but are not limited to, serine proteases (e.g., NS3 / NS4), helicases (e.g., NS3), polymerases (e.g., NS5B), and envelope proteins (e.g., E1, E2, and p7).Hepatitis A nucleic acid sequences are referenced, for example, in Genbank Accession No. NC_001489; hepatitis B nucleic acid sequences are referenced, for example, in Genbank Accession No. NC_003977; hepatitis C nucleic acid sequences are referenced, for example, in Genbank Accession No. NC_004102; hepatitis D nucleic acid sequences are referenced, for example, in Genbank Accession No. NC_001653; hepatitis E nucleic acid sequences are referenced, for example, in Genbank Accession No. NC_001434; and hepatitis G nucleic acid sequences are referenced, for example, in Genbank Accession No. NC_001710. Silencing sequences encoding genes associated with viral infection and survival can be conveniently used in conjunction with the administration of conventional pharmaceutical agents for treating viral diseases.

[0232] Genes associated with metabolic diseases and disorders (e.g., disorders in which the liver is targeted and liver diseases and disorders) include, for example, genes expressed in dyslipidemia (e.g., liver X receptors (e.g., LXRα and LXRβ Genbank Accession No. NM_007121)), farnesoid X receptor (FXR) (Genbank Accession No. NM_005123), sterol regulatory element binding protein (SREBP), site-1 protease (S1P), 3-hydroxy-3-methylglutaryl-Coenzyme-A reductase (HMG-Coenzyme-A reductase), apolipoprotein (ApoB), and apolipoprotein (ApoE)) and diabetes (e.g., glucose-6-phosphate) (see, e.g., Forman et al., Cell 81:687 (1995); Seol et al., Mol. Endocrinol. 9:72 (1995), Zavacki et al., PNAS USA 94: 7909 (1997); Sakai, et al., Cell 85: 1037-1046 (1996); Duncan, et al., J. Biol. Chem. 272: 12778-12785 (1997); Willy, et al., Genes Dev. 9 (9): 1033-45 (1995); Lehmann, et al. al., J. Biol. Chem. 272(6): 3137-3140 (1997); Janowski, et al., Nature 383:728-731 (199; Peet, et al., Cell 93:693-704 (1998)). Those skilled in the art will understand that genes associated with metabolic diseases and disorders (e.g., diseases and disorders in which the liver is targeted and liver diseases and disorders) include genes expressed in the liver itself as well as genes expressed in other organs and tissues. Silencing sequences encoding genes associated with metabolic diseases and disorders can be conveniently used in conjunction with the administration of conventional pharmaceutical agents for treating the disease or disorder.

[0233] Examples of genes associated with tumorigenesis and cell transformation include translocation sequences such as MLL fusion gene, BCR-ABL (Wilda, et al., Oncogene, 21:5716 (2002); Scherr, et al, Blood 101:1566), TEL-AML1, EWS-FLI1, TLS-FUS, PAX3-FKHR, BCL-2, AML1-ETO and AML1-MTG8 (Heidenreich, et al, Blood 101:3157 (2003)); overexpressed sequences such as multidrug resistance genes (Nieth, et al, FEBS Lett. 545:144 (2003); Wu, et al, Cancer Res. 63:1515 (2003)), cell cycle proteins (Li, et al, Cancer Res. 63:3593 (2003); Zou, et al, Cancer Res. 63:3607 (2003)). al., Genes Dev. 16:2923 (2002)), β-catenin (Verma, et al., Clin Cancer Res. 9:1291 (2003)), telomerase gene (Kosciolek, et al., Mol Cancer Ther. 2:209 (2003)), c-MYC, N-MYC, BCL-2, ERBB1 and ERBB2 (Nagy, et al. Exp. Cell Res. 285:39 (2003)); and mutant sequences such as RAS (reviewed in Tuschl and Borkhardt, Mol. Interventions, 2:158 (2002)). Silencing sequences encoding DNA repair enzymes is used in conjunction with administration of chemotherapeutic agents (Collis, et al., Cancer Res. 63:1550 (2003)). Genes encoding proteins associated with tumor migration, such as integrins, selectins, and metalloproteinases, are also target sequences of interest. Any complete or partial gene sequence that is beneficial to or promotes tumorigenesis or cell transformation, tumor growth, or tumor migration can be included as a template sequence.

[0234] Angiogenic genes can promote the formation of new blood vessels, and vascular endothelial growth factor (VEGF) is a key research direction (Reich, et al., Mol. Vis. 9: 210 (2003)).

[0235] Immunomodulator genes are genes that regulate one or more immune responses. Examples of immunomodulator genes include cytokines such as growth factors (e.g., TGF-α, TGF-β, EGF, FGF, IGF, NGF, PDGF, CGF, GM-CSF, SCF, etc.), interleukins (e.g., IL-2, IL-4, IL-12 (Hill, et al., J. Immunol. 171: 691 (2003)), IL-15, IL-18, IL-20, etc.), interferons (e.g., IFN-α, IFN-β, IFN-γ, etc.) and TNF. Fas and Fas ligand genes are also immunomodulator target sequences of interest (Song, et al., Nat. Med. 9: 347 (2003)). Also included in the disclosure are genes encoding secondary signaling molecules in hematopoietic and lymphoid cells, for example, Tec family kinases, such as Bruton's tyrosine kinase (Btk) (Heinonen, et al., FEBS Lett. 527:274 (2002)).

[0236] Cell receptor ligands include ligands that bind to cell surface receptors (e.g., insulin receptors, EPO receptors, G-protein coupled receptors, receptors with tyrosine kinase activity, cytokine receptors, growth factor receptors, etc.) to modulate (e.g., inhibit, activate, etc.) physiological pathways involved in the receptors (e.g., glucose level regulation, blood cell development, mitogenesis, etc.). Examples of cell receptor ligands include cytokines, growth factors, interleukins, interferons, erythropoietin (EPO), insulin, glucagon, G-protein coupled receptor ligands, etc.). Templates encoding trinucleotide repeat sequence (e.g., CAG repeat sequence) expansions have been found to be useful for silencing pathogenic sequences in neurodegenerative diseases caused by trinucleotide repeat sequence expansions, such as spinal bulbar muscular atrophy and Huntington's disease (Caplen, et al., Hum. Mol. Genet. 11: 175 (2002)).

[0237] Injectable delivery: In some cases, as described in U.S. Patent No. 5,543,158; U.S. Patent No. 5,641,515 and U.S. Patent No. 5,399,363, it is desirable to deliver the drug-lipid particles disclosed herein parenterally, intravenously, intramuscularly, subcutaneously, intradermally or intraperitoneally. The drug-lipid particles can be injected locally to the target site (e.g., a disease site such as inflammation or tumor formation or to a target organ or tissue) or systemically for widespread distribution to the organism. Solutions of the drug-lipid particles can be prepared in water, suitably mixed with a surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof, as well as in oils. Optionally, these formulations contain preservatives to prevent the growth of microorganisms. Typically, when administered intravenously, the drug-lipid particle formulation is formulated with a suitable pharmaceutical carrier. Typically, a normal buffered saline solution (135-150 mM NaCl) will be used as a pharmaceutical carrier, but other suitable carriers will suffice. Additional suitable carriers are described, for example, in REMINGTON'S PHARMACEUTICAL SCIENCES, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985). As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce allergic or similar adverse reactions when administered to a human. The formulation of aqueous compositions is conventional in the art, and the compositions contain the protein as the active ingredient. Optionally, these compositions are prepared as injectable solutions, liquid solutions, or suspensions; solid forms suitable for solution or suspension in a liquid prior to injection can also be prepared. The formulations can also be emulsified.

[0238] Can be sterilized by conventional liposome sterilization technology, such as filtering medicine-lipid granule.Described medicine-lipid granule can comprise pharmaceutical auxiliary substance, and described pharmaceutical auxiliary substance is suitable physiological condition, such as pH adjusting agent and buffer agent, toxicity regulator, wetting agent etc.Use the technology indicated above to sterilize these compositions, or alternatively, they can produce under aseptic conditions.Can be packaged to use or filter and carry out lyophilization under aseptic conditions to the aqueous solution obtained, before using, lyophilized preparation is combined together with sterile aqueous solution.

[0239] Prophylactic and therapeutic treatment: In some embodiments, the drug-lipid particle can be used for the prophylactic or therapeutic treatment of a subject (e.g., a mammalian subject) suffering from a disease or condition that is associated with expression or overexpression of a target sequence. The drug-lipid particle is administered to the subject in an amount sufficient to stimulate a therapeutic response in the patient. An amount sufficient to accomplish this is defined as a "therapeutically effective dose or amount" or "effective dose or amount." In determining the effective amount of the drug-lipid particle to be administered for the treatment or prevention of a disease that is due to expression or overexpression of a target gene, the physician evaluates the circulating plasma levels of the drug-lipid particle, the drug-lipid particle toxicity, and the progression of the disease associated with expression or overexpression of the target gene. Administration can be accomplished by single or divided doses.

[0240] In some embodiments, the drug-lipid granule is administered to a subject who is infected by pathogenic microorganisms or who is at risk of being infected by pathogenic microorganisms. The drug should preferably correspond to a sequence, and should also be unique (or at least lacking in the natural genome of the patient who experiences treatment) for microorganisms, and the sequence has a key role in the life history of microorganisms. By ex vivo or intravenous injection, the drug-lipid granule is introduced into target cells, tissues or organs with therapeutically effective dosage. The sequence silencing of the gene encoding the relevant to pathogenic infection can be easily combined with the use of conventional reagents for the treatment of pathogenic diseases. The treatment can be preventively administered to a subject who is at risk of being infected by pathogenic microorganisms or who has been infected by pathogenic microorganisms.

[0241] In a preferred embodiment, the drug-lipid particles of the present disclosure can be conveniently used to treat cancer, viral infections, autoimmune diseases, diabetes, and Alzheimer's disease. Viral infections include hepatitis A, hepatitis B, hepatitis C, SARS-CoV-2, HIV, HPV, influenza, smallpox, and syphilis. For example, suitable sites for inhibiting hepatitis B virus include nucleic acid sequences encoding S, C, P, and X proteins, PRE, EnI, and EnII (see, e.g., FIELDSVIROLOGY, 2001, supra). Those skilled in the art will appreciate that gene silencing associated with hepatitis infection can be combined with conventional treatments for hepatitis, such as, for example, immunoglobulins, interferons (e.g., PEGylated and non-PEGylated interferon alpha) (see, e.g., Medina et al., Antiviral Res. 60(2):135-143 (2003); ribavirin (see, e.g., Hugle and Cerny, Rev. Med. Virol. 13(6):361-71 (2003); adefovir and lamivudine (see, e.g., Kock et al., Hepatology 38(6):1410-8 (2003); prenylation inhibitors (see, e.g., Bordier et al., J. Clin. Invest. 112(3):407-414 (2003)); famciclovir (see, e.g., Yurdaydin et al., J. Hepatol. 37(2):266-71 (2002); and saikosaponins c and d (see, e.g., Chiang et al., Planta Med. 69(8):705-9 (2003).

[0242] In another embodiment, medicine-lipid granule of the present disclosure can be conveniently used for treating the disease and illness characterized by gene or gene cluster expression or overexpression.In some aspects, medicine-lipid granule of the present disclosure can be used for treating metabolic diseases and illness (for example, wherein liver is the disease and illness and liver disease and illness of target object) such as, for example, dyslipidemia and diabetes.Those skilled in the art will appreciate that the silence of the gene relevant to metabolic diseases and illness can be combined with the conventional treatment of these diseases. For example, silencing of genes involved in dyslipidemia can be combined with the use of statins, bile acid sequestrants / resins and cholesterol absorption inhibitors such as ezetimibe, plant stanols / sterols, polyphenols, and nutraceuticals such as oat bran, flaxseed and soy protein, phytostanol analogs, squalene synthase inhibitors, bile acid transport inhibitor SREBP cleavage activating protein (SCAP) activating ligand, nicotinic acid (niacin), acipimox, high-dose fish oil, antioxidants and policosanol, microsomal triglyceride transport protein (MTP) inhibitors, acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors, gemcabene, rifiberol, pantothenic acid analogs, niacin-receptor agonists, anti-inflammatory agents (such as Lp-PLA(2) antagonists and AGI1067) functional oils, PPAR-α, γ, Therapeutic combinations of delta agonists, as well as dual PPAR-α, / γ and 'pan' PPAR-α / γ, / δ agonists, cholesteryl ester transfer protein (CETP) inhibitors (such as torcetrapib), CETP vaccines, upregulators of ATP-binding cassette transporter (ABC) A1, lecithin cholesterol acyltransferase (LCAT) and scavenger receptor class B type 1 (SRB1), and synthetic apolipoprotein (Apo) E-related peptides, extended-release niacin / lovastatin, atorvastatin / amlodipine, ezetimibe / simvastatin, atorvastatin / CETP inhibitors, statin / PPAR agonists, extended-release niacin / simvastatin and pravastatin / aspirin in development, and anti-obesity agents (see, e.g., Bays and Stein, Expert Opin. Pharmacother. 4(11):1901-38 (2003)). Likewise, silencing of genes involved in diabetes can be combined with treatment with insulin, as well as dietary modifications and exercise.

[0243] Similar methods are used to inhibit the expression of endogenous receptor cellular genes that are associated with tumorigenesis and cell transformation, tumor growth and tumor migration; inhibit the expression of angiogenic genes; inhibit the expression of immunomodulator genes, such as those associated with inflammation and autoimmune responses; inhibit the expression of ligand receptor genes; inhibit the expression of genes associated with neurodegenerative disorders; and inhibit the expression of additional genes associated with viral infection and survival. Specific target gene sequences are as described above.

[0244] Detection of the Particles: The drug-lipid particles herein are detected using any method known in the art. For example, a label is coupled directly or indirectly to a component of the drug-lipid particle or other lipid-based carrier system using methods well known in the art. A wide variety of labels can be used, with selection being based on desired sensitivity, ease of conjugation to the drug-lipid particle components, stability requirements, and available tools and processing readiness. Suitable labels include, but are not limited to, spectral labels, such as fluorescent dyes (e.g., (e.g., fluorescein and derivatives, such as fluorescein isothiocyanate (FITC) and Oregon Green™; rhodamine and derivatives, such as Texas Red, tetrarhodimine isothiocynate (TRITC), etc., digoxigenin, biotin, phycoerythrin, AMCA, CyDyes™, etc.; radioactive labels, such as 3H, 125I, 35S, 14C, 32P, 33P, etc.; enzymes such as horseradish peroxidase, alkaline phosphatase, etc.; spectral colorimetric labels such as colloidal gold or colored glass or plastic beads, such as polystyrene, polypropylene, latex, etc.). The label is detected using any means known in the art.

[0245] Detection of Nucleic Acids: Nucleic acids herein can be detected and quantified by any of a number of methods well known to those skilled in the art. Detection of nucleic acids can be performed by methods well known in the art such as Southern blot analysis, Northern blot analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography. Additional analytical biochemical methods such as spectrophotometry, X-ray photography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography can also be used.

[0246] The sensitivity of hybridization assays can be increased by the use of nucleic acid amplification systems that multiply the amount of target nucleic acid being detected. In vitro amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known. Examples of techniques sufficient to guide one skilled in the art by these in vitro amplification methods, including polymerase chain reaction (PCR), ligase chain reaction (LCR), Qβ-replicase amplification, and other RNA polymerase-mediated techniques (e.g., NASBA™) are found in Sambrook, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2000, and Ausubel et al., SHORT PROTOCOLS IN MOLECULAR BIOLOGY, eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (2002), and Mullis et al. (1987), U.S. Pat. No. 4,683,202; PCR Protocols A Guide to Methods and Applications (Innis et al. eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 2001). 1, 1990), C&EN 36; The Journal Of NIH Research, 3: 81 (1991); (Kwoh et al., Proc. Natl. Acad. Sci. USA, 86: 1173 (1989); Guatelli et al., Proc. Natl. Acad. Sci. USA, 87: 1874 (1990); Lomell et al. al., J. Clin. Chem., 35: 1826 (1989); Landegren et al., Science, 241: 1077 (1988); Van Brunt, Biotechnology, 8: 291 (1990); Wu and Wallace, Gene, 4: 560 (1989); Barringer et al. al., Gene, 89: 117 (1990), and Sooknanan and Malek, Biotechnology, 13: 563 (1995).Improved methods for cloning in vitro amplified nucleic acids are described in Wallace et al., US Patent No. 5,426,039. Other methods described in the art are nucleic acid sequence-based amplification (NASBA™, Cangene, Mississauga, Ontario) and the Qβ replicase system.

[0247] Oligonucleotides for use as probes in in vitro amplification methods, as gene probes, or as inhibitor components are chemically synthesized, for example, using an automated synthesizer, typically according to the solid-phase phosphoramidite triester method described by Beaucage and Caruthers, Tetrahedron Letts., 22(20): 1859-1862 (1981), as described by Needham VanDevanter et al., Nucleic Acids Res., 12: 6159 (1984). If necessary, oligonucleotides are typically purified by native acrylamide gel electrophoresis or by anion exchange HPLC, as described by Pearson and Regnier, J. Chrom., 255: 137-149 (1983). The sequence of synthetic oligonucleotides can be confirmed using the chemical degradation method of Maxam and Gilbert (1980) in Grossman and Moldave (eds.) Academic Press, New York, Methods in Enzymology, 65:499.

[0248] The examples that follow provide illustration, but do not limit the claimed disclosure. Those skilled in the art will readily recognize a variety of noncritical parameters that can produce essentially the same results.

[0249] The drug-lipid particles to be protected in the present disclosure refer to drug-lipid particles other than those containing cationic / ionizable lipids, namely, drug-loaded metal-chelated phospholipid complex nanoparticles (drug@MPP).

[0250] Experimental Example 1: Preparation of drug-metal-phospholipid complex particles

[0251] Example 1: Preparation of phospholipid complexes

[0252] To connect a phospholipid molecule with a phosphate group to a linker molecule: Distearoylphosphatidylcholine (DSPC, Formula 46) and curcumin (Formula 19) were added to a reaction flask at a molar ratio of 1:1. An appropriate amount of ethanol was added to dissolve the mixture. After reacting at 65°C for 2 hours, the mixture was concentrated and n-hexane was added. The resulting phospholipid complex was precipitated, filtered, and vacuum dried to obtain the phospholipid complex. The structure of the phospholipid complex is shown below:

[0253] Result analysis: The yield of the target product obtained by reacting curcumin with DSPC at 65°C for 2 hours was 94%.

[0254] Example 2: Preparation of Metal-Phospholipid Complex

[0255] Example 2.1 Preparation of Metal Ions: Fe 3+ Metal-phospholipid complexes

[0256] The phospholipid complex prepared in Example 1 was partially linked to the metal ion: the phospholipid complex and FeCl3 were added to a reaction flask at a molar ratio of 1:1, dissolved in ethanol, and reacted at 60°C for 2 hours. The reaction solution was then suspended to dryness, washed with ultrapure water, and vacuum-dried to obtain a metal-phospholipid complex. The structure of the metal-phospholipid complex is shown below.

[0257] Result analysis: The yield of the target product obtained when the phospholipid complex and FeCl3 were reacted at 60℃ for 2 hours, the phospholipid complex feed concentration was 4.5 mg / mL and the feed ratio of phospholipid complex to FeCl3 was 1:1 was 95%.

[0258] Example 2.2 Preparation of metal ions as Al 3+ Metal-phospholipid complexes

[0259] The difference between this example and Example 2.1 is that FeCl3 is replaced by Al(NO3)3·9H2O. The structure of the prepared metal-phospholipid complex is shown below.

[0260] Result analysis: The yield of the target product obtained when the phospholipid complex and Al(NO3)3·9H2O were reacted at 60℃ for 2 hours, the phospholipid complex feed concentration was 4.5 mg / mL and the feed ratio of phospholipid complex to Al(NO3)3·9H2O was 1:1 was 95%.

[0261] Example 3. Preparation of mRNA-loaded metal-chelated phospholipid complex nanoparticles (mRNA@MPP)

[0262] The metal ion is Fe 3+ mRNA-metal-phospholipid complex particles

[0263] A metal-phospholipid complex was prepared according to the method described in Example 2.1, with DSPC, curcumin, and FeCl3 added at a 1:1:1 ratio. The metal-phospholipid complex, distearoylphosphatidylcholine (DSPC, Formula 46, as a non-cationic or non-ionizable lipid), cholesterol (CHOL, Formula 40, as a non-cationic or non-ionizable lipid), and DSPE-PEG2000 (Formula 53, as a conjugated lipid to inhibit particle aggregation) were dissolved in ethanol at varying molar ratios as the organic phase. The metal-phospholipid complex, DSPC, CHOL, and DSPE-PEG2000 accounted for 15%, 35%, 46%, and 4%, respectively. mRNA was dissolved at a concentration of 20 μg / mL in enzyme-free PBS buffer (PBS composed of 0.137 M sodium chloride, 0.0027 M potassium chloride, 0.01 M disodium hydrogen phosphate, and 0.0018 M potassium dihydrogen phosphate) as the aqueous phase. The mass of the metal-phospholipid complex and the mass of the mRNA were mixed in a microfluidic chip at a mass ratio of 40:1. The volume ratio of the aqueous phase to the organic phase was 3:1. The flow rate of the organic phase and the aqueous phase in the microfluidic chip was 12 ml / min. Among them, the drug mRNA was an mRNA encoding the fluorescent protein eGFP, and its sequence was SEQ ID NO.1 (720 nt). eGFP-mRNA@MPP was prepared. The eGFP-mRNA@MPP was incubated with 293T cells at a concentration of 2 μg / mL (the concentration of the contained mRNA). The control group was incubated with MPP without drug loading. After 48 hours, the cell suspension was collected and the percentage of eGFP-positive cells was detected by flow cytometry.

[0264] The particle size, surface potential and stability of the eGFP-mRNA@MPP prepared in Example 3 were tested, and the efficiency of nucleic acid encapsulation in the eGFP-mRNA@MPP was calculated.

[0265] Method for detecting particle size and result judgment standard: The particle size of nanoparticles was tested using a Malvern Zetasizer laser particle size analyzer, and a particle size within the range of 30 to 400 nm was considered acceptable.

[0266] Method for detecting surface potential and result judgment standard: The surface potential of nanoparticles was tested using a Malvern Zetasizer laser particle size analyzer, and a potential in the range of -10 to 10 mV was considered acceptable.

[0267] Stability testing method and result judgment criteria: The nanoparticles were placed at 4°C for 7 days, and the particle size and surface potential of the nanoparticles were measured using a Malvern Zetasizer. If there was no significant change in the particle size and surface potential within 3-7 days, the stability was considered to be good.

[0268] Method for calculating nucleic acid encapsulation efficiency: agarose gel electrophoresis was used. First, the nucleic acid loading amount of each group of lipid nanoparticles was set to 10 μg / mL, and the metal ion was Fe 3+ The ratio of the metal-phospholipid complex mass to the mRNA mass was 40:1. An equal concentration of nucleic acid was dissolved in PBS buffer as a positive control, and a negative control was PBS buffer. The agarose gel concentration was 1.5%. At this point, the gel's pores only allow the passage of free nucleic acids, not lipid nanoparticles. Electrophoresis was stopped when the free nucleic acid bands were clearly distinguishable. Image J software was used to calculate the grayscale value of the free nucleic acid in different groups. The positive control was set as 100%. The ratio of the free nucleic acid in each group to the positive control was the relative amount of free nucleic acid. The entrapment efficiency of each group was calculated as (100 - relative amount of free nucleic acid)%. A nucleic acid entrapment efficiency above 50% was considered acceptable.

[0269] Cell culture method: Human embryonic kidney cell line 293T was cultured in DMEM containing 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO2.

[0270] Flow cytometry analysis of eGFP-positive cell percentage: 293T cells were seeded in 24-well plates at a seeding density of 5 × 10 5 Cells were plated at 1 mL of MPP or eGFP-mRNA@MPP at a concentration of 2 μg / mL at 80% cell density. After 48 hours, the cell suspension was harvested and 20,000 cells were collected using the FITC channel of a flow cytometer. The percentage of eGFP-positive cells was analyzed using the following formula: eGFP-positive cell percentage = number of eGFP-expressing cells / total number of cells × 100%. An eGFP-positive cell percentage of 40% or higher was considered acceptable.

[0271] Preparation of metal ions as Al 3+ mRNA-metal-phospholipid complex particles

[0272] A metal-phospholipid complex was prepared according to the method described in Example 2.2, with DSPC, curcumin, and Al(NO₃)₃·9H₂O added at a 1:1:1 ratio. The metal-phospholipid complex, distearoylphosphatidylcholine (DSPC, Formula 46, as a non-cationic or non-ionizable lipid), cholesterol (CHOL, Formula 40, as a non-cationic or non-ionizable lipid), and DSPE-PEG2000 (Formula 53, as a conjugated lipid to inhibit particle aggregation) were dissolved in ethanol at varying molar ratios as the organic phase. The metal-phospholipid complex, DSPC, CHOL, and DSPE-PEG2000 accounted for 7%, 34%, 56%, and 3%, respectively. mRNA was dissolved at a concentration of 20 μg / mL in enzyme-free PBS buffer (PBS composed of 0.137 M sodium chloride, 0.0027 M potassium chloride, 0.01 M disodium hydrogen phosphate, and 0.0018 M potassium dihydrogen phosphate) as the aqueous phase. The mass of the metal phospholipid complex and the mass of the mRNA were mixed in a microfluidic chip at a mass ratio of 13.3:1. The volume ratio of the aqueous phase to the organic phase was 3:1. The flow rate of the organic phase and the aqueous phase in the microfluidic chip was 12 ml / min. Among them, the drug mRNA was an mRNA encoding the fluorescent protein eGFP, and its sequence was SEQ ID NO.1 (720nt). The prepared eGFP-mRNA@MPP. The eGFP-mRNA@MPP was incubated with 293T cells at a concentration of 2 μg / mL (the concentration of the contained mRNA). The control group was incubated with MPP without drug loading. After 48 hours, the cell suspension was collected and the percentage of eGFP-positive cells was detected by flow cytometry.

[0273] The particle size, surface potential and stability of the eGFP-mRNA@MPP prepared in Example 3 were tested, and the efficiency of nucleic acid encapsulation in the eGFP-mRNA@MPP was calculated.

[0274] Method for detecting particle size and result judgment standard: The particle size of nanoparticles was tested using a Malvern Zetasizer laser particle size analyzer, and a particle size within the range of 30 to 400 nm was considered acceptable.

[0275] Method for detecting surface potential and result judgment standard: The surface potential of nanoparticles was tested using a Malvern Zetasizer laser particle size analyzer, and a potential in the range of -10 to 10 mV was considered acceptable.

[0276] Stability testing method and result judgment criteria: The nanoparticles were placed at 4°C for 7 days, and the particle size and surface potential of the nanoparticles were measured using a Malvern Zetasizer. If there was no significant change in the particle size and surface potential within 3-7 days, the stability was considered to be good.

[0277] Method for calculating nucleic acid encapsulation efficiency: Agarose gel electrophoresis was used. First, the nucleic acid loading amount of each group of lipid nanoparticles was set to 10 μg / mL, and the metal ion was Al 3+ The ratio of the metal-phospholipid complex mass to the mRNA mass was 13.3:1. An equal concentration of nucleic acid was dissolved in PBS buffer as a positive control, and a negative control was PBS buffer. The agarose gel concentration was 1.5%. At this point, the gel's pores only allow the passage of free nucleic acids, not lipid nanoparticles. Electrophoresis was stopped when the free nucleic acid bands were clearly distinguishable. Image J software was used to calculate the grayscale value of the free nucleic acid in different groups. The positive control was set as 100%. The ratio of the free nucleic acid in each group to the positive control was the relative amount of free nucleic acid. The entrapment efficiency of each group was calculated as (100 - relative amount of free nucleic acid)%. A nucleic acid entrapment efficiency above 50% was considered acceptable.

[0278] Cell culture method: Human embryonic kidney cell line 293T was cultured in DMEM containing 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO2.

[0279] Flow cytometry analysis of eGFP-positive cell percentage: 293T cells were seeded in 24-well plates at a seeding density of 5 × 10 5 Cells were plated at 1 mL of MPP or eGFP-mRNA@MPP at a concentration of 2 μg / mL at 80% cell density. After 48 hours, the cell suspension was harvested and 20,000 cells were collected using the FITC channel of a flow cytometer. The percentage of eGFP-positive cells was analyzed using the following formula: eGFP-positive cell percentage = number of eGFP-expressing cells / total number of cells × 100%. An eGFP-positive cell percentage of 40% or higher was considered acceptable.

[0280] The principle of loading nucleic acid into metal-chelated phospholipid complex nanoparticles (MPP) assembled by metal-phospholipid complex is that curcumin is bound to DSPC through hydrogen bonds, while curcumin is bound to Fe through coordination bonds. 3+ or Al 3+ connected to form a metal-phospholipid complex, the Fe 3+ or Al 3+The metal-phospholipid complex is connected to the nucleic acid through a coordination bond, thereby ensuring that the metal-phospholipid complex self-assembles with other lipid components into the MPP and simultaneously loads the nucleic acid into the nanoparticle. There are two possibilities for curcumin's contribution to MMP loading of nucleic acids: ① Curcumin interacts with nucleic acids and assists MPP loading of nucleic acids, for example, by inserting into the minor groove of nucleic acids to facilitate nucleic acid loading; ② Curcumin may not directly interact with nucleic acids.

[0281] Example 3.1. Dosage ratio of components of metal-phospholipid complex

[0282] DSPC, curcumin, and FeCl3 in Example 3 were added at different ratios (1:1:1, 3:3:2, and 2:2:1), and the other steps were the same as in Example 3 to prepare different eGFP-mRNA@MPPs, and their nucleic acid encapsulation efficiencies were tested.

[0283] Result analysis: As shown in Table 1-1, when the ratio of DSPC, curcumin, and FeCl3 was 1:1:1, the eGFP-mRNA encapsulation efficiency of the prepared drug-lipid particles was 97%; when the ratio of DSPC, curcumin, and FeCl3 was 3:3:2, the eGFP-mRNA encapsulation efficiency of the prepared drug-lipid particles was 70%; when the ratio of DSPC, curcumin, and FeCl3 was 2:2:1, the eGFP-mRNA encapsulation efficiency of the prepared drug-lipid particles was 60%. 3+ The function of Fe is to connect phospholipid complexes with nucleic acids. 3+ Since there are a maximum of three complexation sites, the ratio of DSPC, curcumin, and FeCl3 in the drug-lipid particle should be 1:1:1 to maximize nucleic acid loading. Experimental results also confirmed that a 1:1:1 ratio of DSPC, curcumin, and FeCl3 resulted in the highest eGFP-mRNA loading efficiency in the drug-lipid particle. Nucleic acid loading efficiency exceeded 60% when the ratio of DSPC, curcumin, and FeCl3 ranged from 1:1:1 to 2:2:1.

[0284] Table 1-1 Component ratios of metal-phospholipid complexes and functions of the drug-lipid particles prepared therefrom

[0285] DSPC, curcumin, and Al(NO3)3·9H2O in Example 3 were added at different ratios (1:1:1, 3:3:2, and 2:2:1). Other steps were the same as in Example 3 to prepare different eGFP-mRNA@MPPs, and their nucleic acid encapsulation efficiencies were tested.

[0286] Result analysis: As shown in Table 1-2, when the ratio of DSPC, curcumin, and Al(NO3)3·9H2O was 1:1:1, the eGFP-mRNA encapsulation efficiency of the prepared metal-phospholipid complex particles was 98%; when the ratio of DSPC, curcumin, and Al(NO3)3·9H2O was 3:3:2, the eGFP-mRNA encapsulation efficiency of the prepared metal-phospholipid complex particles was 72%; when the ratio of DSPC, curcumin, and Al(NO3)3·9H2O was 2:2:1, the eGFP-mRNA encapsulation efficiency of the prepared metal-phospholipid complex particles was 58%. In the metal-phospholipid complex particles, Al 3+ The function of Al is to connect the phospholipid complex with the nucleic acid. 3+ Since there are a maximum of three complexation sites, the ratio of DSPC, curcumin, and Al(NO₃)₃·9H₂O in the drug-lipid particles should be 1:1:1 to maximize nucleic acid loading within the metal-phospholipid complex. Experimental results also confirmed that a 1:1:1 ratio of DSPC, curcumin, and Al(NO₃)₃·9H₂O resulted in the highest eGFP-mRNA loading efficiency within the metal-phospholipid complex. Nucleic acid loading rates within the metal-phospholipid complex particles exceeded 58% when the ratios ranged from 1:1:1 to 2:2:1.

[0287] Table 1-2 The proportion of components of metal-phospholipid complexes and the functions of the prepared metal-phospholipid complex particles

[0288] Example 3.2. Preparation of the Proportions of Metal-Phospholipid Complex, Distearoylphosphatidylcholine (DSPC), DSPE-PEG2000, and Cholesterol (CHOL) in Drug-Lipid Particles

[0289] Compared with Example 3, the ratio of metal-phospholipid complex, distearoylphosphatidylcholine (DSPC), DSPE-PEG2000 and cholesterol (CHOL) is as shown in Table 1-3 (the metal ion is Fe 3+ ) and Table 1-4 (metal ions are Al 3+ ), the other conditions are the same.

[0290] Result analysis: As shown in Table 1-3, when the metal-phospholipid complex (metal ion is Fe 3+When the metal-phospholipid complex accounted for 15%, distearoylphosphatidylcholine (DSPC) accounted for 35%, cholesterol (CHOL) accounted for 46%, and DSPE-PEG2000 accounted for 4%, the drug-lipid particles had a particle size of 50-400 nm, a surface potential of -10-10 mV, in vitro stability of more than 3 days, an mRNA entrapment efficiency of more than 50%, and an eGFP protein positive expression rate of more than 70%. The optimal performance of the drug-lipid particles was achieved when the metal-phospholipid complex accounted for 15%, distearoylphosphatidylcholine (DSPC) accounted for 35%, cholesterol (CHOL) accounted for 46%, and DSPE-PEG2000 accounted for 4%, with a particle size of 110 nm, a surface potential of -2.04 mV, in vitro stability of more than 7 days, an mRNA entrapment efficiency of 87%, and an eGFP protein positive expression rate of 97%. Because mRNA@MPP mainly relies on metal-phospholipid complexes to adsorb nucleic acids, the proportion of metal-phospholipid complexes cannot be too low; when the DSPC content is in the range of 0-40%, the stability of its nanoparticles is within an acceptable range. When the DSPC content is 0%, the stability of its nanoparticles can be maintained because the metal-phospholipid complex contains DSPC; the role of DSPE-PEG2000 is to prevent nanoparticle aggregation and increase circulation time in the body. Its performance will be better when its content is in the range of 2-10%; the role of CHOL is to enhance the fluidity of nanoparticles, and maintaining a certain content is beneficial to the stability of nanoparticles.

[0291] The above results suggest that metal-phospholipid complexes (metal ions are Fe 3+ ) accounts for (10-40)%, when DSPC accounts for (0-40)%, when CHOL accounts for (35-75)%, when DSPE-PEG2000 accounts for (2-10)%, mRNA@MPP has better drug loading performance.

[0292] Table 1-3 eGFP-mRNA@MPP(Fe 3+ ) Performance testing

[0293] Result analysis: As shown in Table 1-4, when the metal-phospholipid complex (metal ion is Al 3+When the metal-phospholipid complex accounted for 7%, distearoylphosphatidylcholine (DSPC) accounted for 34%, cholesterol (CHOL) accounted for 56%, and DSPE-PEG2000 accounted for 3%, the drug-lipid particle performance was optimal, with a particle size of 100 nm, a surface potential of -1.57 mV, in vitro stability of more than 7 days, an mRNA entrapment efficiency of 92%, and an eGFP protein positive expression rate of 98%. Because mRNA@MPP mainly relies on metal-phospholipid complexes to adsorb nucleic acids, the proportion of metal-phospholipid complexes cannot be too low; when the DSPC content is in the range of 0-51%, the stability of its nanoparticles is within an acceptable range. When the DSPC content is 0%, the stability of its nanoparticles can be maintained because the metal-phospholipid complex contains DSPC; the role of DSPE-PEG2000 is to prevent nanoparticle aggregation and increase circulation time in the body. Its performance will be better when its content is in the range of 2-10%; the role of CHOL is to enhance the fluidity of nanoparticles, and maintaining a certain content is beneficial to the stability of nanoparticles.

[0294] The above results suggest that metal-phospholipid complexes (metal ions are Al 3+ ) accounts for (5-50)%, when DSPC accounts for (0-51)%, when CHOL accounts for (15-80)%, when DSPE-PEG2000 accounts for (2-10)%, mRNA@MPP has better drug loading performance.

[0295] Table 1-4 eGFP-mRNA@MPP(Al 3+ ) Performance testing

[0296] Example 3.3: Preparation of non-cationic lipids or non-ionizable lipids in eGFP-mRNA@MPP

[0297] Compared with Example 3, the replacement of distearoylphosphatidylcholine (DSPC) is shown in Table 1-5 and Table 1-6, and the other conditions are the same.

[0298] Results: To explore whether DSPC in eGFP-mRNA@MPP can be replaced by other non-cationic lipids or non-ionizable lipids, we selected three other non-cationic lipids or non-ionizable lipids, namely DSPE, DSPA and DSPG, to replace DSPC. By testing the particle size, surface potential, stability and mRNA encapsulation efficiency, we proved that DSPC in eGFP-mRNA@MPP can be replaced by other non-cationic lipids or non-ionizable lipids, and its function after replacement is equivalent to that of eGFP-mRNA@MPP containing DSPC (Table 1-5 (metal ions are Fe 3+ ) and Table 1-6 (metal ions are Al 3+ Because the main function of the non-cationic or non-ionizable lipid DSPC in eGFP-mRNA@MPP is to improve liposome membrane fusion, increase stability, and reduce toxicity, and other non-cationic or non-ionizable lipids also have the function of improving liposome membrane fusion, increasing stability, and reducing toxicity, DSPC in the drug-lipid particles can be replaced by other non-cationic or non-ionizable lipids other than metal-phospholipid complexes and conjugated lipids that inhibit particle aggregation without affecting its efficacy.

[0299] The structural formulas of three non-cationic lipids or non-ionizable lipids (DSPE, DSPA, and DSPG) are shown below.

[0300] Table 1-5 eGFP-mRNA@MPP(Fe) containing different types of non-cationic lipids or non-ionizable lipids other than metal-phospholipid complexes and conjugated lipids that inhibit particle aggregation 3+ ) performance

[0301] Table 1-6 eGFP-mRNA@MPP (Al) containing different types of non-cationic lipids or non-ionizable lipids other than metal-phospholipid complexes and conjugated lipids that inhibit particle aggregation 3+ ) performance

[0302] Example 3.4. Preparation of conjugated lipid species for inhibiting particle aggregation in eGFP-mRNA@MPP

[0303] Compared with Example 3, the substitution of DSPE-PEG2000 (Formula 53) is shown in Table 1-7 (metal ion is Fe 3+ ) and Table 1-8 (metal ions are Al 3+), and the other conditions were the same. Three other conjugated lipids that inhibit particle aggregation are DSPE-PEG700 (Formula 50), DSPE-PEG5000 (Formula 52), and DSPE-PEG1000 (Formula 51).

[0304] Analysis of results: In order to explore whether DSPE-PEG2000 in eGFP-mRNA@MPP can be replaced by other conjugated lipids that inhibit particle aggregation, we selected three other conjugated lipids that inhibit particle aggregation, namely DSPE-PEG700, DSPE-PEG5000 and DSPE-PEG1000, to replace DSPE-PEG2000 respectively. By testing the particle size, surface potential, stability and mRNA encapsulation rate, we proved that DSPE-PEG2000 in eGFP-mRNA@MPP can be replaced by other conjugated lipids that inhibit particle aggregation, and its function after replacement is equivalent to that of eGFP-mRNA@MPP containing DSPE-PEG2000 (Table 1-7 and Table 1-8). Because the main function of DSPE-PEG2000 in eGFP-mRNA@MPP is to inhibit aggregation, and other conjugated lipids that inhibit particle aggregation also have the function of inhibiting aggregation, DSPE-PEG2000 in eGFP-mRNA@MPP can be replaced by other conjugated lipids that inhibit particle aggregation without affecting its efficacy.

[0305] Table 1-7 eGFP-mRNA@MPP(Fe) containing different types of conjugated lipids that inhibit particle aggregation 3+ ) performance

[0306] Table 1-8 eGFP-mRNA@MPP (Al) containing different types of conjugated lipids that inhibit particle aggregation 3+ ) performance

[0307] Example 3.5 Preparation and Effect Characterization of mRNA@MPP

[0308] Example 3.5.1: Metal ion is Fe 3+ Preparation and effect characterization of mRNA@MPP

[0309] The mRNA in Example 3 was replaced with two other mRNAs, and three mRNA@MPPs containing different target protein mRNA sequences were prepared according to the method of Example 3. The three different mRNA sequences are: ① The mRNA sequence encoding the fluorescent protein eGFP is SEQ ID NO.1 (720nt); ② The mRNA sequence encoding the receptor binding domain (RBD) of the new coronavirus S1 subunit is SEQ ID NO.2 (669nt); ③ The mRNA sequence encoding the tumor antigen NY-ESO-1 is SEQ ID NO.3 (543nt). The preparation process of the remaining drug (mRNA)-lipid particles is the same as that in Example 3, and eGFP-mRNA@MPP, RBD-mRNA@MPP, and NY-ESO-1-mRNA@MPP are obtained respectively.

[0310] eGFP-mRNA@MPP was incubated with 293T cells at a concentration of 2 μg / mL (the concentration of the contained mRNA), and the control group was incubated with MPP. After 48 hours, the cell suspension was collected, and the percentage of eGFP-positive cells was detected by flow cytometry. The results are shown in Figure 1-1; RBD-mRNA@MPP was incubated with 293T cells at a concentration of 2 μg / mL (the concentration of the contained mRNA), and the control group was incubated with MPP. After 24 hours, the supernatant was centrifuged and frozen at -20°C for later use. The expression level of the new coronavirus antigen RBD protein on the cells was detected using a commercially available new coronavirus antigen RBD ELISA detection kit. The results are shown in Figure 1-2.

[0311] ELISA method for detecting RBD expression level:

[0312] 1. Sample collection: Place the cell supernatant at room temperature for 2 hours, centrifuge at 1000×g for 20 minutes, and collect the supernatant;

[0313] 2. Sample addition: Set up blank wells, standard wells, and test sample wells on the coated plate. Add 100 μL of sample diluent to the blank wells, add serially diluted standards to the standard wells, and add 100 μL of the test sample wells. Incubate at 37°C for 60 minutes.

[0314] 3. Discard the liquid in the wells and wash the plate 3 times, soaking for 1-2 minutes each time. Add 100 μL of the prepared biotinylated anti-RBD antibody working solution to each well, mix well, and incubate at 37°C for 60 minutes.

[0315] 4. Discard the liquid in the wells and wash the plate 3 times, soaking for 1-2 minutes each time;

[0316] 5. Add 100 μL of prepared streptavidin HRP working solution to each well, mix well, and incubate at 37°C for 45 minutes;

[0317] 6. Discard the liquid in the wells and wash the plate 3 times, soaking for 1-2 minutes each time;

[0318] 7. Add 100 μL of TMB substrate solution (TMB) to each well and incubate at 37°C in the dark for 15 minutes;

[0319] 8. Add 100 μL of stop solution to each well to terminate the reaction;

[0320] 9. Measure the optical density (OD value) of each well at a wavelength of 450 nm.

[0321] Data analysis: Draw a standard curve with the concentration of the standard as the horizontal axis and the OD value as the vertical axis.

[0322] The experimental animals were randomly divided into two groups (experimental group and control group), with 5 mice in each group. Among them, the RBD-mRNA@MPP animal model was BALB / c mice. Each mouse received the first intramuscular administration on the first day and the second intramuscular administration on the 14th day. The experimental group was injected with RBD-mRNA@MPP, and the control group was injected with metal-phospholipid complex particles (MPP) without mRNA loading. The dose of each administration was 100μL, and the RBD-mRNA@MPP preparation in the experimental group contained 30mg of mRNA. On the 28th day after the first administration, the mouse blood was collected, the serum was separated and serially diluted, and the total RBD IgG antibodies against the new coronavirus S1 subunit produced in the mice were detected using a commercially available ELISA kit. The results are shown in Figures 1-3.

[0323] The NY-ESO-1-mRNA@MPP formulation was administered intramuscularly four times on days 1, 7, 14, and 21 to each mouse. The experimental group received NY-ESO-1-mRNA@MPP, while the control group received metal-phospholipid complex particles (MPP) without mRNA loading. Each dose was 100 μL, with the NY-ESO-1-mRNA@MPP formulation in the experimental group containing 30 mg of mRNA. Blood was collected from the mice 28 days after the first dose, and serum was isolated and serially diluted. The total anti-NY-ESO-1 IgG antibodies produced in the mice were detected by ELISA. The results are shown in Figures 1-4.

[0324] Method for detecting total anti-NY-ESO-1 IgG antibodies in mice:

[0325] Preparation of reagents used in ELISA method:

[0326] 1. Coating solution: Accurately weigh 8.4 g of NaHCO3 and dissolve it in 1 L of distilled water (DDW). After the solid is completely dissolved, use 1 M NaOH solution to adjust the pH of the entire solution to 9.6. Store the prepared coating solution at 4°C until use.

[0327] 2. Wash solution: Add 0.5 mL of Tween-20 to 1 L of 0.01 M PBS solution, mix well, and let it stand at room temperature.

[0328] 3. Blocking solution: Accurately weigh 20g of BSA and add it to 1L of 0.01M PBS solution. Ultrasonicate the undissolved BSA powder in the solution. When all the solids in the solution are dissolved and the solution turns light yellow, store it in a refrigerator at 4℃ until use.

[0329] 4. Antibody diluent: Accurately weigh 2.5 g of BSA and dissolve it in 250 mL of 0.01 M PBS solution. After the solid is completely dissolved, add 1.25 mL of Tween-20, mix well, and store at 4°C until ready to use.

[0330] 5. Color development solution: 0.1M citric acid: Add 19.2g of citric acid to 1000mL of DDW water (A). 0.2M disodium hydrogen phosphate: Add 28.4g of anhydrous disodium hydrogen phosphate to 1000mL of DDW water (B). 24.3mL of 0.1M citric acid solution (A), 25.7mL of 0.2M phosphate buffer (B), and 50mL of DDW water. Add 50mg of OPD (o-phenylenediamine) immediately before use, and 0.15mL of 30% H2O2.

[0331] 6. Stop solution: 2M H2SO4: concentrated sulfuric acid 55.5mL, add DDW to 500mL.

[0332] ELISA method was used to determine the titer of antibodies in mouse serum:

[0333] 1. Coating: Dilute NY-ESO-1 antigen to 1 μg / mL with coating solution, add 50 μL / well to a 96-well plate, and coat overnight at 4°C.

[0334] 2. Blocking: Dry the coating solution in the well plate, wash with blocking solution 3 times, 5 minutes each time and dry, add 150 μL blocking solution to each well, and incubate at 37℃ for 2 hours.

[0335] 3. Drying: Shake off the blocking solution and incubate at 37°C for 1-2 hours until the liquid at the bottom of the plate is completely dry.

[0336] 4. Immunization: The serum sample was initially diluted 1:1000 with antibody diluent, and then serially diluted 1:2. The diluted serum sample was added to a closed 96-well plate at 100 μL / well and incubated at 37°C for 2 hours. The liquid in the well plate was shaken dry, and the washing solution was added at 300 μL / well. The plate was shaken slowly for 40 seconds and this step was repeated three times. A 1:1000 diluted biotinylated goat anti-mouse IgG antibody was added at 100 μL / well and incubated at 37°C. 1h; shake dry the liquid in the well plate, add washing solution, and repeat the above washing steps; add freshly prepared streptavidin-labeled horseradish peroxidase HRP working solution, 100μL / well, incubate at 37℃ for 1h; shake dry the liquid in the well plate, add washing solution, and repeat the above washing steps; add color development solution, 100μL / well, react at room temperature for 5min, and then add stop solution, 50μL / well, to stop color development; use a microplate reader to measure the absorbance at 450nm.

[0337] On day 28 after administration of RBD-mRNA@MPP, spleens of normal mice were collected and prepared into single-cell suspensions under sterile conditions. 100,000 spleen cells were plated in a cell plate at a density of 10 mg / mL. RBD protein was added at a final concentration of 10 mg / mL and cultured for 48 hours. The supernatant was removed by centrifugation, and the expression levels of IFN-γ, IL-2, and IL-4 were measured using ELISA kits. The results are shown in Figures 1-5.

[0338] On day 28 after administration of NY-ESO-1-mRNA@MPP, spleens of normal mice were harvested and prepared into single-cell suspensions under sterile conditions. 100,000 spleen cells were plated in a cell plate at a density of 10 mg / mL. NY-ESO-1 protein was added at a final concentration of 10 mg / mL and cultured for 48 hours. The supernatant was removed by centrifugation, and the expression levels of IFN-γ, IL-2, and TNF-α were measured using ELISA kits. The results are shown in Figures 1-6.

[0339] Results: As shown in Figure 1-1, the eGFP-positive cell rate in the eGFP-mRNA@MPP experimental group was 97%, while no eGFP signal was detected in the MPP control group. As shown in Figure 1-2, the RBD protein encoded by the MPP-encapsulated RBD-mRNA was present at 193.3 ng / mL in the supernatant of 293T cells, while the RBD protein content in the supernatant of 293T cells transfected with the empty vector MPP was zero. These results suggest that mRNA-MPP can encapsulate and deliver any mRNA and directly encode polypeptides within cells. As shown in Figures 1-3 and 1-4, both RBD-mRNA@MPP and NY-ESO-1-mRNA@MPP effectively induced humoral immunity in mice, producing high levels of antigen-specific antibodies. IgG antibody titers reached 117,268.8 in mice treated with RBD-mRNA@MPP, and 53,195.2 in mice treated with NY-ESO-1-mRNA@MPP. As shown in Figures 1-5 and 1-6, both RBD-mRNA@MPP and NY-ESO-1-mRNA@MPP effectively induced cellular immunity in mice, activating immune cells and producing large amounts of cytokines. RBD-mRNA@MPP increased the expression of cytokines IFN-γ, IL-2, and IL-4 to 252.8 pg / mL, 207.6 pg / mL, and 56.6 pg / mL, respectively; while NY-ESO-1-mRNA@MPP increased the expression of cytokines IFN-γ, IL-2, and TNF-α to 70.79 pg / mL, 75.29 pg / mL, and 75.27 pg / mL, respectively. These results suggest that mRNA@MPP can encapsulate and deliver any mRNA, thereby promoting the expression of target proteins (antigens), effectively inducing humoral and cellular immunity in mice, producing high levels of antigen-specific binding antibodies and cytokines, and exerting the effects of anti-COVID-19 mRNA vaccines and anti-tumor mRNA vaccines.

[0340] Example 3.5.2: Metal ion is Al 3+ Preparation and effect characterization of mRNA@MPP

[0341] The difference between this embodiment and embodiment 3.5.1 is that the metal ion Fe in embodiment 3.5.1 is replaced by 3+ Replaced by Al 3+ .

[0342] Results: As shown in Figure 1-7, the eGFP-positive cell rate in the eGFP-mRNA@MPP experimental group was 98.02%, while no eGFP signal was detected in the MPP control group. As shown in Figure 1-8, the RBD protein encoded by the MPP-encapsulated RBD-mRNA was present at 212.6 ng / mL in the 293T cell supernatant, while the RBD protein content in the supernatant of 293T cells transfected with the empty vector MPP was zero. These results suggest that mRNA-MPP can encapsulate and deliver any mRNA and directly encode polypeptides within cells. As shown in Figures 1-9 and 1-10, both RBD-mRNA@MPP and NY-ESO-1-mRNA@MPP effectively induced humoral immunity in mice, producing high levels of antigen-specific antibodies. IgG antibody titers reached 1291.13 in mice treated with RBD-mRNA@MPP, and 650.74 in mice treated with NY-ESO-1-mRNA@MPP. As shown in Figures 1-11 and 1-12, both RBD-mRNA@MPP and NY-ESO-1-mRNA@MPP effectively induced cellular immunity in mice, activating immune cells and producing large amounts of cytokines. RBD-mRNA@MPP increased the expression of cytokines IFN-γ, IL-2, and IL-4 to 271.8 pg / mL, 234.6 pg / mL, and 68.4 pg / mL, respectively; while NY-ESO-1-mRNA@MPP increased the expression of cytokines IFN-γ, IL-2, and TNF-α to 83.8 pg / mL, 98 pg / mL, and 97.8 pg / mL, respectively. These results suggest that mRNA@MPP can encapsulate and deliver any mRNA, thereby promoting the expression of target proteins (antigens), effectively inducing humoral and cellular immunity in mice, producing high levels of antigen-specific antibodies and cytokines, and exerting the effects of anti-COVID-19 mRNA vaccines and anti-tumor mRNA vaccines.

[0343] Example 3.6 Preparation and Effect of siRNA-loaded Metal-chelated Phospholipid Complex Nanoparticles (siRNA@MPP)

[0344] Example 3.6.1: Metal ion is Fe 3+ Preparation and effect of siRNA-loaded metal-chelated phospholipid complex nanoparticles (siRNA@MPP)

[0345] The mRNA in Example 3 was replaced with siRNA, and three siRNA@MPPs containing different siRNAs were prepared according to the method of Example 3. The genes, sequences, and corresponding random control sequences of the three different siRNA targeting genes are as follows: ① The sequence of the siRNA targeting the Bcl-2 gene (Bcl-2-siRNA) is SEQ ID No. 4 (antisense strand) and SEQ ID No. 21 (sense strand) (19 bp), and its random control sequence is SEQ ID No. 5 (antisense strand) and SEQ ID No. 22 (sense strand) (19 bp); ② The sequence of the siRNA targeting the PLK1 gene (PLK1-siRNA) is SEQ ID NO. 6 (antisense strand) and SEQ ID No. 23 (sense strand) (21 bp), and its random control sequence is SEQ ID NO. 7 (antisense strand) and SEQ ID No. 24 (sense strand) (19 bp); ③ The sequence of the siRNA targeting the Gal-1 gene (Gal-1-siRNA) is SEQ ID NO. 8 (19 bp); its random control sequence is SEQ ID NO. 9 (19 bp). The preparation process of the remaining siRNA@MPP is the same as that in Example 3.

[0346] The sequence of Bcl-2-siRNA is as follows:

[0347] Antisense: 5′-CAGCUUAUAAUGGAUGUAC-3′ (SEQ ID No. 4);

[0348] Sense: 5′-GUACAUCCAUUAUAAGCUG-3′ (SEQ ID No. 21) (19 bp).

[0349] The random control sequences of Bcl-2-siRNA are as follows:

[0350] Antisense: 5'-ACGUGACACGUUCGGAGAA-3' (SEQ ID No. 5);

[0351] Sense: 5'-UUCUCCGAACGUGUCACGU-3' (SEQ ID No. 22) (19 bp).

[0352] The sequence of PLK1-siRNA is as follows:

[0353] Antisense: 5'-UAAGGAGGGUGAUCUUCUUCA-3' (SEQ ID No. 6);

[0354] Sense: 5'-UGAAGAAGAUCACCCUCCUUA-3' (SEQ ID No. 23) (21 bp).

[0355] The random control sequences of PLK1-siRNA are as follows:

[0356] Antisense: 5'-CUUACGCUGAGUACUUCGA-3' (SEQ ID No. 7);

[0357] Sense: 5'-UCGAAGUACUCAGCGUAAG-3' (SEQ ID No. 24) (19 bp).

[0358] The sequence of Gal-1-siRNA is as follows:

[0359] 5'-GCUGCCAGAUGGAUACGAA-3' (SEQ ID No. 8) (19 bp).

[0360] The random control sequence of Gal-1-siRNA is as follows:

[0361] 5'-GGAAAUCCCCCAACAGUGA-3' (SEQ ID No. 9) (19 bp).

[0362] Cell culture methods: U251 human glioblastoma cells were grown as monolayers in high-glucose (4.5 g / L) DMEM supplemented with 10% fetal bovine serum (FBS), 1% penicillin / streptomycin, and 2 mm l-glutamine (Bio Industries) at 37°C and 5% CO2, and passaged twice a week.

[0363] U251 cells were cultured at 1 × 10 6 After the cells were seeded in a 6-well plate at a high density for approximately 24 hours, each well of cells was incubated with siRNA@MPP containing the above-mentioned siRNA (where the concentration of siRNA was 2 μg / mL) for 72 hours. The cells were then collected and total cellular RNA was extracted. The mRNA expression levels of the target genes (Bcl-2, PLK1, and Gal-1) were detected by RT-PCR, and the ability of siRNA@MPP to silence the target genes in the cells was calculated.

[0364] RT-PCR specific process:

[0365] Extraction of total RNA: Discard the culture medium from the six-well plate, rinse three times with PBS buffer, and add 1 mL of Trizol to each well to lyse the cells. Add 200 μL of chloroform, shake thoroughly, and let stand at room temperature for 10 minutes. Centrifuge at 13,000 rpm at 4°C for 15 minutes to obtain a three-phase liquid, with RNA dissolved in the upper aqueous phase. Pipette the upper aqueous phase into a new enzyme-free 1.5 mL centrifuge tube, add 500 μL of isopropanol, let stand at room temperature for 10 minutes, and centrifuge at 13,000 rpm at 4°C for 15 minutes to obtain an RNA precipitate. Remove the supernatant and add 1 mL of 75% (v / v) ethanol, freshly prepared with RNase-free water, to each tube. Carefully pipette to remove the white RNA precipitate at the bottom of the tube. Centrifuge at 7,500 rpm at 4°C for 10 minutes. Remove the supernatant and aspirate as much of the liquid at the bottom of the tube as possible. Open the lid and air dry the RNA precipitate at the bottom of the tube at room temperature, add 50 μL of enzyme-free water to dissolve it, and use an ultra-micro UV-visible spectrophotometer to detect the purity and concentration of the RNA.

[0366] cDNA reverse transcription: using Ta Ka Ra Prime Script TM The RT reagent kit with gDNA Eraser reverse transcribes RNA into cDNA, removing genomic DNA (gDNA) before the reverse transcription step for more accurate and reliable results. Prepare the total RNA reverse transcription reaction on ice: 1 μL Prime Script RT Enzyme Mix I, 1 μL RT Primer Mix, 4 μL 5× Prime Script Buffer 2, and 4 μL RNase-Free dH2O. After preparing the reaction mixture, incubate at 37°C for 15 minutes, then terminate the reaction by heating at 85°C for 5 seconds. Store at 4°C until ready to use.

[0367] RT-PCR procedure: This detection method uses the SYBR Green dye method and does not require a probe. Specifically, real-time PCR reactions were performed using cDNA from different samples as templates. The reaction solution was prepared on ice: 5 μL SYBR Premix Dimer Eraser (2×), 0.3 μL PCR Forward primer (10 μM), 0.3 μL PCR Reverse primer (10 μM), 0.2 μL ROX Reference Dye II (50×), 1 μL of the cDNA template obtained in the previous step, and 3.2 μL dH2O. The sample was added to the well plate, with 10 μL per well. After addition, the sample was centrifuged (1000 rpm, 5 min) to eliminate liquid adhering to the wall and any bubbles in the reaction solution. Real-time PCR was performed using an ABI ViiA7 real-time fluorescence quantitative PCR instrument. The reaction procedure was: 95°C, 30 seconds (1 cycle) → 95°C, 5 seconds; 55°C, 30 seconds; 72°C, 30 seconds (40 cycles) → 60°C-95°C, 2 minutes (1 cycle). The experiment was repeated three times, and the average Ct value was calculated for each group. The fold difference in expression between the experimental and control groups was calculated. The control gene was GAPDH. RT-PCR primers were as follows: ①Bcl-2 primer: forward: 5'-AGGATTGTGGCCTTCTTTGAG-3', reverse: 5'-AGACAGCCAGGAGAAATC AAAC-3'; ②PLK1 primer: forward: 5'-ACCAGCACGTCGTAGGATTC-3', reverse: 5'-CAAGCAATTTGCCGTAGG-3'; ③Gal-1 primer: forward: 5'-CAATCAT GGCCTGTGGTCTG-3', reverse: 5'-GTG TAGGCACAGGTTGTTGCTG-3'. ④GAPDH primer: forward: 5'-TCAGGGGTTTCACATTTGGCA-3', reverse: 5'-GG AGCGGAA AACCA-3'. The expression level of each target gene was calculated using the RQ value (2 -ΔΔCT ) is expressed as follows: Fold Change = 2 –ΔΔCt

[0368] Where ΔΔCt=ΔCt 实验组 –ΔCt 对照组 , ΔCt=Ct 目的基因 -Ct 内参基因

[0369] Calculation method of gene silencing efficiency: Calculation method of gene silencing efficiency: 100% - gene expression level of experimental group / gene expression level of control group.

[0370] Results: As shown in Figures 1-13, 1-14, and 1-15 (where scr siRNA is a randomized control sequence), all three siRNA@MPPs significantly interfered with their corresponding target genes. Bcl-2-siRNA@MPP achieved a 76% inhibition rate against the target gene Bcl-2; PLK1-siRNA@MPP achieved an 86% inhibition rate against the target gene PLK1; and Gal-1-siRNA@MPP achieved a 73% inhibition rate against the target gene Gal-1. These results suggest that siRNA@MPP can carry any siRNA for target gene intervention therapy, potentially facilitating the development of siRNA-loaded drugs, vaccines, or other products.

[0371] Example 3.6.2: Metal ion is Al 3+ Preparation and effect of siRNA-loaded metal-chelated phospholipid complex nanoparticles (siRNA@MPP)

[0372] The difference between this embodiment and embodiment 3.6.1 is that the metal ion Fe in embodiment 3.6.1 is replaced by 3+ Replaced by Al 3+ .

[0373] Results: As shown in Figures 1-16, 1-17, and 1-18, all three siRNA@MPPs significantly interfered with their corresponding target genes. Bcl-2-siRNA@MPP achieved an 81% inhibition rate against the target gene Bcl-2; PLK1-siRNA@MPP achieved a 90% inhibition rate against the target gene PLK1; and Gal-1-siRNA@MPP achieved a 79% inhibition rate against the target gene Gal-1. These results suggest that siRNA@MPPs can carry any siRNA for target gene intervention therapy, potentially facilitating the development of siRNA-loaded drugs, vaccines, or other products.

[0374] Example 3.7. Preparation and Effect of ASO-loaded Metal-chelated Phospholipid Complex Nanoparticles (ASO@MPP)

[0375] Example 3.7.1: Metal ion is Fe 3+Preparation and effect of ASO-loaded metal-chelated phospholipid complex nanoparticles (ASO@MPP)

[0376] The mRNA in Example 3 was replaced with ASO, and three ASO@MPPs containing different ASOs were prepared according to the method of Example 3. The genes, sequences, and corresponding random control sequences of the three different ASOs were as follows: ① The ASO targeting the STAT3 gene (STAT3-ASO) sequence was SEQ ID No. 10 (17 nt), and its random control sequence was SEQ ID NO. 11 (18 nt); ② The ASO targeting the α-syn gene (α-syn-ASO) sequence was SEQ ID NO. 12 (16 nt), and its random control sequence was SEQ ID NO. 13 (16 nt); ③ The ASO targeting the Bcl-2 gene (Bcl-2-ASO) sequence was SEQ ID NO. 14 (18 nt), and its random control sequence was SEQ ID NO. 15 (20 nt). The preparation process of the remaining ASO-metal-phospholipid complex particles was the same as in Example 3. Different ASO@MPPs were incubated with different cells: ASO@MPP targeting STAT3 gene was incubated with U251 human glioblastoma cells; ASO@MPP targeting α-syn gene was incubated with SH-SY5Y human neuroblastoma cells; ASO@MPP targeting Bcl-2 gene was incubated with Daudi human lymphoma cells. 6 After the cells were seeded in a 6-well plate at a high density for approximately 24 hours, each well of cells was incubated with ASO@MPP containing the above-mentioned ASO (where the concentration of ASO was 1 μg / mL) for 48 hours. The cells were then collected and total RNA was extracted. The mRNA expression levels of the target genes (STAT3, α-syn, and Bcl-2) were detected by RT-PCR, and the ability of ASO@MPP to silence the target genes in the cells was calculated.

[0377] The sequence of SEQ ID No. 10 (SEQ ID No. 10 of STAT3-ASO) is as follows:

[0378] 5'-GCTCCAGCATCTGCTTC-3'(17nt).

[0379] The sequence of SEQ ID No.11 (random control sequence of STAT3-ASO) is as follows:

[0380] 5'-GAAGCAGCAGATGCTGGA-3'(18nt).

[0381] The sequence of SEQ ID No. 12 (sequence of α-syn-ASO) is as follows:

[0382] 5'-GCCTCCCTCCACTGTCT-3'(16nt).

[0383] The sequence of SEQ ID No. 13 (random control sequence of α-syn-ASO) is as follows:

[0384] 5'-ACTCCCGAACCTGTCT-3'(16nt).

[0385] The sequence of SEQ ID No. 14 (sequence of Bcl-2-ASO) is as follows:

[0386] 5'-TCTCCCAGGCGTGCGCCAT-3'(18nt).

[0387] The sequence of SEQ ID No. 15 (random control sequence of Bcl-2-ASO) is as follows:

[0388] 5'-CAGCGTGCGCCATCCTTCCC-3'(20nt).

[0389] Cell culture: ① U251 human glioblastoma cells were grown as monolayers in high-glucose (4.5 g / L) DMEM + 10% fetal bovine serum (FBS), 1% penicillin / streptomycin, and 2 mm l-glutamine (Bio Industries) at 37°C, 5% CO2, and passaged twice per week. ② SH-SY5Y human neuroblastoma cells were grown as monolayers in high-glucose (4.5 g / L) DMEM + 10% fetal bovine serum (FBS), 1% penicillin / streptomycin, and 2 mm l-glutamine (Bio Industries) at 37°C, 5% CO2, and passaged twice per week. ③ Daudi human lymphoma cells were grown in RPMI 1640 + 10% fetal bovine serum (FBS), 1% penicillin / streptomycin, and 2 mm l-glutamine (Bio Industries) at 37°C, 5% CO2, and passaged twice per week.

[0390] RT-PCR specific process:

[0391] Extraction of total RNA: Discard the culture medium from the six-well plate, rinse three times with PBS buffer, and add 1 mL of Trizol to each well to lyse the cells. Add 200 μL of chloroform, shake thoroughly, and let stand at room temperature for 10 minutes. Centrifuge at 13,000 rpm at 4°C for 15 minutes to obtain a three-phase liquid, with RNA dissolved in the upper aqueous phase. Pipette the upper aqueous phase into a new enzyme-free 1.5 mL centrifuge tube, add 500 μL of isopropanol, let stand at room temperature for 10 minutes, and centrifuge at 13,000 rpm at 4°C for 15 minutes to obtain an RNA precipitate. Remove the supernatant and add 1 mL of 75% (v / v) ethanol, freshly prepared with RNase-free water, to each tube. Carefully pipette to remove the white RNA precipitate at the bottom of the tube. Centrifuge at 7,500 rpm at 4°C for 10 minutes. Remove the supernatant and aspirate as much of the liquid at the bottom of the tube as possible. Open the lid and air dry the RNA precipitate at the bottom of the tube at room temperature, add 50 μL of enzyme-free water to dissolve it, and use an ultra-micro UV-visible spectrophotometer to detect the purity and concentration of the RNA.

[0392] cDNA reverse transcription: using Ta Ka Ra Prime Script TM The RT reagent kit with gDNA Eraser reverse transcribes RNA into cDNA, removing genomic DNA (gDNA) before the reverse transcription step for more accurate and reliable results. Prepare the total RNA reverse transcription reaction on ice: 1 μL Prime Script RT Enzyme Mix I, 1 μL RT Primer Mix, 4 μL 5× Prime Script Buffer 2, and 4 μL RNase-Free dH2O. After preparing the reaction mixture, incubate at 37°C for 15 minutes, then terminate the reaction by incubating at 85°C for 5 seconds. Store at 4°C until ready to use.

[0393] RT-PCR Procedure: This detection method uses the SYBR Green dye method and does not require a probe. Specifically, real-time PCR reactions were performed using cDNA from different samples as templates. The reaction solution was prepared on ice: 5 μL SYBR Premix Dimer Eraser (2×), 0.3 μL PCR Forward Primer (10 μM), 0.3 μL PCR Reverse Primer (10 μM), 0.2 μL ROX Reference Dye II (50×), 1 μL of the cDNA template obtained in the previous step, and 3.2 μL dH2O. Samples were added to the well plate, with 10 μL per well. After addition, the plate was centrifuged (1000 rpm, 5 min) to eliminate any bubbles in the reaction solution and any liquid adhering to the wall. Real-time PCR was performed using an ABI ViiA7 real-time fluorescence quantitative PCR instrument. The reaction procedure was: 95°C, 30 seconds (1 cycle) → 95°C, 5 seconds; 55°C, 30 seconds; 72°C, 30 seconds (40 cycles) → 60°C-95°C, 2 minutes (1 cycle). The experiment was repeated three times, and the average Ct value was calculated for each group. The fold difference in expression between the experimental and control groups was calculated. The control gene was GAPDH. The RT-PCR primer sequences are as follows: ①STAT3 primer: forward: 5'-TGATCACCTTTGAGACCGAGG-3', reverse: 5'-GATCACCACAACTGG CAA GG-3'; ②α-syn primer: forward: 5'-TGACGGGTGTGACAGCAGTAG-3', reverse: 5'-CAGTGGCTGCTGCAATG-3'; ③Bcl-2 primer: forward: 5'-AGGATT GTG GCCTTCTTTGAG-3', reverse: 5'-AGACAGCCAGGAGAAATCAAAC-3'; ④GAPDH primer: forward: 5'-TCAGGGG TTTCACATTTGGCA-3', reverse: 5'-GGAGCGGAA AACCA-3'. The expression levels of each target gene were calculated using the RQ value (2 -ΔΔCT ) is expressed as follows: Fold Change = 2 –ΔΔCt

[0394] Where ΔΔCt=ΔCt 实验组 –ΔCt 对照组 , ΔCt=Ct 目的基因 -Ct 内参基因

[0395] The calculation method of gene silencing efficiency is: 100% - gene expression level of experimental group / gene expression level of control group.

[0396] Results: As shown in Figures 1-19, 1-20, and 1-21 (where the scr ASO is a randomized control sequence), all three ASO@MPPs significantly interfered with their corresponding target genes. STAT3-ASO@MPP achieved a 75% inhibition rate against the target gene STAT3; α-syn-ASO@MPP achieved a 71% inhibition rate against the target gene α-syn; and Bcl-2-ASO@MPP achieved a 66% inhibition rate against the target gene Bcl-2. These results suggest that ASO@MPPs can carry any ASO for target gene intervention therapy, potentially maximizing the potential of ASO-carrying drugs, vaccines, or other products.

[0397] Example 3.7.2: Metal ion is Al 3+ Preparation and effect of ASO-loaded metal-chelated phospholipid complex nanoparticles (ASO@MPP)

[0398] The difference between this embodiment and embodiment 3.7.1 is that the metal ion Fe in embodiment 3.7.2 is replaced by 3+ Replaced by Al 3+ .

[0399] Results: As shown in Figures 1-22, 1-23, and 1-24, all three ASO@MPPs significantly interfered with their corresponding target genes. STAT3-ASO@MPP achieved a 79% inhibition rate against the target gene STAT3; α-syn-ASO@MPP achieved an 80% inhibition rate against the target gene α-syn; and Bcl-2-ASO@MPP achieved a 74% inhibition rate against the target gene Bcl-2. These results suggest that ASO@MPPs can carry any ASO for target gene intervention therapy, potentially maximizing the potential of ASO-carrying drugs, vaccines, or other products.

[0400] Example 3.8 Preparation of drug (different types of nucleic acids)-metal-phospholipid complex particles and their effects

[0401] Example 3.8.1: Preparation of Metal Ions: Fe 3+ Drug (different types of nucleic acids)-metal-phospholipid complex particles and their effects

[0402] The mRNA in Example 3 was replaced by double-stranded RNA (siRNA), single-stranded DNA (ASO), single-stranded RNA (mRNA), double-stranded DNA, and single-stranded DNA, respectively. The different types of nucleic acid sequences are: ① The sequence of double-stranded RNA (Bcl-2-siRNA) is SEQ ID NO.4 (antisense chain) and SEQ ID No.21 (sense chain) (19 bp), and its random control sequence is SEQ ID NO.5 (antisense chain) and SEQ ID No.22 (sense chain) (19 bp); ② The sequence of single-stranded DNA (STAT3-ASO) is SEQ ID NO.10 (17 nt), and its random control sequence is SEQ ID NO.11 (18 nt); ③ The sequence of single-stranded RNA (mRNA encoding wild-type SARS-CoV-2 S protein) is SEQ ID No.16 (3822 nt); ④ The sequence of double-stranded DNA (dsDNA) is SEQ ID NO.17 (antisense chain) and SEQ ID NO.25 (sense chain) (22 bp) (the 3' end of the sequence is labeled with fluorescent probe Cy3); ⑤ The sequence of single-stranded DNA (ssDNA) is SEQ ID NO.18 (22 nt) (the 3' end of the sequence is labeled with fluorescent probe Cy3). Drug-metal-phospholipid complex particles (Bcl-2-siRNA@MPP, STAT3-ASO@MPP, S-mRNA@MPP, dsDNA@MPP, ssDNA@MPP) encapsulating the above-mentioned different types of nucleic acids were prepared respectively according to the method of Example 3. The preparation process of the remaining drug-lipid particles was the same as that of Example 3.

[0403] The sequence of double-stranded DNA is as follows:

[0404] Antisense: 5'-TAGCTTATCAGACTGATGTTGA-3' (SEQ ID No. 17);

[0405] Sence: 5'-TCAACATCAGTCTGATAAGCTA-3' (SEQ ID No. 25) (22 bp).

[0406] The sequence of SEQ ID No. 18 (single-stranded DNA sequence) is as follows:

[0407] 5'-TCAACATCAGTCTGATAAGCTA-3'(22nt).

[0408] U251 cells were cultured at 1 × 10 5After the cells were seeded at a high density in a 12-well plate for approximately 24 hours, each well of cells was incubated with siRNA@MPP (wherein the concentration of siRNA was 2 μg / mL) or ASO@MPP (wherein the concentration of ASO was 2 μg / mL) for 72 hours, and then the cells were collected and total cellular RNA was extracted. The mRNA expression levels of the target genes (Bcl-2, STAT3) were detected by RT-PCR, and the ability of siRNA@MPP or ASO@MPP to silence the target genes in the cells was calculated. The results are shown in Figures 1-13 of Example 3.6 and Figures 1-19 of Example 3.7.

[0409] S-mRNA@MPP was incubated with 293T cells at a concentration of 2 μg / mL (the concentration of the contained mRNA). The control group was incubated with MPP. After 24 hours, the supernatant was centrifuged and stored at -20°C for later use. The cell pellet was resuspended in 100 μL PBS buffer solution, frozen and thawed twice, and sonicated for 10 minutes before centrifugation to obtain the supernatant. The expression levels of S protein in both the cell supernatant and cell lysate were detected using a commercially available SARS-CoV-2 S protein ELISA kit. The results are shown in Figure 1-25.

[0410] A549 lung cancer cells were incubated with ds-DNA@MPP at a concentration of 100 nM (the concentration of DNA contained) for 2 hours, and then the remaining drug-lipid particles were removed. The cells were washed twice with PBS, and the cell nuclei were stained with Hochest33342 dye for 3 minutes, after which the dye was removed. The cells were washed twice with PBS and observed using a high-content imaging system. The efficiency of drug-lipid particle transfection with DNA was calculated. The results are shown in Figure 1-26.

[0411] HT22 mouse hippocampal neurons were incubated with ss-DNA@MPP at a concentration of 200 nM (the concentration of DNA contained) for 2 hours. The remaining drug-lipid particles were removed, and the cells were washed twice with PBS. The cells were observed using a high-content imaging system, and the efficiency of drug-lipid particle transfection with DNA was calculated. The results are shown in Figure 1-26.

[0412] The culture method of human glioblastoma U251 cells is the same as that in Example 3.6.

[0413] The culture method of 293T cells is the same as that in Example 3.

[0414] Culture method of HT22 mouse hippocampal neurons: culture in DMEM containing 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO2.

[0415] The RT-PCR method is the same as in Example 3.6.

[0416] ELISA detection of S protein expression level: replace the "anti-RBD antibody working solution" in the ELISA method for detecting RBD in Example 3.5 with "anti-S protein antibody working solution", and the remaining steps are the same as Example 3.5.

[0417] The calculation method of gene silencing efficiency is the same as Example 3.6.

[0418] Method for calculating transfection efficiency: Use a high-content imaging system to randomly select 3-5 fields of view to obtain cell morphology under ordinary light source, fluorescence signal under excitation / emission light of 550nm / 570nm (excitation light of the fluorescent dye Cy3 that labels DNA) and fluorescence signal under excitation / emission light of 352nm / 461nm (excitation light of the fluorescent dye Hoechst33342 that labels the cell nucleus) in the same field of view. The ratio of the number of cells with Cy3 fluorescent signal in the randomly selected field of view to the number of cells with Hoechst33342 fluorescent signal in the same field of view is calculated as the transfection efficiency.

[0419] Result analysis: As shown in Figure 1-13 of Example 3.6.1, the inhibition rate of drug (double-stranded RNA)-metal-phospholipid complex particles (Bcl-2-siRNA@MPP) on the target gene Bcl-2 reached 76%; as shown in Figure 1-19 of Example 3.7.1, the inhibition rate of drug (single-stranded DNA)-metal-phospholipid complex particles (STAT3-ASO@MPP) on the target gene STAT3 reached 75%; as shown in Figure 1-25, drug (single-stranded RNA)-metal-phospholipid complex particles (S The S protein expression level in the supernatant of 293T cells transfected with the drug (double-stranded DNA)-metal-phospholipid complex particles (dsDNA@MPP) was 161.3 ng / mL, while the S protein content in the supernatant of 293T cells transfected with the empty vector MPP was 0. The efficiency of double-stranded DNA transfection into cells using the drug (double-stranded DNA)-metal-phospholipid complex particles (dsDNA@MPP) was 100% (Figure 1-26); the efficiency of single-stranded DNA transfection into cells using the drug (ssDNA)-metal-phospholipid complex particles (ssDNA@MPP) was 100% (Figure 1-26). The results suggest that the drug-metal-phospholipid complex particles can encapsulate any nucleic acid (double-stranded RNA, single-stranded RNA, double-stranded DNA, single-stranded DNA) and achieve its function, with the nucleic acid length ranging from 16 to 3822 nt.

[0420] Example 3.8.2: Preparation of Metal Ions: Al 3+ Drug (different types of nucleic acids)-metal-phospholipid complex particles and their effects

[0421] The difference between this embodiment and embodiment 3.8.1 is that the metal ion Fe in embodiment 3.8.1 is replaced by 3+ Replaced by Al3+ .

[0422] Result analysis: As shown in Figure 1-16 of Example 3.6.2, the inhibition rate of drug (double-stranded RNA)-metal-phospholipid complex particles (Bcl-2-siRNA@MPP) on the target gene Bcl-2 reached 81%; as shown in Figure 1-22 of Example 3.7.2, the inhibition rate of drug (single-stranded DNA)-metal-phospholipid complex particles (STAT3-ASO@MPP) on the target gene STAT3 reached 79%; as shown in Figure 1-27, drug (single-stranded RNA)-metal-phospholipid complex particles (S The S protein expression level in the supernatant of 293T cells transfected with the drug (double-stranded DNA)-metal-phospholipid complex particles (dsDNA@MPP) was 178.7 ng / mL, while the S protein content in the supernatant of 293T cells transfected with the empty vector MPP was 0. The efficiency of double-stranded DNA transfection into cells using the drug (double-stranded DNA)-metal-phospholipid complex particles (dsDNA@MPP) was 100% (Figure 1-28); the efficiency of single-stranded DNA transfection into cells using the drug (ssDNA)-metal-phospholipid complex particles (ssDNA@MPP) was 100% (Figure 1-28). The results suggest that the drug-metal-phospholipid complex particles can encapsulate any nucleic acid (double-stranded RNA, single-stranded RNA, double-stranded DNA, single-stranded DNA) and achieve its function, with the nucleic acid length ranging from 16 to 3822 nt.

[0423] Experimental Example 2: Performance Characterization of Drug-Metal-Phospholipid Complex Particles

[0424] Example 4: Synthesis and Characterization of Metal-Phospholipid Complexes

[0425] Example 4.1: Metal ion is Fe 3+ Synthesis and characterization of metal-phospholipid complexes

[0426] The connection between DSPC and curcumin was characterized by differential scanning calorimetry. The following conditions were used: 3–5 mg of the test sample was weighed and the temperature was raised at a rate of 10°C / min over a range of 30–300°C. Curcumin, DSPC, and the phospholipid complex were scanned separately. Curves were plotted based on the data obtained, as shown in Figure 2-1. The curves show that curcumin has a lattice structure, with a distinct melting peak at 185°C. DSPC is a mixture, with multiple depressions on the curve, likely due to thermal variations in the different components under different temperature conditions. The phospholipid complex exhibits no peaks near the curcumin melting peak, essentially forming a straight line. This indicates that curcumin and DSPC are bound together and exist in an amorphous form, confirming the successful preparation of the phospholipid complex.

[0427] Phospholipid complex with Fe 3+The connection is characterized by spectrophotometry: As shown in Figure 2-2, the phospholipid complex (CUR-HSPC) and Fe 3+ After binding, the maximum absorption wavelength shifted from 420nm to 375nm, and the conjugated structure of the phospholipid complex changed, proving that Fe 3+ Successfully complexed with curcumin.

[0428] Example 4.2: Metal ion is Al 3+ Synthesis and characterization of metal-phospholipid complexes

[0429] The difference between this embodiment and embodiment 4.1 is that the phospholipid complex and Al 3+ The connection is characterized by spectrophotometry: As shown in Figure 2-3, the phospholipid complex (CUR-HSPC) and Al 3+ After binding, the maximum absorption wavelength shifted from 420nm to 433nm, and the conjugated structure of the phospholipid complex changed, proving that Al 3+ Successfully complexed with curcumin.

[0430] Example 5: Metal ion is Fe 3+ At low pH, Fe 3+ Characterization of shedding from metal-phospholipid complexes

[0431] The phospholipid complex in the metal-phospholipid complex binds Fe through coordination bonds 3+ Under the low pH conditions of lysosomes, phospholipid complexes and Fe 3+ The coordination bonds between them will be protonated (absorb hydrogen ions) and broken. 3+ Indeed, it is through the above mechanism that the metal-phospholipid complex is detached from the lipid complex. We designed the following experiment: Under physiological pH (pH = 7.4) and lysosomal low pH (pH = 5.0), the color of the metal-phospholipid complex was observed. As shown in Figure 2-4, the metal-phospholipid complex changed from brown-red to bright yellow under lysosomal low pH (pH = 5.0), indicating that Fe 3+ The results suggest that under the low pH conditions of lysosomes, Fe 3+ Can be detached from the metal-phospholipid complex.

[0432] Under low pH conditions, Fe 3+ The principle of shedding from the metal-phospholipid complex is: curcumin and Fe 3+ The coordination bonds between them are protonated under low pH conditions (pH = 5.0), that is, curcumin binds a large number of protons (H + ), leading to Fe 3+ The coordination bond between Fe and curcumin is broken, which makes Fe 3+Separation from curcumin, ultimately leading to Fe 3+ Separated from the metal-phospholipid complex (Figure 2-4).

[0433] Example 6: Elemental Analysis of MPP in Drug-Metal-Phospholipid Complex Particles

[0434] Example 6.1: Metal ion is Fe 3+ Elemental Analysis of MPP in Drug-Metal-Phospholipid Complex Particles

[0435] The mRNA in Example 3 was replaced with thiol-modified siRNA, and the drug-metal-phospholipid complex particles siRNA@MPP were prepared according to the method of Example 3. Elemental analysis was performed using a transmission electron microscope. The results are shown in Figures 2-5: C, N, O, and P are common elements. The Fe elemental analysis shows that Fe 3+ Evenly distributed on the lipid nanoparticles, because the siRNA is modified with sulfhydryl groups, the S element analysis diagram can specifically indicate the location of the siRNA. It can be seen from the figure that the siRNA is well complexed with Fe 3+ , proving that the drug-lipid nanoparticles successfully encapsulated siRNA.

[0436] Example 6.2: Metal ion is Al 3+ Electron microscopic analysis of MPP in drug-metal-phospholipid complex particles

[0437] Drug-metal-phospholipid complex particles (MPPs) were prepared according to the method of Example 3. Morphological analysis was performed using a transmission electron microscope. The results are shown in Figures 2-6: The MPPs in the drug-metal-phospholipid complex particles were spherical in shape and had a uniform particle size of approximately 100 nm.

[0438] Example 7: Metal ion is Fe 3+ Or Al 3+ The efficiency of metal-phospholipid complex particles MPP encapsulating nucleic acids (siRNA and mRNA) and its comparison with LNP.

[0439] The mRNA in Example 3 was replaced with siRNA targeting the Bcl-2 gene (SEQ ID No. 4, 19 bp) and mRNA encoding the receptor binding domain (RBD) of the novel coronavirus S1 subunit (SEQ ID No. 2, 669 nt), respectively, to prepare nucleic acid-encapsulated drug-metal-phospholipid complex particles siRNA@MPP and mRNA@MPP, respectively. The preparation process of the remaining drug-metal-phospholipid complex particles was the same as in Example 3.

[0440] siRNA@LNPs and mRNA@LNPs were prepared using the same drug loading as in Example 3.6 for siRNA@MPP and Example 3.5 for mRNA@MPP. The specific method was as follows: an organic phase solution was prepared according to the Onpattro lipid nanoparticle formulation, wherein the ionizable lipid ALC0315, DSPE-PEG2000, DSPC, and cholesterol were dissolved in ethanol at a molar ratio of 50%:1.5%:10%:38.5%. Bcl-siRNA or RBD-mRNA was added to the aqueous phase (0.1 M acetic acid-sodium acetate buffer, pH 4.0). The amino lipid to phosphate-containing nucleotide ratio (N / P) was 6:1, ensuring the same nucleic acid drug loading as in the siRNA@MPP and mRNA@MPP formulations described above. The aqueous and organic phases were rapidly mixed at a volume ratio of 3:1 at a flow rate of 14 mL / min. After mixing, the mixture was diluted tenfold with enzyme-free PBS buffer solution and concentrated to one-tenth using a 100 kDa ultrafiltration tube. After repeating the dilution and concentration operation three times, the ethanol concentration in the mixture was reduced to below 0.0005% and the pH value of the solution was increased to the normal pH value of PBS buffer solution (7.2-7.4), thus producing siRNA@LNP and mRNA@LNP, respectively.

[0441] Agarose gel electrophoresis was used to examine the nucleic acid (siRNA and mRNA) loading efficiency of siRNA@MPP, mRNA@MPP, siRNA@LNP, and mRNA@LNP. The loading efficiency was determined as follows: the nucleic acid (siRNA and mRNA) loading rate for each lipid nanoparticle group was set at 10 μg / mL, with a lipid-to-nucleic acid mass ratio of 40:1. The nucleic acids were dissolved in PBS buffer as a positive control, while a nucleic acid-free PBS buffer solution was used as a negative control. The agarose gel concentration was 1.5%, which allows only free nucleic acids to pass through the gel, not the lipid nanoparticles. Electrophoresis was stopped when the free nucleic acid bands were clearly distinguishable to prevent nucleic acid degradation due to prolonged electrophoresis. Image J software was used to calculate the grayscale value of free nucleic acid in each group. The positive control group was set at 100%. The ratio of free nucleic acid in each group to the positive control was the relative amount of free nucleic acid. The loading efficiency for each group was calculated as (100 - relative amount of free nucleic acid)%.

[0442] Result analysis: As shown in Figure 2-7, MPP(Fe 3+ ) encapsulation efficiency of siRNA and mRNA was 85.86% and 87.11% respectively; MPP (Al 3+ The efficiency of MPP and LNP in encapsulating siRNA and mRNA was 89.73% and 92.23% respectively; the efficiency of LNP in encapsulating siRNA and mRNA was 84.98% and 79.12% respectively. The results showed that there was no significant difference in the efficiency of nucleic acid encapsulation between MPP and LNP.

[0443] Example 8: Metal ion is Fe 3+ Or Al 3+ The lysosomal escape ability of metal-phospholipid complex particles (MPP) and its comparison with LNP

[0444] The Bcl-2-siRNA (SEQ ID No. 4) of Example 3.6 was replaced with Cy5-labeled Bcl-2-siRNA to prepare Cy5-siRNA@MPP (the concentration of the siRNA contained was 100 nM), and the Bcl-2-siRNA (SEQ ID No. 4) of Example 7 was replaced with Cy5-labeled Bcl-2-siRNA to prepare Cy5-siRNA@LNP (the concentration of the siRNA contained was 100 nM); the eGFP-mRNA (SEQ ID No. 1) of Example 3.5 was replaced with Cy5-labeled eGFP-mRNA to prepare Cy5-mRNA@MPP (the concentration of the mRNA contained was 2 μg / mL), and the RBD-mRNA of Example 7 was replaced with Cy5-labeled RBD-mRNA to prepare Cy5-mRNA@LNP (the concentration of the mRNA contained was 2 μg / mL), and they were respectively mixed with the cell lysosome probe Lysotracker After co-incubating A549 cells with Cy5 and Lysotracker Green for 3 hours, a high-content imaging system was used to observe the overlap of the Cy5 fluorescence signal (red) and the Lysotracker Green fluorescence signal (green) to determine the ability of the drug-lipid particles to promote nucleic acid lysosomal escape.

[0445] The ability of drug-metal-phospholipid complex particles to promote nucleic acid lysosomal escape was determined by incubating cells with the drug-lipid nanoparticles for 3 hours. High-content imaging was used to observe the overlap between the Cy5 fluorescence signal (red) and the Lysotracker Green fluorescence signal (green). ImageJ software was used to calculate the overlap ratio between the red and green fluorescence signals. A 3-hour overlap ratio of less than 50% between the red and green fluorescence signals indicated rapid nucleic acid escape from lysosomes, indicating that the lipid nanoparticles possessed robust lysosomal escape ability.

[0446] Result analysis: As shown in Figure 2-8, when Cy5-siRNA@MPP(Fe 3+ ) and Cy5-mRNA@MPP(Fe 3+) incubated A549 cells for 3 hours, the overlap rates of red fluorescence signal and green fluorescence signal were 36.05% and 43.07%, respectively, that is, the lysosomal escape rates were 63.95% and 56.93%, respectively; when Cy5-siRNA@MPP(Al 3+ ) and Cy5-mRNA@MPP(Al 3+ After incubation of A549 cells with Cy5-siRNA@LNP and Cy5-mRNA@LNP for 3 hours, the overlap rates of the red and green fluorescence signals were 32.39% and 40.17%, respectively, indicating lysosomal escape rates of 67.61% and 59.83%, respectively. In contrast, after incubation of A549 cells with Cy5-siRNA@LNP and Cy5-mRNA@LNP for 3 hours, the overlap rates of the red and green fluorescence signals were 76.89% and 86.87%, respectively, indicating lysosomal escape abilities of 23.11% and 13.13%, respectively. This suggests that the drug-lipid nanoparticle MPP has a strong ability to promote nucleic acid lysosomal escape, and that MPP's ability to promote lysosomal escape is significantly stronger than that of LNP.

[0447] Example 9: Metal ion is Fe 3+ Or Al 3+ The ability of metal-phospholipid complex particles (MPP) to promote nucleic acid expression and its comparison with LNP

[0448] The RBD-mRNA in Example 7 was replaced with mRNA encoding the fluorescent protein eGFP, and the rest of the preparation method was the same as Example 7 to obtain eGFP-mRNA@LNP.

[0449] The eGFP-mRNA@MPP prepared in Example 3 and the above-mentioned eGFP-mRNA@LNP (containing mRNA at a concentration of 2 μg / mL) were incubated with 293T cells, respectively. The control group was incubated with MPP or LNP. After 48 h, the cell suspension was collected and the percentage of eGFP-positive cells was detected by flow cytometry.

[0450] The method for analyzing the eGFP-positive cell rate by flow cytometry is as described in Example 3.

[0451] Result analysis: As shown in Figure 2-9, MPP(Fe 3+ )、MPP(Al 3+ ) and LNP treatment of 293T cells, the percentages of eGFP-positive cells were 97.2%, 98.1%, and 63.03%, respectively. These results suggest that MPP is superior to LNP in promoting nucleic acid expression. This may be due to the fact that, as described in Example 8, MPP's ability to promote lysosomal escape of nucleic acids is stronger than LNP, allowing more nucleic acids loaded with MPP to be effectively released into the cytoplasm, where they are translated into proteins.

[0452] Example 10: Metal ion is Fe3+ Or Al 3+ The ability of drug-metal-phospholipid complex particles (MPP) to promote humoral and cellular immunity and its comparison with LNP

[0453] The RBD-mRNA@MPP of Example 3.5 and the RBD-mRNA@LNP of Example 7 were incubated with 293T cells at a concentration of 2 μg / mL (the concentration of the contained mRNA). The control group was incubated with MPP. After 24 hours, the supernatant was centrifuged and frozen at -20°C for later use; the cell pellet was resuspended in 100 μL PBS buffer solution, frozen and thawed twice, and sonicated for 10 minutes before centrifugation to obtain the supernatant. The expression level of RBD protein in both the cell supernatant and the cell lysate was detected using a commercially available new coronavirus antigen RBD ELISA detection kit. The results are shown in Figures 2-10.

[0454] The ELISA method for detecting RBD expression levels is as described in Example 3.5.

[0455] The experimental animals were randomly divided into 3 groups (experimental group and control group), with 5 mice in each group. The animal model was BALB / c mice. Each mouse was injected intramuscularly for the first time on the first day and for the second time on the 14th day. The experimental group was injected with RBD-mRNA@MPP(Fe 3+ )、RBD-mRNA@MPP(Al 3+ ) or RBD-mRNA@LNP, and the control group was injected with MPP and LNP without mRNA. The dose of each administration was 100 μL, of which RBD-mRNA@MPP(Fe 3+ )、RBD-mRNA@MPP(Al 3+ ) and RBD-mRNA@LNP formulations each contained 30 mg of mRNA. Blood was collected from mice 28 days after the first dose, and serum was separated and serially diluted. The titer of total RBD IgG antibodies against the novel coronavirus S1 subunit produced in the mice was measured using a commercially available ELISA kit. The results are shown in Figures 2-11.

[0456] The ELISA method for detecting the titer of total RBD IgG antibodies against the novel coronavirus S1 subunit is as described in Example 3.5.

[0457] In the presence of RBD-mRNA@MPP(Fe 3+ )、RBD-mRNA@MPP(Al 3+) and RBD-mRNA@LNP, the spleens of normal mice were collected 28 days after injection, and single-cell suspensions were prepared under sterile conditions. 100,000 spleen cells were plated in a cell plate at a density of 10 mg / mL. RBD protein was added at a final concentration of 10 mg / mL and cultured for 48 hours. The supernatant was removed by centrifugation, and the expression levels of IFN-γ, IL-2, and IL-4 were determined by ELISA kits. The results are shown in Figure 2-12.

[0458] The method for detecting the expression levels of IFN-γ, IL-2, and IL-4 by ELISA is as described in Example 3.5.

[0459] Result analysis: As shown in Figure 2-10, RBD-mRNA@MPP(Fe 3+ )、RBD-mRNA@MPP(Al 3+ ) and RBD-mRNA@LNP can induce 293T cells to express a certain amount of RBD, but RBD-mRNA@MPP(Al 3+ ) was significantly more effective in inducing cell expression of RBD than RBD-mRNA@MPP(Fe 3+ )、RBD-mRNA@MPP(Fe 3+ ) was significantly stronger in inducing cell expression of RBD than RBD-mRNA@LNP: RBD-mRNA@MPP(Fe 3+ ) treatment group in the cell supernatant was 205ng / mL, RBD-mRNA@MPP(Al 3+ ) treatment group in the supernatant of RBD was 230ng / mL, and the RBD expression level in the supernatant of RBD-mRNA@LNP treatment group was 115.7ng / mL. As shown in Figure 2-11, RBD-mRNA@MPP effectively induced humoral immunity in mice and produced high levels of antigen-specific binding antibodies, and RBD-mRNA@MPP(Al 3+ ) is clearly superior to RBD-mRNA@MPP(Fe 3+ ), RBD-mRNA@MPP(Fe 3+ ) is clearly superior to RBD-mRNA@LNP in inducing humoral immunity in mice: RBD-mRNA@MPP(Fe 3+ ) treatment group mice IgG antibody titer reached 117233.8; RBD-mRNA@MPP(Al 3+ ) treatment group mice IgG antibody titer reached 133116; while the IgG antibody titer in the RBD-mRNA@LNP treatment group mice was only 67476. As shown in Figure 2-12, RBD-mRNA@MPP(Al 3+) can effectively induce cellular immunity in mice, namely activate immune cells and produce a large number of cytokines, and mRNA@MPP(Al 3+ ) is clearly superior to RBD-mRNA@MPP(Fe 3+ ), RBD-mRNA@MPP(Fe 3+ ) is clearly superior to RBD-mRNA@LNP in inducing cellular immunity in mice: RBD-mRNA@MPP(Fe 3+ ) made the expression levels of cytokines IFN-γ, IL-2, and IL-4 reach 256.8 pg / mL, 207.6 pg / mL, and 61.8 pg / mL, respectively; RBD-mRNA@MPP(Al 3+ ) made the expression levels of cytokines IFN-γ, IL-2, and IL-4 reach 298pg / mL, 249pg / mL, and 74.6pg / mL, respectively; while RBD-mRNA@LNP made the expression levels of cytokines IFN-γ, IL-2, and IL-4 only 104.2pg / mL, 79.2pg / mL, and 27pg / mL. The results suggest that mRNA@MPP(Al 3+ ) is significantly better than RBD-mRNA@MPP(Fe 3+ ), RBD-mRNA@MPP(Fe 3+ ) is clearly superior to RBD-mRNA@LNP in inducing cellular immunity in mice: RBD-mRNA@MPP can more effectively promote cell expression of target proteins and can more effectively activate humoral immunity and cellular immunity in the body. Therefore, the drug (mRNA)-lipid particles are significantly superior to the existing technology LNP in terms of the effects of mRNA-carrying drugs, vaccines or other products. The possible reasons are: 1) Compared with LNP, MPP has a stronger ability to promote nucleic acid lysosomal escape; 2) Compared with LNP, MPP has a stronger ability to promote nucleic acid expression into protein (antigen); 3) Compared with LNP, the curcumin in MPP is separated from DSPC in the body and acts as an immune adjuvant (also known as an immunomodulator), which can activate humoral immunity and cellular immunity to enhance the effect of MPP in delivering mRNA vaccines, and can also suppress the immune factor storm to suppress excessive and harmful immune responses to the body.

[0460] Example 11: Metal ion is Fe 3+ Or Al 3+ In vivo safety evaluation of metal-chelated phospholipid complex nanoparticles (MPP)

[0461] A 20-day subchronic toxicity study of MPP was conducted using SD rats, with a 20-day recovery period. The specific experimental methods are as follows:

[0462] Fifty-six SPF Sprague-Dawley rats (220 ± 20 g), half male and half female, were housed at 25°C, 45%-55% humidity, and 12 hours of light. After 3-5 days of acclimatization, they were randomly divided into the following groups: an experimental group (32 rats) and a recovery group (24 rats). The blank control group consisted of 14 rats (8 in the experimental group and 6 in the recovery group), half male and half female; the low-dose MPP group (8 mg / kg) consisted of 14 rats (8 in the experimental group and 6 in the recovery group), half male and half female; the medium-dose MPP group (16 mg / kg) consisted of 14 rats (8 in the experimental group and 6 in the recovery group), half male and half female; and the high-dose MPP group (32 mg / kg) consisted of 14 rats (8 in the experimental group and 6 in the recovery group), half male and half female. The experimental group (32 rats) was autopsied after the end of drug administration. The recovery group (24 rats) was autopsied after 20 days of continued normal feeding.

[0463] Administration: Experimental animals were administered via tail vein injection every two days for 20 days, and the body weight of SD rats was recorded weekly. The prepared MPP was dissolved in DPBS. The control group was injected with an equal volume of DPBS, while the low-dose MPP group, medium-dose MPP group, and high-dose MPP group were injected with 8 mg / kg, 16 mg / kg, and 32 mg / kg of MPP, respectively.

[0464] The above MPP dosage was determined based on the following: When encapsulating 200 μg / kg of mRNA (the actual dosage required for mRNA animal studies), the required dosage of empty vector MPP is 8 mg / kg. To fully demonstrate the safety of MPP, we selected dosages of 1, 2, and 4 times the actual dosage required for animal studies: 8 mg / kg, 16 mg / kg, and 32 mg / kg.

[0465] General Index Testing Methods: After each administration, the general condition of each group of animals was observed, including survival, diet, appearance, behavior, body weight, and any local reactions to the administration. A gross autopsy was performed, including timely weighing of the wet weights of major organs, such as the brain, heart, liver, spleen, lungs, and kidneys. Organ-to-body ratios were calculated, and pathological changes in each organ were recorded. Organ-to-body ratio = organ wet weight / body weight × 100%.

[0466] Collection and storage of whole blood and serum from SD rats: 20 days after administration and a 20-day recovery period, rats were dissected and blood was collected from the abdominal aorta. The rats were anesthetized with isoflurane and fixed on a dissecting board. The abdomen was disinfected with 75% ethanol. Sterile ophthalmic scissors were used to cut the rat's abdomen open. The internal organs were gently parted with cotton balls to expose the abdominal aorta. Whole blood was collected using a 500μL negative pressure EDTAK2 anticoagulant blood collection tube and stored at 4°C for routine blood testing. Whole blood was collected using a 5mL negative pressure conventional blood collection tube and allowed to stand at room temperature for 30 minutes. The supernatant was collected in a 1.5mL centrifuge tube and stored at -20°C for the detection of blood biochemical and immunological indicators.

[0467] Routine blood test method: Routine blood test parameters include: white blood cell count, lymphocyte count, monocyte count, neutrophil count, lymphocyte percentage, monocyte percentage, neutrophil percentage, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin content, mean corpuscular hemoglobin concentration, coefficient of variation of red blood cell distribution width, platelet count, mean platelet volume, platelet distribution width, and platelet hematocrit. Gently invert the whole blood sample to mix thoroughly. A small amount of whole blood is then collected and analyzed using an automated hematology analyzer.

[0468] Blood biochemical index detection method: Blood biochemical index includes inorganic ions (Fe 2+ , Na + , K + , Cl - , Ca 2+ ), liver function indicators (ALT, AST, γ-GT, T-BIL, D-BIL, ALP, ALB), renal function indicators (BUN, UA, CR), cardiac function indicators (LDH, CK), glucose metabolism indicators (GSP, GLU, INS), lipid metabolism indicators (CHO, TG, LDL-C, HDL-C). Thaw serum samples and centrifuge at 3000 rpm for 15 minutes. Remove the supernatant and aliquot it for later use. Set the corresponding parameters on the automatic biochemical analyzer, add the prepared working solution, and then add the serum to be tested. The automatic biochemical analyzer will automatically determine the results.

[0469] Immunological indicators include thyroid function markers (TT3, TT4, TSH), cytokines (IL-1, IL-2, IL-4, IFN-γ, IFN-α, TNF-α), immunoglobulins (IgG, IgA, IgM), and serum complement (C3, CH50). These indicators are measured using ELISA.

[0470] Pathological examination method of the main organs of SD rats: At the end of the administration period and the recovery period, the rats in each group were anesthetized, and the main organs of the rats, including the whole brain, heart, liver, spleen, lungs, and kidneys, were removed by ophthalmic scissors. The organs were gently rinsed with 0.9% saline, fixed in 4% paraformaldehyde fixative, routinely paraffin-embedded, and stained with H&E. The histopathological changes of various organs of the rats in the control group and the experimental group were observed under an optical microscope.

[0471] Results analysis: As shown in Table 2-1, at the end of the administration period and the end of the recovery period, compared with the control group, the low, medium and high doses of MPP (Fe3 + ) or MPP(Al 3+ ) group survived well, had normal diet, normal appearance and behavior, and no obvious adverse reactions were observed after administration; compared with the control group, there was no significant difference in the weight gain of male SD rats and female SD rats in the low, medium and high doses of MPP groups; compared with the control group, there was no significant difference in the organ-to-body ratio of the low, medium and high doses of MPP groups.

[0472] At the end of the treatment period and the end of the recovery period, compared with the control group, the low, medium and high doses of MPP (Fe 3+ ) or MPP(Al 3+ The blood routine parameters (white blood cell count, lymphocyte count, monocyte count, neutrophil count, lymphocyte percentage, monocyte percentage, neutrophil percentage, red blood cell count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin content, mean corpuscular hemoglobin concentration, coefficient of variation of red blood cell distribution width, platelet count, mean platelet volume, platelet distribution width, platelet hematocrit) of the low, medium and high doses of MPP groups were normal compared with the control group. 2+ , Na + , K + , Cl - , Ca 2+ ), liver function indicators (ALT, AST, γ-GT, T-BIL, D-BIL, ALP, ALB), renal function indicators (BUN, UA, CR), cardiac function indicators (LDH, CK), glucose metabolism indicators (GSP, GLU, INS), lipid metabolism indicators (CHO, TG, LDL-C, HDL-C), all showed no abnormalities; compared with the control group, the immunological related indicators of the low, medium and high doses of MPP groups included thyroid function indicators (TT3, TT4, TSH), cytokines (IL-1, IL-2, IL-4, IFN-γ, IFN-α, TNF-α), immunoglobulins (IgG, IgA, IgM), and serum complement (C3, CH50), all showed no abnormalities.

[0473] At the end of the treatment period and the end of the recovery period, compared with the control group, the low, medium and high doses of MPP (Fe 3+ ) or MPP(Al 3+ ) group had intact brain tissue structure, normal tissue staining, intact cell morphology and structure, no nuclear pyknosis and inflammatory cell infiltration; intact myocardial tissue structure, myocardial cells arranged neatly, continuously and tightly, cell nuclei clearly visible, no obvious cell congestion, edema or necrosis; normal hepatocyte morphology, no inflammatory cell aggregation and necrosis; normal spleen structure, clear boundaries between red and white pulp; intact lung tissue structure, uniform alveolar size, no obvious inflammatory cell aggregation and infiltration; and normal kidney structure.

[0474] The above results suggest that long-term and large-scale injection of MPP (Fe 3+ ) or MPP(Al 3+ ) No obvious chronic toxic reactions were found, indicating that MPP is relatively safe.

[0475] Table 2-1 In vivo safety evaluation of MPP Note: ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, glutamyl transpeptidase; T-BIL, total bilirubin; D-BIL, direct bilirubin; ALP, alkaline phosphatase; ALB, albumin; BUN, blood urea nitrogen; UA, uric acid; CR, creatinine; LDH, lactate dehydrogenase; CK, creatine phosphokinase; GSP, fructosamine; GLU, glucose; INS, insulin; CHO, cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein; HDL-C, high-density lipoprotein; TT3, triiodothyronine; TT4, tetraiodothyronine; TSH, thyroid-stimulating hormone; IL-1, interleukin 1; IL-2, interleukin 2; IL-4, interleukin 4; IFN-γ, interferon gamma; IFN-α, interferon alpha; TNF-α, tumor necrosis factor alpha; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M; C3, complement C3; CH50, total complement CH50

[0476] Example 12: Metal ion is Fe 3+ Or Al 3+ Comparison of the in vivo safety of metal-phospholipid complex particles (MPP) and LNP

[0477] The main toxicity of LNP comes from its main components - cationic lipids and / or ionizable lipids. When LNP is metabolized in the body, the free cationic lipids and / or ionizable lipids will produce significant toxicity to the body. The median lethal dose (IC50) of cationic lipids and / or ionizable lipids to biological cells is 50) is an important parameter for evaluating the toxicity of LNP to the body. Metal-chelated phospholipid complex nanoparticles (MPP) replace the cationic lipids / ionizable lipids in LNP with metal-phospholipid complexes. Therefore, we studied the median lethal dose (IC50) of metal-phospholipid complexes and cationic lipids / ionizable lipids on biological cells. 50 ), compare LNP and MPP (Fe 3+ ) or MPP(Al 3+ ) differences in toxicity.

[0478] 293T cells were incubated with different concentrations of the metal-phospholipid complex (0, 0.1, 0.3, 0.9, 2.7, 8.1, 24.3, 72.9, 218.7 μM), cationic lipid (DOTAP, 0, 0.1, 0.3, 0.9, 2.7, 8.1, 24.3, 72.9, 218.7 μM, structural formula as follows) and ionizable lipid (ALC0315, 0, 0.1, 0.3, 0.9, 2.7, 8.1, 24.3, 72.9, 218.7 μM, structural formula as follows) for 48 hours, and then the cell viability was detected using a CCK8 activity detection kit. The median lethal dose (IC50) of the metal-phospholipid complex, cationic lipid (DOTAP) and ionizable lipid (ALC0315) on 293T cells was calculated. 50 .

[0479] CCK8 detection method:

[0480] 1. Cell culture: Culture cells in DMEM containing 10% FBS and 1% double antibody until the cell density reaches 80%-90% of the culture flask;

[0481] 2. Wash the remaining culture medium in the culture flask with PBS, add trypsin, and quickly transfer the culture flask to a 37°C incubator with 5% CO2. Observe carefully until the cells slightly round up, then add culture medium to terminate the digestion. Transfer the cells to a centrifuge tube, centrifuge at 1500 RPM for 5 minutes, and resuspend the cells in fresh culture medium.

[0482] 3. Counting: Dilute the cell suspension to 10,000 cells per mL according to the intended cell count. Add 100 μL per well of a 96-well plate, with at least five replicates per group. Incubate at 37°C, 5% CO2 for 24 hours before adding the drug.

[0483] 4. After drug incubation for 48 hours, add 10% CCK8 and incubate for 1-3 hours. Measure the absorbance at 450 nm with a microplate reader.

[0484] 5. Survival rate (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] x 100%.

[0485] IC50 calculation method: With survival rate as the vertical axis and drug concentration as the horizontal axis, use Graphpad to calculate IC using the [Inhibitor] vs. normalized response--Variable slope analysis method. 50 .

[0486] To compare the in vivo safety of MPP and LNP, MPP (8 mg / kg) and LNP (3.24 mg / kg) capable of carrying an equal amount of nucleic acid (200 μg / kg mRNA) were used to conduct an in vivo experiment according to the method of Example 11 to evaluate and compare the in vivo toxicity of MPP and LNP.

[0487] Result analysis: As shown in Table 2-2, the IC 50 The results showed that the toxicity of metal-phospholipid complexes was significantly lower than that of cationic lipids (DOTAP) and ionizable lipids (ALC0315).

[0488] As shown in Table 2-3, at the end of the treatment period and the end of the recovery period, MPP (Fe 3+ ) or MPP(Al 3+ There were no significant abnormalities in liver function (ALT, AST, ALP) and cytokines (IL-6, IL-1β) in the LNP group. However, compared with the control group, the liver function (ALT, AST, ALP) and cytokines (IL-6, IL-1β) in the LNP group were significantly increased. 3+ ) or MPP(Al 3+ ) is safer in vivo than LNP because the core component of LNP is artificially synthesized "cationic lipid / ionizable lipid", which has high cytotoxicity and immunogenicity, and its structure is relatively stable and difficult to decompose and metabolize in the body; while MPP (Fe 3+ ) or MPP(Al 3+ The core component of MPP (Fe 2+) is a metal-phospholipid complex, which is composed of phospholipid molecules, a highly safe natural small molecule substance, curcumin (a food additive and pharmaceutical excipient approved by the FDA), and safe metal ions. After the drug is delivered, it is decomposed into natural molecules in the body. 3+ ) or MPP(Al 3+ ) components do not contain cationic lipids / ionizable lipids and will not cause toxic side effects related to cationic lipids / ionizable lipids, so MPP(Fe 3+) or MPP(Al 3+ ) is safer than LNP.

[0489] Table 2-2 Metal ions are Fe 3+ Or Al 3+ IC of metal-phospholipid complexes with cationic lipids (DOTAP) and ionizable lipids (ALC0315) 50 Compared with

[0490] Table 2-3 Comparison of chronic toxicity test indicators of MPP and LNP

[0491] Example 3: Clinical Application and Administration Route of Drug-Metal-Phospholipid Complex Particles

[0492] Example 13: Metal ion is Fe 3+ or Al 3+ Clinical application and administration route of drug-metal-phospholipid complex particles

[0493] The mRNA in Example 3 was replaced with siRNA targeting the B7-H4 gene (B7-H4-siRNA) and its control (scr-siRNA), and mRNA encoding the receptor binding domain (RBD) of the novel coronavirus S1 subunit (RBD-mRNA).

[0494] The sequences of the above-mentioned different nucleic acids are as follows: ① The sequence of B7-H4-siRNA is SEQ ID No.19 (sense chain) and SEQ ID No.26 (antisense chain) (25 bp), and its random control sequence is SEQ ID No.20 (sense chain) and SEQ ID No.27 (antisense chain) (19 bp); ② The mRNA sequence encoding the receptor binding domain (RBD) of the novel coronavirus S1 subunit is SEQ ID No.2 (669 nt). Referring to the method of Example 3, drug-metal-phospholipid complex particles (B7-H4-siRNA@MPP(Fe 3+ )、 RBD-mRNA@MPP(Fe 3+ )、B7-H4-siRNA@MPP(Al 3+ )、RBD-mRNA@MPP(Al 3+), the preparation process of the remaining drug-metal-phospholipid complex particles was the same as that in Example 3. The above two different drug-metal-phospholipid complex particles (B7-H4-siRNA@MPP and RBD-mRNA@MPP) were used to treat liver cancer and as mRNA vaccines for the prevention of the new coronavirus.

[0495] The sequence of B7-H4-siRNA is as follows:

[0496] sense 5'-GGG AGA CAC UCC AUC ACA GUC ACU A-3' (SEQ ID No. 19).

[0497] antisense 5'-UAG UGA CUG UGA UGG AGU GUC UCC C-3' (SEQ ID No. 26) (25 bp).

[0498] The random control sequence of B7-H4-siRNA is as follows:

[0499] sense 5'-UUCUCCGAACGUGUCACGU-3' (SEQ ID No. 20).

[0500] antisense 5'-ACGUGACACGUUCGGAGAA-3' (SEQ ID No. 27) (19 bp).

[0501] To evaluate the B7-H4-siRNA@MPP(Fe 3+ ) and B7-H4-siRNA@MPP(Al 3+ ) to treat liver cancer. Animal models of liver cancer were established using HepG2 cells. When the tumor size increased to about 100 mm 3 The liver cancer mice were randomly divided into 7 groups (5 mice in each group): PBS control group, blank vector MPP (Fe 3+ ) group, blank carrier MPP (Al 3+ ) group, Scr-siRNA@MPP(Fe 3+ ) control group, B7-H4-siRNA@MPP(Fe 3+ ) treatment group, Scr-siRNA@MPP(Al 3+ ) control group, B7-H4-siRNA@MPP(Al 3+ ) treatment group. Each group of mice was injected intratumorally with PBS, MPP (Fe 3+ )、MPP(Al 3+ )、Scr-siRNA@MPP(Fe 3+)、B7-H4 siRNA@MPP(Fe 3+ )、Scr-siRNA@MPP(Al 3+ )、B7-H4 siRNA@MPP(Al 3+ ) once, at a dose of 200 μg siRNA / kg, for eight injections. Tumor volume was measured and recorded every three days. The results are shown in Figure 3-1.

[0502] To evaluate the effect of RBD-mRNA@MPP as an mRNA vaccine in preventing the new coronavirus, the experimental process and experimental methods are as shown in the previous Example 3.5.

[0503] The ELISA detection method is as described in Example 3.5.

[0504] Establishment of liver cancer mouse model: HepG2 cells were collected and cultured at 1×10 7 The cells were resuspended in PBS at a density of 100 μL and kept on ice before inoculation. 100 μL of the cell suspension was then injected subcutaneously into the dorsal region near the hind legs of female Balb / c nude mice to establish a liver cancer mouse model.

[0505] Result analysis:

[0506] As shown in Figure 3-1, Scr-siRNA@MPP(Fe 3+ )、Scr-siRNA@MPP(Al 3+ ) had almost no inhibitory effect on the growth of HepG2 cells, while B7-H4-siRNA@MPP(Fe 3+ ) and B7-H4 siRNA@MPP(Al 3+ ) showed a highly effective therapeutic effect, effectively inhibiting the growth of liver cancer tumors. The results suggest that drug-metal-phospholipid complex particles can encapsulate and deliver B7-H4 siRNA, inhibiting the expression of the target gene, thereby inhibiting the development of liver cancer.

[0507] As shown in Figures 1-3 and 1-5 of Example 3.5, RBD-mRNA@MPP(Fe 3+ ) increased the expression level of mouse IgG antibody to 117268.8 (Figure 1-3), and the expression levels of cytokines IFN-γ, IL-2, and IL-4 to 252.8 pg / mL, 207.6 pg / mL, and 56.6 pg / mL, respectively (Figure 1-5). RBD-mRNA@MPP(Al 3+) increased the expression level of mouse IgG antibodies to 129113 (Figure 1-9), and the expression levels of cytokines IFN-γ, IL-2, and IL-4 to 271.8 pg / mL, 234.6 pg / mL, and 68.4 pg / mL, respectively (Figure 1-11). The results suggest that RBD-mRNA@MPP can effectively induce humoral immunity in mice and produce high levels of antigen-specific binding antibodies; at the same time, it can effectively induce cellular immunity in mice, that is, activate immune cells and produce a large amount of cytokines. Therefore, RBD-mRNA@MPP can effectively prevent infection with the new coronavirus.

[0508] As shown in Figure 3-1, B7-H4-siRNA@MPP is effective in treating liver cancer via intratumoral injection. As shown in Figures 1-3, 1-5, 1-9, and 1-11 of Example 3.5, RBD-mRNA@MPP is effective in preventing novel coronavirus infection by activating humoral and cellular immunity via intramuscular injection. These results suggest that drug-metal-phospholipid complex particles can be administered via a variety of routes.

[0509] Example 4: DSPC, curcumin, Fe 3+ or Al 3+ Function after being replaced by similar products

[0510] Example 15, DSPC, curcumin, Fe 3+ or Al 3+ Function after being replaced by similar products

[0511] With reference to Example 1, Example 2 and Example 3, DSPC, curcumin, Fe 3+ The analogs of DSPC, curcumin, Fe 3+ 28 different eGFP-mRNA@MPPs were prepared by different combinations, and the concentration of mRNA in each eGFP-mRNA@MPP was 2 μg / mL. 3+ The names and structures of their analogs are shown in Table 4-1. DSPC, curcumin, Fe 3+ The combination of the same and similar products is shown in Table 4-2. In Example 1, the reaction temperature is 65°C and the reaction time is 2 hours, and in Example 2, the reaction temperature is 60°C and the reaction time is 2 hours, and other conditions remain unchanged.

[0512] To compare the effects of the 28 different eGFP-mRNA@MPPs and eGFP-mRNA@LNPs, we prepared LNPs encapsulating equal amounts of eGFP-mRNA with reference to Example 9 to obtain eGFP-mRNA@LNPs.

[0513] The above 28 different eGFP-mRNA@MPPs and the above eGFP-mRNA@LNPs (all containing mRNA at a concentration of 2 μg / mL) were incubated with 293T cells, respectively. The control group was incubated with MPP or LNP. After 48 hours, the cell suspension was collected and the percentage of eGFP-positive cells was detected by flow cytometry.

[0514] The method for analyzing the eGFP-positive cell rate by flow cytometry is as described in Example 3.

[0515] The main toxicity of LNP comes from its main component - cationic lipids / ionizable lipids. When LNP is metabolized in the body, the free cationic lipids / ionizable lipids will produce significant toxicity to the body. The median lethal dose (IC50) of cationic lipids / ionizable lipids to biological cells is 50 ) is an important parameter for evaluating the toxicity of LNP to the body. Metal-chelated phospholipid complex nanoparticles (MPP) replace the cationic lipids / ionizable lipids in LNP with metal-phospholipid complexes. Therefore, we studied the median lethal dose (IC50) of 28 metal-phospholipid complexes and cationic lipids (DOTAP) / ionizable lipids (ALC0315) on biological cells. 50 ), and compared the differences in toxicity between LNP and 28 MPPs.

[0516] The calculation method of IC50 is as described in Example 12.

[0517] Results analysis: As shown in Table 4-3, the percentage of eGFP-positive cells in 293T cells treated with 28 different eGFP-mRNA@MPPs was significantly higher than that of eGFP-mRNA@LNPs, among which DSPC, curcumin, Fe 3+ The percentage of eGFP-positive cells of mRNA@MPP was the highest. 3+ The function of mRNA@MPP formed after being replaced by its congeners is not as good as that of DSPC, curcumin, Fe 3+ The mRNA@MPP composed of mRNA@MPP is superior to mRNA@LNP in function. The possible reason is that, as described in Example 8, MPP has a stronger ability to promote lysosomal escape of nucleic acids than LNP, so more nucleic acids loaded by MPP can be effectively released into the cytoplasm and translated into proteins.

[0518] The above results suggest that as long as the following conditions are met, DSPC, curcumin, Fe 3+The function of drug-metal-phospholipid complex particles formed after being replaced by its congeners is not affected: ① DSPC congeners are amphiphilic phospholipid molecules; ② Fe 3+ The congeners of curcumin are metal ions; ③ The congeners of curcumin and DSPC form phospholipid complexes and can also complex with metal ions; ④ Curcumin and Fe 3+ The coordination bonds between them can be broken in response to the low pH environment of the lysosome.

[0519] As shown in Table 4-3, the IC values ​​of 28 metal-phospholipid complexes 50 The toxicity of metal-phospholipid complexes is obviously lower than that of cationic lipids (DOTAP) and ionizable lipids (ALC0315). 3+ The safety of lipid nanoparticles (MPP) composed of DSPC and its analogs is higher than that of LNP. The reasons are as follows: the core component of LNP is artificially synthesized "cationic lipid / ionizable lipid", which has high cytotoxicity and immunogenicity, and its structure is relatively stable and difficult to decompose and metabolize in the body; while the core component of MPP is metal-phospholipid complex, which is composed of phospholipid molecules, natural small molecules with high safety (among which curcumin is a food additive and pharmaceutical excipient approved by the FDA) and safe metal ions, and it has been decomposed into natural molecules in the body after completing drug delivery. In summary, the drug composed of DSPC, curcumin, Fe 3+ The lipid particles (MPP) composed of LNP and its analogs do not contain cationic lipids / ionizable lipids and will not cause toxic side effects related to cationic lipids / ionizable lipids, so the safety of MPP is higher than that of LNP.

[0520] Table 4-1 DSPC, curcumin, Fe 3+ The names and structures of its analogs

[0521] Table 4-2 DSPC, curcumin, Fe 3+ List of combinations and functions of metal-phospholipid complexes in drug-lipid particles prepared from and their analogs

[0522] Table 4-3 DSPC, curcumin, Fe 3+ IC of metal-phospholipid complexes prepared from its analogs 50

[0523] Example 16, DSPC, curcumin and its analogs, Fe 3+ Component dosage ratio and function of drug-metal-phospholipid complex particles prepared therefrom

[0524] According to Example 3, metal-phospholipid complexes were prepared, and curcumin was replaced with its analogs hesperetin (one hesperetin molecule contains four hydroxyl groups) and tea polyphenols (one tea polyphenol molecule contains eight hydroxyl groups), respectively, to prepare three metal-phospholipid complexes (mRNA@MPP1, mRNA@MPP4, and mRNA@MPP29). The ratios of DSPC, curcumin or its analogs, and FeCl3 used in the preparation of these three metal-phospholipid complexes were 1:1:1, 1:1:1, and 1:1:2, respectively. Corresponding drug-metal-phospholipid complex nanoparticles were prepared using these three metal-phospholipid complexes (mRNA@MPP1, mRNA@MPP4, and mRNA@MPP29). The mRNA encoding the eGFP fluorescent protein is represented by SEQ ID No. 1 (720 nt). The mRNA loading efficiency of these four drug-lipid nanoparticles and their ability to promote eGFP fluorescent protein expression after treatment with 293T cells were tested according to the experimental procedures and methods described in Example 3.5.

[0525] Analysis of results: As shown in Table 4-4, the mRNA encapsulation efficiency and the ability to promote the expression of target proteins of drug-metal-phospholipid complex particles prepared using different dosage ratios based on the chemical structure of the metal-phospholipid complex components are comparable. The results suggest that the dosage ratio of the metal-phospholipid complex components can be adjusted according to the structure of the specific metal-phospholipid complex components. The basis for adjusting the dosage ratio is: because the DSPC congeners and curcumin congeners are connected by hydrogen bonds, as long as the DSPC congeners contain multiple phosphate groups, then when synthesizing the phospholipid complex, the dosage ratio of the DSPC congeners and the curcumin congeners can be adjusted according to the number of phosphate groups contained in the DSPC congeners, that is, when the DSPC congeners contain two phosphate groups, the dosage ratio of the DSPC congeners and the curcumin congeners can be adjusted to 1:2; when the DSPC congeners contain three phosphate groups, the dosage ratio of the DSPC congeners and the curcumin congeners can be adjusted to 1:3; because the hydroxyl groups of the curcumin congeners react with Fe 3+ As long as the congeners of curcumin contain multiple binding sites, the congeners of curcumin and Fe 3+ The dosage ratio of the congeners can be adjusted according to the number of binding sites contained in the curcumin congeners.

[0526] Table 4-4 Component ratios of different metal-phospholipid complexes and functions of the drug-lipid particles prepared therefrom

[0527] Example 17, DSPC, curcumin and its analogs, Al 3+ Component dosage ratio and function of drug-metal-phospholipid complex particles prepared therefrom

[0528] According to Example 3, metal-phospholipid complexes were prepared, and curcumin was replaced with its analogues hesperetin (one hesperetin molecule contains four hydroxyl groups) and tea polyphenols (one tea polyphenol molecule contains eight hydroxyl groups), respectively, to prepare three metal-phospholipid complexes (mRNA@MPP2, mRNA@MPP5, and mRNA@MPP30). The ratios of DSPC, curcumin or its analogue, and Al(NO3)3·9H2O used to prepare these three metal-phospholipid complexes were 1:1:1, 1:1:1, and 1:1:2, respectively. Corresponding drug-metal-phospholipid complex nanoparticles were prepared using these three metal-phospholipid complexes (mRNA@MPP1, mRNA@MPP4, and mRNA@MPP29). The mRNA encoding the eGFP fluorescent protein is shown in SEQ ID No. 1 (720 nt). The mRNA encapsulation efficiency of these four drug-lipid nanoparticles and their ability to promote eGFP fluorescent protein expression after treating 293T cells were detected according to the experimental process and experimental methods described in Example 3.5.

[0529] Analysis of results: As shown in Tables 4-5, the mRNA encapsulation efficiency and the ability to promote the expression of target proteins of drug-metal-phospholipid complex particles prepared using different dosage ratios based on the chemical structure of the metal-phospholipid complex components are comparable. The results suggest that the dosage ratio of the metal-phospholipid complex components can be adjusted according to the structure of the specific metal-phospholipid complex components. The basis for adjusting the dosage ratio is: because the analogs of DSPC and the analogs of curcumin are connected by hydrogen bonds, as long as the analogs of DSPC contain multiple phosphate groups, then when synthesizing phospholipid complexes, the dosage ratio of the analogs of DSPC and the analogs of curcumin can be adjusted according to the number of phosphate groups contained in the analogs of DSPC, that is, when the analogs of DSPC contain two phosphate groups, the dosage ratio of the analogs of DSPC and the analogs of curcumin can be adjusted to 1:2; when the analogs of DSPC contain three phosphate groups, the dosage ratio of the analogs of DSPC and the analogs of curcumin can be adjusted to 1:3; because the hydroxyl groups of the analogs of curcumin react with Al 3+ As long as the congeners of curcumin contain multiple binding sites, the congeners of curcumin and Al 3+ The dosage ratio of the congeners can be adjusted according to the number of binding sites contained in the curcumin congeners.

[0530] Table 4-5 Component ratios of different metal-phospholipid complexes and functions of the drug-lipid particles prepared therefrom

[0531] The preparation of mRNA@MPP in Example 3 was completed by Professor Wang Shan's research group in the Department of Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Central South University.

[0532] Unless otherwise defined, all technical and scientific terms used throughout this disclosure have the same meanings as those commonly understood by those skilled in the art to which this disclosure belongs. In the event of any inconsistency, the meanings described in the full text of this disclosure or derived from the contents recorded in the full text of this disclosure shall prevail. In addition, the terms used in this description are only for the purpose of describing the embodiments of the present disclosure and are not intended to limit the present disclosure.

[0533] Note that the above are only preferred embodiments of the present disclosure and the technical principles used. Those skilled in the art will understand that the present disclosure is not limited to the specific embodiments described herein, and that various obvious changes, readjustments, and substitutions can be made by those skilled in the art without departing from the scope of protection of the present disclosure. Therefore, although the present disclosure has been described in more detail through the above embodiments, the present disclosure is not limited to the above embodiments, and may also include more other equivalent embodiments without departing from the technical concept of the present disclosure, all of which fall within the scope of protection of the present disclosure.

Claims

1. A metal-phospholipid complex, wherein: The metal-phospholipid complex is composed of a phospholipid molecule portion, a linker molecule portion and a metal ion portion, wherein the phospholipid molecule portion is connected to the linker molecule portion, and the linker molecule portion is connected to the metal ion portion via a coordination bond, and the metal-phospholipid complex is not a cationic lipid or an ionizable lipid.

2. The metal-phospholipid complex according to claim 1, wherein The phospholipid molecule is selected from phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), phosphatidylglycerol (PG), 1-phosphoceramide (SP), phosphatidylinositol (PI), phosphatidylthreonine (PT), sphingomyelin (SM), lysophosphatidylcholine (LPC), lysophosphatidylethanolamine (LPE), lysophosphatidylserine (LPS), lysophosphatidic acid (LPA), lysophosphatidylglycerol (LPG), lysophosphatidylinositol (LPI), lysophosphatidylthreonine (LPT), lysosphingomyelin (LSM), 1-sphingosine phosphate (S1P), and a combination of one or more of their derivatives.

3. The metal-phospholipid complex according to claim 2, wherein The phospholipid molecule is selected from Phosphatidylcholine (PC) Phosphatidylethanolamine (PE) Phosphatidylserine (PS) Phosphatidic acid (PA) Phosphatidylglycerol (PG) 1-phosphoceramide (SP) Phosphatidylinositol (PI) Phosphatidylthreonine (PT) Sphingomyelin (SM) Lysolecithin (LPC) Lysophosphoethanolamine (LPE) Lysophosphatidylserine (LPS) Lysophosphatidic acid (LPA) Lysophosphatidylglycerol (LPG) Lysophosphatidylinositol (LPI) Lysophosphatidylthreonine (LPT) Lysosphingomyelin (LSM) Sphingosine 1-phosphate (S1P) and combinations of one or more of their derivatives; Wherein, R1 and R2 are independently: Capryloyl Lauroyl Myristoyl Palmitoyl Stearyl Oleoyl Linoleyl Erucyl Arachidoyl Phytanoyl 4. The metal-phospholipid complex according to claim 3, wherein The phospholipid molecule is selected from phosphatidylcholine (PC, formula 1), phosphatidylethanolamine (PE, formula 2), phosphatidic acid (PA, formula 4), phosphatidylglycerol (PG, formula 5), ​​and a combination of one or more of their derivatives.

5. The metal-phospholipid complex according to claim 4, wherein The phospholipid molecule is selected from DSPC, DSPE, DSPA, DSPG, and a combination of one or more of their derivatives. The metal-phospholipid complex according to claim 5 , wherein The phospholipid molecule is selected from DSPC (Formula 46) DSPE (Equation 47) DSPA (Equation 48) DSPG (Equation 49) and combinations of one or more of their derivatives.

7. The metal-phospholipid complex according to claim 6, wherein The phospholipid molecule portion is selected from DSPC (Formula 46), DSPE (Formula 47) or DSPA (Formula 48).

8. The metal-phospholipid complex according to any one of claims 1 to 7, wherein The linker molecule is selected from curcumin, chlorogenic acid, anthocyanin, quercetin, dihydromyricetin, hesperetin, naringenin, apigenin, catechin, tea polyphenols, epigallocatechin gallate, ellagic acid, morin, epicatechin gallate, catechin gallate, epigallocatechin gallate or picarapine C, and a combination of one or more thereof.

9. The metal-phospholipid complex according to claim 8, wherein The linker molecule is selected from Curcumin Chlorogenic acid anthocyanin Wherein, R7 and R8 are H, OH or OCH3, R3 is H or glycosyl, R4, R5 and R6 are OH or glycosyl, Quercetin Dihydromyricetin Hesperetin Naringenin Apigenin catechins Tea polyphenols Epigallocatechin gallate Ellagic acid mulberry pigment Epicatechin gallate Epigallocatechin gallate Epigallocatechin gallate Pingbeiline C and combinations of one or more of their derivatives.

10. The metal-phospholipid complex according to claim 9, wherein The linker molecule is selected from curcumin (Formula 19), dihydrocurcumin (Formula 36) Hexahydrocurcumin (Formula 37) Curcumin sulfate (Formula 38) Bisdemethoxycurcumin (Formula 39) A combination of one or more of . The metal-phospholipid complex according to claim 9 , wherein The linker molecule is selected from curcumin (Formula 19), hesperetin (Formula 24), tea polyphenols (Formula 28), and a combination of one or more of their derivatives.

12. The metal-phospholipid complex according to claim 11, wherein The linker molecule is selected from curcumin (Formula 19), hesperetin (Formula 24) or tea polyphenols (Formula 28).

13. The metal-phospholipid complex according to any one of claims 1 to 12, wherein The metal ion portion is selected from Fe 3+ 、Ag + 、Ba 2+ , Ca 2+ 、Cd 2+ 、Cu 2+ 、Fe 2+ 、Mn 2+ Mg 2+ 、Mo 2+ 、Zn 2+ , Pt 2+ 、Au 2+ 、Al 3+ 、Ce 3+ 、Co 3+ Cr 3+ 、Eu 3+ 、Gd 3+ 、Ni 3+ 、W 3+ 、V 3+ 、Zr 3+ A combination of one or more of . The metal-phospholipid complex according to claim 13 , wherein The metal ion portion is selected from Fe 3+ , Ca 2+ 、Al 3+ A combination of one or more of . The metal-phospholipid complex according to claim 14 , wherein The metal ion portion is selected from Fe 3+ , Ca 2+ or Al 3+ .

16. The metal-phospholipid complex according to any one of claims 1 to 15, wherein The metal-phospholipid complex is made of a phospholipid molecule part, a linker molecule part and a metal ion part, wherein the phospholipid molecule part is selected from DSPC, DSPE or DSPA, the linker molecule part is selected from curcumin, hesperidin or tea polyphenols, and the metal ion part is selected from Fe 3+ , Ca 2+ or Al 3+ .

17. The metal-phospholipid complex according to claim 16, wherein The metal-phospholipid complex is made of a phospholipid molecule part, a linker molecule part and a metal ion part, wherein the phospholipid molecule part is selected from DSPC (Formula 46), DSPE (Formula 47) or DSPA (Formula 48), the linker molecule part is selected from curcumin (Formula 19), hesperidin (Formula 24) or tea polyphenols (Formula 28), and the metal ion part is selected from Fe 3+ , Ca 2+ or Al 3+ .

18. The metal-phospholipid complex according to claim 16 or 17, wherein The molar ratio of the phospholipid molecule part, the linker molecule part and the metal ion part is 1:1:(0.5-2). The metal-phospholipid complex according to claim 18 , wherein the molar ratio of the phospholipid molecule portion, the linker molecule portion and the metal ion portion is 1:1:

1.

20. The method for preparing the metal-phospholipid complex according to any one of claims 1 to 19, wherein: The preparation method comprises the following steps: Step 1: Reaction of phospholipid molecules with linker molecules to form phospholipid complexes; Step 2: reacting the phospholipid complex prepared in step 1 with metal ions through coordination bonds to form a metal-phospholipid complex.

21. The preparation method according to claim 20, wherein In step 1, the phospholipid molecules and the linker molecules are dissolved in ethanol for reaction, and then n-hexane is added for precipitation to obtain the phospholipid complex.

22. The preparation method according to claim 21, wherein The molar ratio of the phospholipid molecules to the linker molecules is 1:

1.

23. The preparation method according to claim 21 or 22, wherein The reaction conditions included 65° C. for 2 hours.

24. The preparation method according to any one of claims 20 to 23, wherein In step 2, the phospholipid complex and the metal ion are dissolved in ethanol and reacted to obtain the metal-phospholipid complex.

25. The preparation method according to claim 24, wherein The molar ratio of the phospholipid complex to the metal ion is 1:(1-2).

26. The preparation method according to claim 24 or 25, wherein The reaction conditions included reaction at 60°C for 2 hours.

27. A metal-phospholipid complex particle, wherein: The metal-phospholipid complex particles contain: (i) a metal-phospholipid complex, wherein the metal-phospholipid complex is the metal-phospholipid complex according to any one of claims 1 to 19; (ii) a conjugated lipid that inhibits particle aggregation, wherein the conjugated lipid that inhibits particle aggregation is not a cationic lipid or an ionizable lipid; as well as (iii) non-cationic lipids or non-ionizable lipids other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation.

28. The metal-phospholipid complex particles according to claim 27, wherein The conjugated lipids that inhibit particle aggregation include PEG-lipid conjugates and / or PEG-DAA.

29. The metal-phospholipid complex particles according to claim 28, wherein The PEG-lipid conjugate is selected from phosphatidylethanolamine-polyethylene glycol 2000 (Formula 42) Phosphatidylethanolamine-polyethylene glycol 700 (Formula 43) Phosphatidylethanolamine-polyethylene glycol 1000 (Formula 44) Phosphatidylethanolamine-polyethylene glycol 5000 (Formula 45) , and a combination of one or more of their derivatives; R1 and R2 are independently: caproyl, lauroyl, myristoyl, palmitoyl, stearoyl, oleoyl, linoleoyl, erucyl, arachidoyl or phytanoyl.

30. The metal-phospholipid complex particles according to claim 29, wherein The PEG-lipid conjugate is selected from a combination of one or more of DSPE-PEG2000, DSPE-PEG700, DSPE-PEG1000 and DSPE-PEG5000. The metal-phospholipid complex particles according to claim 30 , wherein The PEG-lipid conjugate is selected from DSPE-PEG2000 (Formula 53) DSPE-PEG700 (Formula 50) DSPE-PEG1000 (Formula 51) or DSPE-PEG5000 (Formula 52) 32. The metal-phospholipid complex particles according to any one of claims 27 to 31, wherein The non-cationic lipid or non-ionizable lipid described in (iii) is a combination of one or more of cholesterol and its derivatives.

33. The metal-phospholipid complex particles according to claim 32, wherein The non-cationic lipid or non-ionizable lipid described in (iii) is cholesterol (Formula 40) 34. The metal-phospholipid complex particles according to claim 32, wherein The non-cationic lipids or non-ionizable lipids described in (iii) further include one or more combinations selected from phosphatidylcholine PC, phosphatidylethanolamine PE, phosphatidylserine PS, phosphatidic acid PA, phosphatidylglycerol PG, 1-phosphoceramide SP, phosphatidylinositol PI, phosphatidylthreonine PT, sphingomyelin SM, lysophosphatidylcholine LPC, lysophosphatidylethanolamine LPE, lysophosphatidylserine LPS, lysophosphatidic acid LPA, lysophosphatidylglycerol LPG, lysophosphatidylinositol LPI, lysophosphatidylthreonine LPT, lysosphingomyelin LSM, 1-phospho-sphingosine S1P, cholesterol sulfate, and derivatives thereof.

35. The metal-phospholipid complex particles according to claim 34, wherein The non-cationic lipid or non-ionizable lipid described in (iii) further comprises phosphatidylcholine (PC, Formula 1), phosphatidylethanolamine (PE, Formula 2), phosphatidylserine (PS, Formula 3), phosphatidic acid (PA, Formula 4), phosphatidylglycerol (PG, Formula 5), ​​1-phosphoceramide (SP, Formula 6), phosphatidylinositol (PI, Formula 7), phosphatidylthreonine (PT, Formula 8), sphingomyelin (SM, Formula 9), lysophosphatidylcholine (LPC, Formula 10), lysophosphatidylethanolamine (LPE, Formula 11), lysophosphatidylserine (LPS, Formula 12), lysophosphatidic acid (LPA, Formula 13), lysophosphatidylglycerol (LPG, Formula 14), lysophosphatidylinositol (LPI, Formula 15), lysophosphatidylthreonine (LPT, Formula 16), lysosphingomyelin (LSM, Formula 17), 1-phospho-sphingosine (S1P, Formula 18), cholesterol sulfate and combinations of one or more of their derivatives.

36. The metal-phospholipid complex particles according to claim 34 or 35, wherein The non-cationic lipid or non-ionizable lipid described in (iii) includes cholesterol, and a combination of one or more selected from DSPC, DSPE, DSPA or DSPG.

37. The metal-phospholipid complex particles according to claim 36, wherein The non-cationic lipid or non-ionizable lipid described in (iii) includes cholesterol (Formula 40) and DSPC (Formula 46).

38. The metal-phospholipid complex particles according to any one of claims 34 to 37, wherein The metal-phospholipid complex particles are made of (i) a metal-phospholipid complex, (ii) a conjugated lipid that inhibits particle aggregation, and (iii) a non-cationic lipid or a non-ionizable lipid. The metal-phospholipid complex has a molar proportion of 10% to 40% in the raw material, the conjugated lipid that inhibits particle aggregation has a molar proportion of 2% to 10% in the raw material, the cholesterol has a molar proportion of 35% to 75% in the raw material, and the non-cationic lipid or non-ionizable lipid other than cholesterol has a molar proportion of 0% to 40% in the raw material.

39. The metal-phospholipid complex particles according to any one of claims 34 or 37, wherein The metal-phospholipid complex particles are made of (i) a metal-phospholipid complex, (ii) a conjugated lipid that inhibits particle aggregation, and (iii) a non-cationic lipid or a non-ionizable lipid, wherein the metal-phospholipid complex accounts for 5% to less than 10% by mole in the raw material, the conjugated lipid that inhibits particle aggregation accounts for 2% to 10% by mole in the raw material, the cholesterol accounts for 15% to less than 35%, 35% to 75%, or greater than 75% to 80% by mole in the raw material, and the non-cationic lipid or non-ionizable lipid other than cholesterol accounts for 0% to 40% or greater than 40% to 51% by mole in the raw material; or The molar proportion of the metal-phospholipid complex in the raw material is greater than 40% to 50%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 2% to 10%, the molar proportion of cholesterol in the raw material is 15% to less than 35%, 35% to 75% or greater than 75% to 80%, and the molar proportion of the non-cationic lipid or non-ionizable lipid other than cholesterol in the raw material is 0% to 40% or greater than 40% to 51%; or The molar proportion of the metal-phospholipid complex in the raw material is 10% to 40%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 2% to 10%, the molar proportion of cholesterol in the raw material is 15% to less than 35% or greater than 75% to 80%, and the molar proportion of the non-cationic lipid or non-ionizable lipid other than cholesterol in the raw material is 0% to 40% or greater than 40% to 51%.

40. The metal-phospholipid complex particles according to claim 38 or 39, wherein The metal-phospholipid complex accounts for 7% to less than 10%, 10% to 30%, or 20% to 30% by mole in the raw material, and is preferably 25%.

41. The metal-phospholipid complex particles according to claims 38 to 40, wherein The molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10% or 5% to 10%, preferably 10%.

42. The metal-phospholipid complex particles according to any one of claims 38 to 41, wherein The molar proportion of cholesterol in the raw material is 15% to less than 35%, 35% to 56% or 35% to 55%, preferably 40%.

43. The metal-phospholipid complex particles according to any one of claims 38 to 42, wherein The molar proportion of non-cationic lipids or non-ionizable lipids other than cholesterol in the raw material is 5% to 30%, 25% to 40%, greater than 40% to 45% or 20% to 25%.

44. The metal-phospholipid complex particles according to claim 38, wherein The molar proportion of the metal-phospholipid complex in the raw material is 15% to 25%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 4% to 10%, the molar proportion of the cholesterol in the raw material is 40% to 46%, the molar proportion of the DSPC in the raw material is 25% to 35%, and the metal ion part of the metal-phospholipid complex is selected from Fe 3+ .

45. The metal-phospholipid complex particles according to claim 44, wherein The molar proportion of the metal-phospholipid complex in the raw material is 15%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 4%, the molar proportion of the cholesterol in the raw material is 46%, and the molar proportion of the DSPC in the raw material is 35%; or the molar proportion of the metal-phospholipid complex in the raw material is 25%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 10%, the molar proportion of the cholesterol in the raw material is 40%, and the molar proportion of the DSPC in the raw material is 25%; the metal ion portion in the metal-phospholipid complex is selected from Fe 3+ . The metal-phospholipid complex particles according to claim 38 , wherein The molar proportion of the metal-phospholipid complex in the raw material is 10% to 30%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10%, the molar proportion of the cholesterol in the raw material is 35% to 56%, and the molar proportion of the DSPC in the raw material is 34% to 40%; the metal ion part in the metal-phospholipid complex is selected from Al 3+ .

47. The metal-phospholipid complex particles according to claim 39, wherein The molar proportion of the metal-phospholipid complex in the raw material is 10% to 30%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10%, the molar proportion of the cholesterol in the raw material is 35% to 56%, and the molar proportion of the DSPC in the raw material is 40% to 45%; or The molar proportion of the metal-phospholipid complex in the raw material is 10% to 30%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10%, the molar proportion of the cholesterol in the raw material is 15% to 35%, and the molar proportion of the DSPC in the raw material is 34% to 40% or greater than 40% to 45%; or The molar proportion of the metal-phospholipid complex in the raw material is 7% to less than 10%, the molar proportion of the conjugated lipid that inhibits particle aggregation in the raw material is 3% to 10%, the molar proportion of the cholesterol in the raw material is 15% to less than 35% or 35% to 56%, and the molar proportion of the DSPC in the raw material is 34% to 40% or greater than 40% to 45%; the metal ion part of the metal-phospholipid complex is selected from Al 3+ . The metal-phospholipid complex particles according to claim 47 , wherein The metal-phospholipid complex accounts for 7% by mole in the raw material, the conjugated lipid that inhibits particle aggregation accounts for 3% by mole in the raw material, the cholesterol accounts for 56% by mole in the raw material, and the DSPC accounts for 34% by mole in the raw material; the metal ion part in the metal-phospholipid complex is selected from Al 3+ .

49. The method for preparing the metal-phospholipid complex particles according to any one of claims 27 to 48, wherein: The preparation method comprises mixing (i) a metal-phospholipid complex, (ii) a conjugated lipid that inhibits particle aggregation, and (iii) a non-cationic lipid or a non-ionizable lipid other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation to obtain the metal-phospholipid complex particles.

50. A drug-lipid particle, wherein The drug-lipid particles contain: (a) a drug, wherein the drug is a negatively charged molecule; and (b) Metal-phospholipid complex particles, wherein the metal-phospholipid complex particles are the metal-phospholipid complex particles according to any one of claims 27 to 48.

51. The drug-lipid particle according to claim 50, wherein The drug is encapsulated in the metal-phospholipid complex particles.

52. according to the described medicine-lipid particle of claim 50 or 51, wherein said medicine is selected from one or more combinations in nucleic acid, protein, polypeptide, small molecule, nucleic acid analog, protein analog and polypeptide analog.

53. The drug-phospholipid particle according to claim 52, wherein The nucleic acid is selected from one or more combinations of mRNA, siRNA, sgRNA, ASO, circRNA, microRNA, DNA, ecDNA, and artificial nucleic acid.

54. The drug-phospholipid particle according to claim 52 or 53, wherein The nucleic acid is an mRNA sequence encoding eGFP as shown in SEQ ID No. 1, an mRNA sequence encoding the receptor binding domain RBD of the novel coronavirus S1 subunit as shown in SEQ ID No. 2, an mRNA sequence encoding NY-ESO-1 as shown in SEQ ID No. 3, an siRNA sequence of the Bcl-2 gene with an antisense chain of SEQ ID No. 4 and a sense chain of SEQ ID No. 21, an siRNA sequence of the PLK1 gene with an antisense chain of SEQ ID No. 6 and a sense chain of SEQ ID No. 23, an siRNA sequence of the Gal-1 gene as shown in SEQ ID No. 8, an ASO sequence of the STAT-3 gene as shown in SEQ ID No. 10, an ASO sequence of the α-syn gene as shown in SEQ ID No. 12, an ASO sequence of the Bcl-2 gene as shown in SEQ ID No. 14, an mRNA sequence encoding the wild-type novel coronavirus S protein as shown in SEQ ID No. 16, a double-stranded DNA sequence with an antisense chain of SEQ ID No. 17 and a sense chain of SEQ ID No. 25, a single-stranded DNA sequence with a sense chain of SEQ ID No. 18, or a single-stranded DNA sequence with a sense chain of SEQ ID No. No.19 and the antisense strand are the siRNA sequences of the B7-H4 gene shown in SEQ ID No.

26.

55. The method for preparing the drug-lipid particles according to any one of claims 50 to 54, wherein: The drug is loaded into the metal-phospholipid complex particles to obtain the drug-lipid particles.

56. The preparation method according to claim 55, wherein The metal-phospholipid complex, the conjugated lipid that inhibits particle aggregation, and non-cationic lipids or non-ionizable lipids other than the metal-phospholipid complex and the conjugated lipid that inhibits particle aggregation are dissolved in an organic compound to form an organic phase, the drug is dissolved in a buffer solution to form an aqueous phase, and the organic phase and the aqueous phase are mixed to obtain drug-lipid particles.

57. The preparation method according to claim 56, wherein The organic compound is ethanol.

58. The preparation method according to claim 56 or 57, wherein The buffer is enzyme-free PBS buffer.

59. The preparation method according to any one of claims 56 to 58, wherein The mixing methods of the organic phase and the aqueous phase include microfluidic chip or ultrasound.

60. Use of the metal-phospholipid complex according to any one of claims 1 to 19 in a nucleic acid delivery system.

61. The use according to claim 60, wherein The nucleic acid delivery system is used to introduce nucleic acids into cells.

62. The use according to claim 61, wherein The nucleic acid is used to silence expression of a target sequence in a mammalian subject, to deliver a drug in vivo in a mammal, to deliver a drug from the body to a mammalian cell, or to treat a disease or disorder in a mammal.

63. Use of the metal-phospholipid complex particle according to any one of claims 27 to 48 or the drug-lipid particle according to any one of claims 47 to 51 in a composition for drug delivery.

64. The use according to claim 63, wherein The composition is used to introduce the drug into cells.

65. The use according to claim 63 or 64, wherein The composition is a medicament.

66. The use according to claim 65, wherein The medicament is used for silencing the expression of a target sequence in a mammalian subject, for delivering a drug in a mammal, for delivering a drug from the body to a mammalian cell, or for treating a disease or disorder in a mammal.

67. The use according to claim 62 or 66, wherein The mammal is a human.

68. The use according to claim 62 or 66, wherein The disease or condition is associated with the expression of a gene that contains a target sequence for the drug.

69. The use according to claim 62 or 66, wherein The disease or condition includes cancer, viral infection, autoimmune disease, diabetes or Alzheimer's disease.

70. The use according to claim 69, wherein The viral infection includes hepatitis A, hepatitis B, hepatitis C, SARS-Cov-2, HIV, HPV, influenza, smallpox or syphilis.

71. The use according to claim 69, wherein The cancer includes liver cancer, glioma, melanoma, lung cancer, pancreatic cancer or breast cancer.

72. The use according to claim 65, wherein The medicament is a vaccine.

73. The use according to claim 65 or 72, wherein The administration routes of the agent include intrathecal injection, intramuscular administration, intracranial injection, intravenous injection or intratumoral injection.

74. A pharmaceutical agent comprising the metal-phospholipid complex according to any one of claims 1 to 19, the metal-phospholipid complex particles according to any one of claims 27 to 48, or the drug-lipid particles according to any one of claims 50 to 54.

75. The agent according to claim 74, wherein The medicament is a vaccine.

76. The agent according to claim 75, wherein The vaccine is a new coronavirus vaccine.

77. Use of the metal-phospholipid complex according to any one of claims 1 to 19, the metal-phospholipid complex particles according to any one of claims 27 to 48, the drug-lipid particles according to any one of claims 50 to 54, or the medicament according to any one of claims 74 to 76 in preventing / treating a disease or condition in a mammal.

78. The use according to claim 77, wherein The mammal is a human.

79. The use according to claim 77, wherein The disease or condition is associated with the expression of a gene that contains a target sequence for the drug.

80. The use according to claim 77, wherein The disease or condition includes cancer, viral infection, autoimmune disease, diabetes or Alzheimer's disease.

81. The use according to claim 80, wherein The viral infection includes hepatitis A, hepatitis B, hepatitis C, SARS-Cov-2, HIV, HPV, influenza, smallpox or syphilis.

82. The use according to claim 80, wherein The cancer includes liver cancer, glioma, melanoma, lung cancer, pancreatic cancer or breast cancer.